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Abstract 
 
Several cell cycle events require specific forms of the cyclin-CDK complexes. It 
has been known for some time that cyclins not only contribute by activating the 
CDK but also by choosing substrates and/or specifying the location of the CDK 
holoenzyme. There are several examples of B-type cyclins identifying certain 
peptide motifs in their specific substrates through a conserved region in their 
structure. Such interactions were not known for the G1 class of cyclins, which are 
instrumental in helping the cell decide whether or not to commit to a new cell 
cycle, a function that is non-redundant with B-type cylins in budding yeast. In this 
dissertation, I have presented evidence that some G1 cyclins in budding yeast, 
Cln1/2, specifically identify substrates by interacting with a leucine-proline rich 
sequence different from the ones used by B-type cyclins. These “LP” type 
docking motifs determine cyclin specificity, promote phosphorylation of 
suboptimal CDK sites and multi-site phosphorylation of substrates both in vivo 
and in vitro. Subsequently, we have discovered the substrate-binding region in 
Cln2 and further showed that this region is highly conserved amongst a variety of 
fungal G1 cyclins from budding yeasts to molds and mushrooms, thus suggesting 
a conserved function across fungal evolution. Interestingly, this region is close to 
but not same as the one implicated in B-type cyclins to binding substrates. We 
discovered that the main effect of obliterating this interaction is to delay cell cycle 
entry in budding yeast, such that cells begin DNA replication and budding only at 
vi 
a larger than normal cell size, possibly resulting from incomplete multi-site 
phosphorylation of several key substrates. The docking-deficient Cln2 was also 
defective in promoting polarized bud morphogenesis. Quite interestingly, we 
found that a CDK inhibitor, Far1, could regulate the Cln2-CDK1 activity partly by 
inhibiting the Cln2-substrate interaction, thus demonstrating that docking 
interactions can be targets of regulation. Finally, by studying many fungal cyclins 
exogenously expressed in budding yeast, we discovered that some have the 
ability to make the CDK hyper-potent, which suggests that these cyclins confer 
special properties to the CDK. My work provides mechanistic clues for cyclin-
specific events during the cell cycle, demonstrates the usefulness of synthetic 
strategies in problem solving and also possibly resolves long-standing 
uncertainties regarding functions of some cell cycle proteins. 
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CHAPTER I 
Introduction 
 
 
Eukaryotic cell cycle progression – drivers and regulators 
 
The eukaryotic cell cycle is a highly complex set of sequential events by which 
living cells duplicate their genomic content and divide it equally between two 
daughter cells. Most eukaryotes display four distinct cell cycle stages with 
varying lengths depending on the cell type. The main stages, namely S phase 
(DNA replication) and M phase (chromosome segregation), are interspersed with 
two growth phases (G1 before S and G2 before M). The main components that 
drive the periodic fluctuation of events in all eukaryotic cell cycles are (a) Cyclin-
dependent kinases, or CDKs; (b) two sequential waves of transcriptional 
upregulation and (c) two large-scale protein degradation events (Breeden, 2003; 
Morgan, 2007; Vodermaier, 2004).  
 
CDKs are the master regulators of the cell cycle with hundreds of potential 
substrates even in a single cell eukaryote like budding yeast (Holt et al., 2009). 
As the name suggests, they bind to partner proteins called cyclins for their 
activity. There are many specialized forms of CDK and activities of different 
forms rise and fall in a sequential process thereby pushing cells through the cell 
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cycle (Morgan, 2007). The CDKs help to generate two transcriptional bursts 
during two distinct stages of the cell cycle. The first and the more pronounced 
one is at the G1 to S boundary when cells need to massively and robustly 
upregulate hundreds of transcripts for an irreversible commitment to the cell 
cycle and successful, error-free DNA replication (Charvin et al., 2010; Morgan, 
2007; Novak et al., 2007). This task is carried out by the E2F family of 
transcription factors in higher eukaryotes and by SBF and MBF transcription 
complexes in budding yeast (Morgan, 2007). CDKs help this process in the G1 
phase by inhibiting the repressors of these transcription factor complexes 
(retinoblastoma in higher eukaryotes and its analog Whi5 in budding yeast) 
(Hasan et al., 2013; Morgan, 2007). The second transcriptional wave happens at 
the G2/M transition and include, in budding yeast the mitotic cyclin Clb2 
transcript (Morgan, 2007). There are many other periodically expressed genes in 
budding yeast cell cycle, but their transcription is not thought to be under CDK 
control (Orlando et al., 2008). 
 
One key aspect of the cell cycle is irreversibility which is ensured through a 
series of biochemical switches resulting from factors such as robust positive 
feedback loops, stoichiometric CDK-inhibitors and proteolytic degradation. In 
budding yeast, the upstream G1 cyclin-CDK complex turns on the expression of 
downstream G1/S cyclins. These later G1/S cyclin-CDK complexes drive their 
own expression (positive-feedback loop) (Skotheim et al., 2008) and promote the 
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degradation of inhibitors of the S-phase cyclin-CDKs, in addition to turning on the 
massive SBF/MBF transcriptional program. This sequence of events lets the 
now-unchallenged S-phase cyclin-CDKs ensure irreversible entry into the cell 
cycle (Morgan, 2007; Schwob and Nasmyth, 1993; Yang et al., 2013). This 
irreversible commitment step is aided by proteolytic degradation through the SCF 
family of ubiquitin ligases, which target, among other things, the S-phase CDK-
inhibitor (CKI) and also the G1 cyclins (Morgan, 2007). A Positive feedback loop 
of a different kind operates at the G2 to M transition. During Xenopus oocyte 
maturation, the mitotic CDK1-cyclinB complex promotes its own activation by 
inhibiting Wee1 kinase and activating Cdc25 phosphatase, which control an 
inhibitory tyrosine phosphorylation site on CDK1. These opposing regulations set 
up another positive feedback loop and CDK1 remains active even when stimulus 
is removed (Ferrell; Ferrell and Machleder, 1998; Gould and Nurse, 1989; 
Morgan, 2007; Potapova et al., 2011; Trunnell et al., 2011). This irreversible 
process continues until an external factor is introduced. This external factor is the 
degradation of the mitotic cyclins by another large multi-subunit ubiquitin ligase 
complex known as the APC (Morgan, 1999; Wasch and Cross, 2002). The APC 
is involved in promoting chromosome segregation and mitotic exit. From APC 
activation until the end of G1, mitotic CDK activity will remain low because of the 
activated status of the APC. The G1 cyclins are refractory to the APC and 
promote the inhibition of a key APC component (Morgan, 2007), thus allowing 
the mitotic CDK to get activated again. Interestingly, the mitotic CDK complex 
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activates the APC, thus promoting its own destruction – a negative feedback loop 
that generates robust oscillations of mitotic CDK activity (Morgan, 2007). It is 
worth noting that this Wee1-Cdc25 regulation is not required in budding yeast 
(Amon et al., 1992), thus bringing out subtle differences between different model 
systems. 
 
CDKs and cyclins – mechanisms and controls – general principles 
 
CDKs are proline-directed serine/threonine kinases, which require binding to 
cyclin proteins (Morgan, 1997) and the resulting conformational change to 
become active (De Bondt et al., 1993). In higher eukaryotes, there are multiple 
CDKs involved in cell cycle control (CDK 1,2,4,6) and multiple cyclins (Cyclin D, 
E, A, B and their subtypes like Cyclin D1, D2, D3). But in some single-celled 
eukaryotes like fission yeast and budding yeast, one main CDK, CDK1, controls 
all of cell cycle in partnership with several periodic cyclins (Figure 1.1) (Morgan, 
1997; Morgan, 2007). Once activated, cyclin-CDK complexes phosphorylate 
proteins at specific serine/threonine residues that are a part of either a full 
consensus sequence (S/T-P-x-K/R) or a minimal consensus sequence (S/T-P) 
(Langan et al., 1989; Songyang et al., 1994). Interestingly, a large-scale 
proteomic screen done in budding yeast showed that about two-thirds of all 
phosphorylated CDK sites belonged to the minimal consensus category (Holt et 
al., 2009). Also, one study using human cell lysates show that only 43% of all  
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Figure 1.1. CDKs and their role in cell-cycle progression  
(Reproduced from Bardin and Amon, 2001) 
During G1, the levels of G1 cyclins rise, and these cyclins associate with cyclin-
dependent kinases (CDKs). Activity of G1 CDKs promotes the passage of cells 
through START (budding yeast), also known as the restriction point (R) in fission 
yeast and higher eukaryotes. After passing through this point, a cell is committed 
to continue through the cell cycle. In budding yeast, the G1 cyclins are Cln1, Cln2 
and Cln3. Cln3 is present throughout the cell cycle at low levels, and this cyclin 
promotes the accumulation of Cln1 and Cln2 (Nasmyth, 1993). In fission yeast, 
puc1 seems to be important — although not essential — for entry into the cell 
cycle (Forsburg and Nurse, 1991). In higher eukaryotes, cyclin D-associated 
kinases are thought to have a function similar to that of Cln3–CDKs in budding 
yeast, and they are important for promoting the accumulation of the other G1 
CDKs, cyclin E–CDK (Morgan, 1997; Nigg, 1995), . 
S-phase CDKs begin to increase towards the end of G1, and are inactivated 
during G2 and mitosis. On reaching a critical level, they promote DNA replication. 
In budding yeast, Clb5 and Clb6-associated kinases are important for promoting 
DNA synthesis, but in their absence, mitotic CDKs (Clb1, Clb2, Clb3 and Clb4-
associated kinases) can support DNA replication. In S. pombe, cig1 and cig2-
associated kinases promote DNA replication, but as in S. cerevisiae, the mitotic 
cyclin cdc13 can function in their absence. In higher eukaryotes, cyclin E–CDKs 
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— directly or indirectly — and cyclin A–CDKs promote DNA replication (Morgan, 
1997). 
Mitotic CDKs are activated at the onset of mitosis and, among other processes, 
promote chromosome condensation, formation of the mitotic spindle and 
breakdown of the nuclear envelope. These functions are performed by CDKs 
associated with Clb1, Clb2, Clb3, Clb4 and Clb5 (perhaps also Clb6) in budding 
yeast, cdc13–cdc2 in fission yeast, and cyclin A and cyclin B-associated kinases 
in higher eukaryotes. For cells to exit from mitosis, undergo cytokinesis and enter 
the following G1, mitotic CDKs must be inactivated (Koepp et al., 1999; Morgan, 
1997),.  
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Figure 1.1. CDKs and their role in cell-cycle progression  
(Reproduced from (Bardin and Amon, 2001) 
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sites phosphorylated by cyclinA-CDK2 were full consensus sites (Chi et al., 
2008). The expression of CDK1 in yeast is not regulated, such that it remains 
constant during the entire cell cycle and always in excess of its cyclin partners 
(Mendenhall et al., 1987). 
 
Apart from cyclin binding, the activation state of CDKs is controlled by post-
translational modifications (Mendenhall and Hodge, 1998). Full activation of 
CDKs requires the phosphorylation of a highly conserved threonine residue in the 
T-loop region near the catalytic cleft by CDK-activating kinase or CAK (Espinoza 
et al., 1996; Morgan, 1995, 1997). The result of this phosphorylation in the 
mammalian cyclin A-CDK2 pair, is that the T-loop, which otherwise blocks the 
catalytic cleft, changes position upon phosphorylation, thereby freeing the active 
site for substrate binding. Also, the residues responsible for ATP binding change 
position after this phosphorylation event (Jeffrey et al., 1995; Russo et al., 1996). 
Other cyclin-CDK pairs are expected to behave in the same manner although 
differences in activity has been noted between them which probably points to 
different abilities of different cyclins to activate their CDK partner (Koivomagi et 
al., 2011b). Budding yeast differs from higher eukaryotes in having the activating 
phosphorylation event precede the cyclin binding event (Ross et al., 2000). 
CDK’s activity is negatively regulated by phosphorylation at a conserved Tyr19 
residue (and another threonine residue for mammalian CDKs). These 
phosphorylation sites regulate the orientation of the ATP phosphates and the 
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affinity for substrate peptides (Welburn et al., 2007). This inhibitory 
phosphorylation forms the basis of a positive feedback loop that strongly 
activates the M-phase CDK (mentioned above) at the beginning of mitosis in 
metazoans but not in budding yeast.  
 
It is interesting to note that not all cyclin-CDK pairs are equally susceptible to this 
inhibitory phosphorylation. For example, in budding yeast, even though the same 
CDK1 partners with both G1 phase and M phase cyclins, only the M phase 
cyclin-CDK complex is inhibited strongly by the inhibitory phosphorylation carried 
out by Swe1 kinase (Hu and Aparicio, 2005; Keaton et al., 2007). This difference 
demonstrates that not all CDK complexes are similarly regulated. Also, only the 
M phase cyclin-CDK complex can phosphorylate and inactivate Swe1, not other 
CDK complexes (Asano et al., 2005; Bhaduri and Pryciak, 2011; Harvey et al., 
2005), thus showing differences in the substrate specificity of different cyclin-
CDK complexes (to be discussed in detail later). 
 
Unlike the CDK, cyclin levels are tightly controlled by transcription and 
proteolysis (Bloom and Cross, 2007; Murray, 2004). Nearly all cyclins are 
expressed in specific phases during the cell cycle and each cell cycle stage has 
its associated cyclins (Evans et al., 1983; Murray, 1995; Murray and Kirschner, 
1989). Cyclins are rapidly degraded by the proteasome (Glotzer et al., 1991; 
Murray, 1995) and thus allow the CDK to rapidly exchange their cyclins even 
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though dissociation rates are low (Kobayashi et al., 1994). All cyclins have a well-
conserved domain called the cyclin box fold or CBF (Kobayashi et al., 1992), 
which binds the CDK and changes the conformation of the active site of the CDK 
(Jeffrey et al., 1995).  
 
Budding yeast cyclin-CDK complexes – functions and regulations 
 
In budding yeast, the major CDK is Cdc28 (also called CDK1), originally 
discovered by Lee Hartwell in the early seventies (Hartwell, 1974; Hartwell et al., 
1974; Hartwell et al., 1973). Cdc28 associates with nine cyclins to carry out 
different jobs during distinct cell cycle stages (Bloom and Cross, 2007; Cross, 
1995a; Enserink and Kolodner, 2010; Koivomagi et al., 2011b; Nasmyth, 1996).  
Among these cyclins, there are two distinct groups, namely the G1 cyclins (Cln1-
Cln3) that control the decision whether or not to begin a new cell cycle, and the 
B-type cyclins (Clb1-Clb6) that control DNA replication and mitosis. These cyclins 
are expressed sequentially.  Cln3 triggers expression of Cln1/2, which then 
induce the expression of Clb5 and Clb6, which drive DNA replication but also 
terminate the expression of Cln1/2 during S phase. The next wave of cyclin 
expression produces Clb3 and Clb4 at the G2/M stage and finally, Clb1 and 
Clb2, which take the cell through mitosis (Mendenhall and Hodge, 1998; Morgan, 
1997; Pines, 1995). Apart from the G1 cyclin Cln3, all others are expressed in 
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paralogous pairs (i.e., Cln1/2, Clb1/2, Clb3/4, and Clb5/6) as a result of a whole 
genome duplication event in the evolution of Saccharomyces cerevisiae.  
Although having any one of the three G1 cyclins is enough to begin a new cell 
cycle, there are specific differences in their mechanism of action and not all of 
their functions are redundant (Dirick et al., 1995; Skotheim et al., 2008). 
Expression of Cln3 is low and more or less constant through out the cell cycle, 
peaking slightly in late mitosis and early G1 (MacKay et al., 2001; McInerny et 
al., 1997; Tyers et al., 1993) where it orchestrates the first step towards cell cycle 
entry, whereas Cln1 and Cln2 are expressed periodically with a peak in late G1 
(Wittenberg et al., 1990). Although originally (in above studies) Cln3 expression 
was shown to be less periodic than other cyclins, a recent study has shown that 
Cln3 protein cycles quite a bit with a peak in M phase (Landry et al., 2012). Cln3 
and Cln1/2 are thought to promote Start through different mechanisms. Start 
(restriction point in metazoan cell cycle) is a small window before DNA replication 
when the cell irreversibly commits to a new cell cycle (Johnson and Skotheim, 
2013). Cln3 largely contributes to this event by turning on the expression of some 
key genes required for cell cycle entry including Cln1/2. Whereas, Cln1/2 can not 
only drive their own expression (positive feedback loop) (Skotheim et al., 2008) 
but also control other Start related events such as a) polarized growth for bud 
emergence; b) spindle pole body duplication and c) promoting degradation of S 
phase cyclin-CDK inhibitor, Sic1 (Bloom and Cross, 2007; Nasmyth, 1996). 
Another distinct feature of Cln1/2 is that they can restrict pheromone signaling to 
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the G1 phase (Oehlen and Cross, 1994; Strickfaden et al., 2007; Wassmann and 
Ammerer, 1997), a task not fulfilled by Cln3.  
 
Cln3 controls the first step towards cell cycle entry (Stuart and Wittenberg, 1995; 
Tyers et al., 1993). Many genes (about 200) are transcribed at this stage 
including key G1/S regulators. These genes are transcriptionally controlled by 
hetero-dimeric transcription factors SBF (Swi4/Swi6) and MBF (Mbp1/Swi6). SBF 
and MBF (analogs of E2F in higher eukaryotes) are kept inhibited by a protein 
called Whi5 (analog of Rb in higher eukaryotes) in the nucleus. The main job of 
Cln3-CDK1 is to phosphorylate Whi5 and initiate its exit from the nucleus, thus 
relieving SBF and MBF of repression (Costanzo et al., 2004; de Bruin et al., 
2004). Once de-repressed, SBF and MBF start a massive program of 
transcribing about 200 genes including the G1/S cyclins Cln1 and Cln2 and the S 
phase cyclins Clb5 and Clb6, in a temporally separated manner. Cln1 and Cln2 
are among the earliest transcripts (Eser et al., 2011; Skotheim et al., 2008) and 
in partnership with the CDK1, they can further phosphorylate Whi5 to completion 
(Costanzo et al., 2004; Skotheim et al., 2008) and restrict its re-entry to the 
nucleus (Charvin et al., 2010). Cln1/2-CDK1 can promote their own transcription, 
thereby setting off a robust positive feedback loop (Figure 1.2A) (Cross and 
Tinkelenberg, 1991; Dirick and Nasmyth, 1991; Skotheim et al., 2008) resulting in 
the quick accumulation of strong CDK activity needed to pass through Start,  
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Figure 1.2. Positive feedback loops operating at G1/S transition. 
 
(A)  Model for G1/S transcriptional regulon activation and bud emergence; red 
lines indicate pathways generating positive feedback in Start transition 
(reproduced from Skotheim et al., 2008). 
(B) Model of Sic1 degradation; red line indicates positive feedback in Sic1 
degradation at Start transition  (reproduced from (Yang et al., 2013). 
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Figure 1.2. Positive feedback loops operating at G1/S transition 
 
 
 
 
              
  
A
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defined molecularly as the point where roughly 50% of Whi5 has left the nucleus 
(Doncic et al., 2011). Another very important job that Cln1/2-CDK1 does is to 
start the multisite phosphorylation of CKI Sic1, which specifically inhibits the S 
phase Clb5/6-CDK1 complexes. Later, as Clb5/6 gets transcribed in small 
amounts, Clb5/6-CDK1 completes the phosphorylation of Sic1 and promotes its 
degradation by the proteasome – another positive feedback loop (Figure 1.2B) 
(Koivomagi et al., 2011a; Yang et al., 2013). This event contributes to the 
mechanism of switch-like transition from G1 to S phase (Venta et al., 2012). 
Clb5/6 transcription at G1/S is controlled by SBF/MBF (Nasmyth and Dirick, 
1991; Schwob and Nasmyth, 1993) but the other four Clbs are controlled through 
a different group of transcription factors known as the Mcm1-Fkh1/2-Ndd1 
complex which turn on the expression of about 35 genes at G2/M including the 
mitotic cyclins (Futcher, 2002; Spellman et al., 1998; Wittenberg and Reed, 
2005). Moreover, SBF/MBF are inactivated by mitotic Clb2-CDK1 (Amon et al., 
1993) and Clb2-CDK1 can drive its own transcription by phosphorylating its 
transcription factors Fkh2 and Ndd1 (Reynolds et al., 2003).  
 
Cyclin abundance is controlled by proteolysis throughout the cell cycle and this 
negative regulation is very important for generating sharp peaks of specific kinds 
of CDK activity during distinct cell cycle stages (Bloom and Cross, 2007).  Yeast 
G1/S cyclins have very short half-lives (~ 5-10 minutes) (Barral et al., 1995; 
Lanker et al., 1996; Salama et al., 1994) and are targeted for degradation by a 
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ubiquitin ligase complex known as SCF (Skp1/Cdc53-F-box) (Deshaies et al., 
1995; Willems et al., 1996). The F-box protein is the substrate-specificity 
determining factor, which is Grr1 in the case of Cln1/2 (Skowyra et al., 1997; 
Skowyra et al., 1999). Degradation of Cln2 is preceded by the 
autophosphorylation of its C-terminus by Cln2-CDK1 at multiple phosphorylation 
sites encompassing a PEST degradation domain, which is then recognized by 
Grr1(Lanker et al., 1996; Salama et al., 1994; Schneider et al., 1998). Cln3 is 
degraded by not only SCF-Grr1 but also SCF-Cdc4 and its degradation also 
requires CDK1 dependent phosphorylation of its C-terminus (Landry et al., 2012). 
SCF also controls the abundance of the B-type cyclin Clb6 through the F-box 
protein Cdc4 after phosphorylation by CDK1 and another cyclin-dependent 
kinase Pho85 (Jackson et al., 2006). Other B-type cyclins in budding yeast are 
degraded by the Anaphase Promoting Complex or APC. At early M phase, APC 
partners with substrate specific adaptor protein, Cdc20 and targets mitotic cyclins 
and Clb5 (Shirayama et al., 1999; Visintin et al., 1997; Wasch and Cross, 2002). 
The mitotic Clb2-CDK1 complex can phosphorylate and activate APC-Cdc20 
components, thereby promoting its own degradation (negative feedback loop) 
(Rudner et al., 2000). During late M phase, APC partners with another adaptor 
protein Cdh1 with different substrate specificities. APC-Cdh1 can target mitotic 
cyclins but not Clb5 or Cln1-3. This insensitivity to APC lets G1/S and Clb5 
cyclin-CDKs phosphorylate and inactivate Cdh1 at G1/S, thereby allowing the 
  
17 
mitotic Clb2-CDK activity to accumulate at the onset of M phase (Jaspersen et 
al., 1999; Kramer et al., 2000; Zachariae et al., 1998). 
 
Specific roles of G1/S CDK at Start transition – substrates of the early CDK 
 
Over the past two decades, considerable effort has gone into discovering 
substrates of cyclin-CDK complexes in eukaryotes, and budding yeast has 
proved to be a valuable model system in this effort. Through these studies, 
approximately 75 proteins functioning in different critical cell cycle events like 
DNA replication and morphogenesis in budding yeast have been shown to be 
under CDK1 control (Enserink and Kolodner, 2010). A similar number of targets 
have been identified in higher eukaryotes (Blethrow et al., 2008; Errico et al., 
2010). However, even conservative estimates predict that CDK1 must have 
hundreds of targets in any cell. Several large-scale screening and computational 
studies have generated a larger list of predicted CDK targets and CDK controlled 
processes (Archambault et al., 2004; Chang et al., 2007; Holt et al., 2009; Moses 
et al., 2007a; Ubersax et al., 2003). One study in budding yeast (Ubersax et al., 
2003) identified 181 targets for the major mitotic cyclin Clb2-CDK. Another large-
scale study (Holt et al., 2009) identified 308 substrates containing a total of 547 
phosphorylated CDK sites. Similarly, there are some large-scale studies 
performed in higher eukaryotes to identify CDK substrates. For example, using a 
gel-shift assay combined with radioactive labeling, many candidates of individual 
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cyclin-CDK complexes were identified in Xenopus extracts (35 potential 
substrates for cyclin B-CDK1, 70 for cyclin A-CDK2, and 42 for cyclin E-CDK2) 
(Errico et al., 2010). There was considerable overlap in substrates between the 
complexes tested in this study, but one interesting point that emerged is that not 
everything with a consensus CDK site works as a substrate; instead, some other 
requirement may need to be met, such as the presence of RxL type cyclin 
docking motifs (Errico et al., 2010). A study using human cell lysates and an 
analogue-sensitive allele of CDK2 combined with mass-spectrometry identified 
180 potential substrates belonging to various categories including cell cycle 
progression, mRNA transcription, cellular structure and organization (Chi et al., 
2008). One large class of proteins in this study is uncharacterized, thus drawing 
our attention to the fact that we are yet to fully realize the functions of CDK 
phosphorylations.  More than half of the identified phospho-sites were minimal-
consensus (S/TP) sites and about 50% of them contained an RxL type motif 
distal to the sites themselves (Chi et al., 2008). 
 
The studies described above, as well as others(Blethrow et al., 2008), have 
identified and/or predicted a large number of targets in both yeast and higher 
eukaryotes for specific forms of CDK.  Of particular relevance to this thesis are 
substrates of the yeast G1/S cyclin-CDK complexes, and therefore the key 
substrates and processes are discussed in greater detail in the following 
paragraphs. 
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Whi5: Whi5 is an inhibitor of the SBF transcription factor complex, which is key to 
the G1/S transition. Following mitosis, Whi5 resides in the nucleus and inhibits 
transcription of the G1/S regulon. Before cells can commit to a new cell cycle at 
least 50% of Whi5 needs to be exported from the nucleus (Costanzo et al., 2004; 
Doncic et al., 2011). Phosphorylation of Whi5 promotes its nuclear export. Whi5 
has 12 CDK sites and the current understanding suggests that several of these 
CDK sites need to be phosphorylated to achieve nuclear export and SBF de-
repression (Skotheim et al., 2008; Wagner et al., 2009) although there is some 
ambiguity regarding how many and which sites need to be phosphorylated. 
Phosphorylation of Whi5 is initiated (but not completed) by Cln3-CDK1  and that 
phosphorylation is probably sufficient to promote some SBF de-repression and 
allow some Cln1/2 to be transcribed. Subsequently Cln1/2-CDK1 completes the 
phosphorylation of Whi5 and fully turns on the transcriptional program. In the 
absence of Cln1/2, the nuclear exit of Whi5 is not sharp and incomplete as 
shown by single cell microscopy (Skotheim et al., 2008). In that study, it was also 
shown that a whi5-6A mutant cannot make a sharp and complete exit from the 
nucleus at Start and neither can it turn on some of the SBF controlled genes 
coherently (Skotheim et al., 2008). 
 
Sic1: Sic1 is an inhibitor of S phase Clb5/6-CDK1 complexes and is key to 
setting the correct timing for the initiation of DNA replication. Sic1 keeps a 
temporal window in G1 free of Clb5/6-CDK1 activity, which is essential for new 
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origin licensing (Lengronne and Schwob, 2002). Clb5/6-CDK1 activity can rise 
only when Sic1 is degraded (Schwob et al., 1994; Verma et al., 1997). Sic1 has 
nine CDK phosphorylation sites and multiple sites need to be phosphorylated for 
SCFCdc4 mediated degradation of Sic1 at the onset of S phase (Feldman et al., 
1997; Nash et al., 2001; Verma et al., 1997). Both Cln2-CDK1 and CLB5-CDK1 
can phosphorylate Sic1 in vitro (Koivomagi et al., 2011a; Skowyra et al., 1997). 
Although population-average studies (Sedgwick et al., 2006; Verma et al., 1997) 
in the past had implicated Cln2-CDK1 in Sic1 phosphorylation, recent in vitro and 
single cell in vivo time-lapse microscopy studies show that in fact the rate of 
degradation of Sic1 depends on Clb5-CDK1, not Cln2-CDK1 (Koivomagi et al., 
2011a; Yang et al., 2013). However, Cln2-CDK1 mediated initial phosphorylation 
of Sic1 at certain sites is thought to play a priming role which then allows Clb5-
CDK1 to complete the multiple site phosphorylation that is required for efficient 
Cdc4 recognition (Koivomagi et al., 2011a). An in vivo study looking at 
fluorescently labeled Sic1 in both mother and daughter cells observed that Cln2-
CDK1 controls the timing of Sic1 degradation (“defined as the time from Whi5 
nuclear exclusion to the point of the fastest Sic1 degradation”), such that when 
Cln1/2 are absent, this timing is highly variable among cells. Also, removing a 
Cln2 docking site in Sic1 causes variability in this timing (Yang et al., 2013).  The 
use of two different CDK complexes to separately initiate and then complete 
substrate phosphorylation is an emerging theme at key cell cycle transition 
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points(Yang et al., 2013), as with the dual-stage inhibition of Whi5 by Cln3-CDK1 
and then Cln1/2-CDK1 (discussed above).  
 
Cdh1: Cdh1 (originally known as Hct1) is an important component of the APC 
complex and one of its main targets is the mitotic cyclin Clb2 (Baumer et al., 
2000). In order to let the mitotic cyclin-CDK activity build up before mitosis, Cdh1 
activity needs to be kept in check during G1 and S phase. This regulation is 
achieved through phosphorylation of Cdh1 by G1/S and S phase cyclin-CDKs 
(Jaspersen et al., 1999; Zachariae et al., 1998). Cdh1 has eleven CDK sites and 
the phosphorylation of multiple sites is correlated with its degree of inactivation 
by CDK(Zachariae et al., 1998). Also, Cln2 has been shown to bind Cdh1 
(Archambault et al., 2004) but less is known about the mechanism of Cln2-CDK1 
mediated phosphorylation of Cdh1 and it remains to be seen if its 
phosphorylation depends on docking and processivity mechanisms similar to that 
in Sic1.  
 
Polarized bud morphogenesis: Several proteins involved in bud emergence are 
specific targets of Cln1/2-CDK1. Specific cell size and shape are maintained 
through a coordination of cell growth with the cell-division cycle. But cell growth is 
not thought to be controlled by the cell cycle (Cross, 1990; Culotti and Hartwell, 
1971; Gross et al., 1997; Johnston et al., 1977; Kipreos et al., 1996). G1/S cyclin-
CDK1 activity in yeast is thought to promote polarized apical bud growth, which 
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later shifts to isotropic bud growth during S phase (when Cln1/2 protein levels 
have gone down). Heightened activity of G1 cyclin-CDK has been shown to drive 
extremely elongated bud growth (Barral et al., 1995; Lew and Reed, 1993). 
Recent work (McCusker et al., 2007) has shown disruption of CDK1 activity 
disrupts the secretory pathway, important for delivering vesicles to the growing 
bud. Cdc42-GTPase signaling is required for the initiation of polarized bud 
growth and this process is CDK1 dependent (Butty et al., 2002; Gulli et al., 2000; 
Lew and Reed, 1993; Moffat and Andrews, 2004). Cdc42 is instrumental in 
polarized bud emergence in G1 (Adams et al., 1990) and polarized localization of 
exocyst components Sec4 and Sec15 (Zajac et al., 2005). Cdc42 needs Cdc24-
GEF for activation and inhibition of Cdc24 during bud emergence stops polarized 
growth (Sloat et al., 1981; Sloat and Pringle, 1978). Cdc24 was found to be 
associated with many other polarity-related proteins such as Bem1, Rga2, Boi1, 
Boi2 (McCusker et al., 2007). Therefore, it appears that bud emergence requires 
a large complex containing a GEF, a GAP and a scaffold protein for Cdc42 along 
with some other proteins needed for actin polarization. Many of these proteins 
associated with Cdc24, including itself, get hyperphosphorylated at the time of 
bud emergence (G1/S boundary). The authors went on to further show that these 
proteins are specific targets of the Cln2-CDK and not Clb2-CDK1 (McCusker et 
al., 2007). Interestingly, all of these proteins contain multiple CDK sites and it 
was shown that Cln2-CDK1 mediated multi-phosphorylation of Boi1 is important 
for maintaining proper polarized bud morphogenesis (McCusker et al., 2007).  
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Inhibition of pheromone signaling: The pheromone-responsive mating pathway 
inhibits entry into the cell cycle by activating a CKI protein, Far1 (discussed in 
detail later and in Chapter 4).  In turn, the mating pathway is itself inhibited by the 
cell cycle, such that pheromone signaling is prevented in cells that have already 
passed Start (Oehlen and Cross, 1994; Oehlen et al., 1998), which ensures that 
the cell does not commit to differentiate and divide at the same time. This 
inhibition is mediated by the G1/S cyclin-CDK complexes, but not by CDK 
complexes from S or M phases. There are two ways in which G1/S cyclin-CDKs 
influence the mating pathway. Firstly Cln2-CDK1 promotes the degradation of 
Far1 as the cells enter G1 (Henchoz et al., 1997; McKinney et al., 1993). 
Secondly Cln2-CDK1 inhibits the membrane localization of an essential pathway 
component, the MAPK scaffold protein Ste5 (Bhattacharyya et al., 2006; Winters 
and Pryciak, 2005). Cln1/2-CDK1 but not other forms of CDK1, phosphorylates 
the eight CDK sites flanking a membrane localization domain in Ste5. This 
inhibits the membrane binding of the scaffold protein Ste5 and as a 
result MAPK signal propagation is stopped (Strickfaden et al., 2007). 
Interestingly, all of these CDK sites are of the minimal consensus category and 
Ste5 has a Cln1/2 specific docking motif (Bhaduri and Pryciak, 2011). This 
mechanism ensures that once proper CDK activity levels are reached, 
pheromone response is inhibited so that DNA replication can proceed without 
hindrance. 
Pheromone signaling can antagonize G1/S cyclin-CDK activity through the CKI 
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Far1, if cells get exposed to pheromone early on in G1. The molecular 
mechanism behind Far1’s inhibition of Cln-CDK activity has been a matter of 
ambiguity because while some early reports showed Far1 as a CKI, later studies 
failed to confirm that observation (Gartner et al., 1998; Peter and Herskowitz, 
1994). Recent work from our group (Pope et al., 2014) has given the first direct in 
vivo evidence that Far1 can inhibit Cln2-CDK phosphorylation of Ste5. At least 
part of this mechanism is inhibiting the substrate binding of Cln2, but there is 
another component of it, which probably affects the activity of the CDK directly 
(more details later and in Chapter 4) 
 
The two models for regulation of CDK activity during the cell cycle 
 
There are two leading models to explain how different cell cycle events are 
triggered at different cell cycle stages.  One posits different threshold levels of 
cyclin-CDK activity (the quantitative model), and the other relies on different 
substrate specificities of different cyclin-CDK complexes (the qualitative model). 
Studies on the main mitotic cyclin in fission yeast, Cdc13, led early researchers 
to propose a quantitative model for CDK activity (Fisher and Nurse, 1996). This 
model stated that low levels of CDK activity is enough to take the cell through the 
S phase (DNA replication) but is not enough to promote mitosis. Later, CDK 
activity rises and that, besides promoting mitosis, also prevents re-replication. 
After mitosis, CDK activity again subsides and the cell gets ready for the next 
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division cycle. Among other things, this model requires S phase and M phase 
substrates to respond to different thresholds of CDK activity (namely mitotic 
substrates will get phosphorylated only by high CDK activity while S phase 
substrates respond to low CDK activity) (Fisher et al., 2012; Stern and Nurse, 
1996; Uhlmann et al., 2011). In support of this model, it has been shown that 
fission yeast cells lacking three important G1 and S phase cyclins (Puc1, Cig1 & 
Cig2) are still viable (Martin-Castellanos et al., 2000). More recent work, using an 
engineered cyclin-CDK fusion protein regulated by different doses of an inhibitor, 
demonstrated that a fission yeast cell cycle can be driven by a single cyclin-CDK 
pair (Coudreuse and Nurse, 2010). Several other recent studies show different 
mitotic events require different levels of CDK1 activity. One study involving the 
mammalian cyclinB1-CDK1 pair showed that earlier mitotic events required less 
cyclinB1-CDK1 activity than later ones (Gavet and Pines, 2010). Also, in vitro 
studies confirmed that late mitotic substrates were phosphorylated by only high 
levels of cyclinB1-CDK1 activity (Deibler and Kirschner, 2010). Also budding 
yeast mitotic events like spindle formation and elongation require different levels 
of mitotic cyclin Clb2 (Oikonomou and Cross, 2011). In this dissertation (Chapter 
5) I will present evidence that S. pombe Cdc13 may belong to class of special 
cyclins which can activate the CDK1 kinase to unusually higher levels as 
compared to other B-type cyclins. 
Although it’s apparent that different cell-cycle events require different levels of 
CDK activity, this observation cannot explain all of the specificities in cyclin-CDK 
  
26 
function. For example, most organisms use, not only numerous cyclins, but also 
several CDKs for their cell cycle progression (Roberts, 1999). In budding yeast, 
the abundance of different cyclins is quite similar (Cross et al., 2002) thus hinting 
that there is not much change in net CDK1 activity from G1 to M phase. 
Therefore, there must be other mechanisms regulating substrate specificities of 
different cyclin-CDK complexes. In budding yeast, several cell-cycle events 
require a specific type of cyclin-CDK complex. For example, mitotic events 
cannot be driven by G1 cyclins and conversely B-type cyclins cannot drive the 
G1-specific transcriptional program (Nasmyth, 1996; Schwob and Nasmyth, 
1993). In fact mitotic cyclins could not even initiate replication properly unless 
overexpressed (Cross et al., 1999; Nasmyth, 1996). Also, the pheromone 
response pathway can only be inhibited by G1/S cyclin-CDK complexes (Oehlen 
et al., 1998). This distinction between G1 and B-type cyclins is likely to be true 
even for fission yeast, as the absence of the major G1 cyclin, Puc1, causes a cell 
cycle delay in G1 (Martin-Castellanos et al., 2000). So the quantitative model 
only pertains to B-type cyclins. A thorough quantitative comparison of activity and 
substrate specificity between budding yeast S phase Clb5-CDK1 with M phase 
Clb2-CDK1 complexes showed that even though Clb2 modulates the CDK1 
active site towards higher activity than Clb5, some substrates are still more 
specific towards Clb5-CDK1 (Loog and Morgan, 2005). The intrinsic activity of S 
phase Clb5-CDK1 is low and hence it phosphorylates several mitotic substrates 
poorly but for some S phase substrates, this low intrinsic activity is compensated 
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by a cyclin-specific docking interaction with the substrates. Conversely, although, 
Clb2-CDK1 activity is intrinsically high, allowing broader range of substrate 
selection in mitosis, lack of substrate docking renders it ineffective on several S 
phase substrates. More recent work has further advanced this model to include 
that the two methods of substrate targeting changes reciprocally during cell cycle 
progression (Koivomagi et al., 2011a; Koivomagi et al., 2011b). In this in vitro 
study, the authors showed, as the cell cycle progresses, the intrinsic activity of 
each successive cyclin-CDK pair increases but substrate-specific binding 
decreases. So this new data supports the quantitative model of CDK activity 
while incorporating the fact that several cell cycle events require cyclin-specific 
substrate targeting which compensates for low intrinsic CDK activity of early 
cyclin-CDK complexes (key aspects of the qualitative model). Work to be 
presented later in this dissertation will further bolster the cyclin-specificity model 
with respect to a different class of cyclins, namely the G1/S cyclins Cln1 and 
Cln2 (Bhaduri and Pryciak, 2011). In vivo evidence will be presented to advance 
the claim that some substrates are specific to the Cln1/2-CDK1 complexes 
because they have Cln1/2 specific docking motifs (Chapter 2). 
 
Mechanisms of substrate specificity of CDK complexes 
 
In spite of the wide functional redundancy within distinct subclasses of cyclins 
and CDKs, there are many examples of cyclin specific behavior during the cell 
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cycle. In budding yeast, pheromone response can be inhibited only by Cln1/2-
CDK complexes and not by Clb5-CDK or even Cln3-CDK (Oehlen and Cross, 
1994). Four G1 cyclin-CDK complexes, namely Cln1/2-CDK1 and Pcl1/2-PHO85, 
together share an essential function of initiating polarized bud morphogenesis 
and deletion of all of these four cyclins causes inviability which cannot be 
rescued by Cln3 or the Clbs (Moffat and Andrews, 2004). The mitotic Clb2-CDK1 
complex in yeast cannot trigger the expression of the G1/S regulon, normally 
turned on by Cln3-CDK1. Instead Clb2-CDK1 can repress the expression of 
those genes (Amon et al., 1993). Also, Cln1/2-CDK1 promotes polarized bud 
growth whereas Clbs, especially Clb2-CDK1 promotes isotropic bud growth (Lew 
and Reed, 1993). From several studies in budding yeast, it was clear that Cln3 
and Cln1/2 promote the entry into cell cycle through different mechanisms: Cln3 
turns on the massive G1 transcriptional program (Dirick and Nasmyth, 1991; 
Koch and Nasmyth, 1994; Stuart and Wittenberg, 1995), whereas Cln2 promotes 
additional G1 events like bud morphogenesis and activation of Clb-CDK 
complexes (Benton et al., 1993; Cvrckova and Nasmyth, 1993; Lew and Reed, 
1993). Then, by putting Cln2 under control of the Cln3 promoter, a subsequent 
study (Levine et al., 1996) showed that Cln2 and Cln3 still differed in their ability 
to promote viability in certain genetic backgrounds although this study did not 
take into account different post-translational regulation of cyclins. This clearly 
showed that the difference between Cln2 and Cln3 is not simply due to their 
difference in the timing of expression and of expression levels. Budding yeast 
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mitotic cyclin, Clb2, expressed from Clb5 promoter, is not as potent as Clb5 in 
promoting the onset of DNA replication (Cross et al., 1999) and conversely, a 
proteolysis-resistant Clb5 is unable to inhibit mitotic exit when overexpressed, 
unlike a similar Clb2 allele (Jacobson et al., 2000). Similarly, in metazoans, cyclin 
D2 and D3 can prevent differentiation of 32D myeloid cells when stimulated by 
granulocycle colony-stimulating factor but cyclin D1 is unable to do this job (Kato 
and Sherr, 1993). In mice, replacing cyclin D1 coding sequence with cyclin E, 
resulted in normal cell cycle progression, but a detailed investigation found that 
cyclin E failed to fully recapitulate cyclin D1 specific events like Rb 
phosphorylation, but instead bypassed the need for cyclin D1 whose main job is 
to promote cyclin E-CDK2 activity (Geng et al., 1999).  
 
Cyclin-CDKs employ several different mechanisms to specifically select their 
substrates. The very first selection happens at the level of the CDK active site. In 
order to get phosphorylated by CDK, a substrate has to have either a full 
consensus sequence (S/T-P-x-R/K) or at least a minimal consensus sequence 
(S/T-P) (Beaudette et al., 1993; Nigg, 1993a, b; Songyang et al., 1994). In a 
crystal structure of metazoan cyclinA with CDK2, a substrate-derived peptide 
containing the consensus site is shown to present the consensus residues to the 
active site of the CDK, with no direct contact with cyclinA (Brown et al., 1999). 
Interestingly, in most cases, CDK phosphorylation sites are located in poorly 
conserved and intrinsically disordered part of the substrates (Holt et al., 2009; 
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Moses et al., 2007a; Moses et al., 2007b). One recent study in budding yeast has 
shown that different cyclins can, however, activate the same CDK1 holoenzyme 
to different extents, thereby altering the substrate specificity at the active site of 
the CDK (Koivomagi et al., 2011b). Mechanisms controlling this effect on activity 
are not well understood but may involve different modulations of the enzymatic 
efficiency of the CDK active site by different cyclins as observed for mammalian 
cyclins B1 and A2 with CDK2 (Brown et al., 2007). 
 
Not only can cyclins indirectly influence CDK’s substrate specificity, but they can 
also perform a more direct role in choosing substrates. Many B-type cyclins 
contain a hydrophobic patch (hp) composed of some version of a Met-Arg-Ala-
Ile-Leu (M-R-A-I-L) sequence that binds to a Arg-x-Leu-Ф or Arg-x-Leu-x 
Ф (where x is any amino acid and Ф is large hydrophobic amino acid) motif, 
commonly referred to as the RxL motif (Adams et al., 1996; Cross and Jacobson, 
2000; Kelly et al., 1998; Schulman et al., 1998). The RxL docking site has a 
dramatic impact on the efficiency of phosphorylation of a substrate by some 
cyclin-CDK complexes while not by others (Schulman et al., 1998; Takeda et al., 
2001; Ubersax and Ferrell, 2007). One study found that the RxL motif increased 
the catalytic efficiency of phosphorylation at a minimal consensus (simply S/T-P) 
site, but did not affect the full consensus site much (Stevenson-Lindert et al., 
2003). This suggests that suboptimal phosphorylation sites coupled with a cyclin 
specific docking motif can be a method for promoting substrate selectivity of CDK 
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complexes. Suboptimal sites will ensure that the phosphorylation site is not 
favored by any of the CDK forms while a cyclin specific docking motif may 
increase the local concentration of a particular form of the CDK around the 
substrate, enough to favor even a slow reaction at the CDK active site. Using 
linkers of varying length between the RxL motif and the CDK sies, one study 
suggested that both regions must be simultaneously bound to the cyclin-CDK to 
maximize the phosphorylation of a substrate (Takeda et al., 2001). The structure 
of mammalian cyclin A-CDK2 with the CKI p27Kip1 and a peptide for the 
transcription factor p107, show that the RxL docking site binds to a surface 
exposed hydrophobic patch (hp) on the cyclin (Brown et al., 1999). This hp site is 
conserved in all cyclins A, B, D, E, in higher eukaryotes and in S-phase cyclins 
(Clb5/6) in budding yeast (Brown et al., 1999; Cross and Jacobson, 2000; Cross 
et al., 1999). Mutating the hp region disrupts function in vivo and reduces 
enzymatic activity on RxL containing substrates in vitro (Adams et al., 1996; Loog 
and Morgan, 2005; Schulman et al., 1998). In yeast, the S-phase cyclin Clb5 
interacts with a number of substrates in an hp dependent manner (Archambault 
et al., 2005; Wilmes et al., 2004). On the contrary, budding yeast mitotic cyclins 
Clb1 and Clb2 do not seem to depend so much on their hydrophobic patch (Loog 
and Morgan, 2005) in choosing substrates and at the sequence level, the hp 
region of Clb1/2 looks different than the hp regions of other B-type cyclins 
(Archambault et al., 2005), although it may be involved in interacting with the 
Swe1 kinase which is both a substrate and a regulator of Clb2 (Asano et al., 
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2005; Harvey et al., 2005; Hu and Aparicio, 2005; Hu et al., 2008; Keaton et al., 
2007). Recent work on budding yeasts G1/S cyclins, show that they too contain a 
region which can interact with LLPP type hydrophobic sequences in certain 
substrates (Bhaduri and Pryciak, 2011; Koivomagi et al., 2011a; Koivomagi et al., 
2011b) and we will present evidence in this dissertation that the substrate-
binding region in G1/S cyclin Cln2 is close to but not same as the MRAIL region 
in B-type cyclins (Chapter 3). 
 
The substrate specificity of different cyclin-CDK complexes are also regulated 
through differential localizations of cyclins (Pines, 1999). Localizations of cyclins 
to particular compartments may help control their access to both substrates and 
regulators, and thereby affect their functions. For example, mammalian cyclins 
B1 and B2 localize to microtubules and the Golgi apparatus, respectively. At the 
microtubule, cyclin B1 reorganizes nuclear, cytoskeletal and membrane 
compartments whereas cyclin B2 helps disassemble the Golgi apparatus. By 
making chimeras between cyclin B1 and B2, it was possible to switch their roles 
(Draviam et al., 2001). In budding yeast, G1 cyclin Cln3 is primarily nuclear and it 
correlates well with its role of phosphorylation of the transcriptional repressor 
Whi5. Forcibly excluding Cln3 from the nucleus makes Cln3-CDK1 largely 
nonfunctional in this capacity. Likewise, most of Cln2’s functions correlate well 
with its largely cyctoplasmic and bud tip localization pattern. However, restricting 
Cln2 solely to the cytoplasmic compartment compromises some of its functions, 
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thus suggesting that Cln2 also has an important nuclear role. Quite interestingly, 
targeting Cln3 to the cytoplasm gives it a limited ability to carry out some of the 
cytoplasmic roles of Cln2. For example, cytoplasmically targeted Cln3, but not 
wild type Cln3, can somewhat rescue a cln1Δcln2Δpcl1Δpcl2Δ cell, which is 
inviable (Edgington and Futcher, 2001; Miller and Cross, 2000, 2001a, b). These 
results demonstrate that cyclin localization can control its substrate specificity. 
There are numerous other examples of how in vivo functions of cyclins are 
controlled by their subcellular localizations (Baldin et al., 1993; Cardoso et al., 
1993; Diehl and Sherr, 1997; Hagting et al., 1998; Hood et al., 2001; Knoblich et 
al., 1994; Lukas et al., 1994; Maridor et al., 1993; Ohtsubo et al., 1995; Pines 
and Hunter, 1991).  
 
Of course, apart from the above-mentioned mechanisms, the ability of individual 
cyclin-CDK complexes to act on particular substrates is also influenced by their 
patterns of expression; i.e., whether they are co-expressed at the same cell cycle 
stage, versus at non-overlapping stages, and their different susceptibility to 
activating or inhibiting factors (Bloom and Cross, 2007).   
 
Inhibition of CDKs by CKIs 
 
CDK inhibitors play a very important role in regulating the activity of various 
cyclin-CDK complexes. In mammalian cells there are two different families, the 
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INK4 family that inhibits CDK4/6 (Guan et al., 1994; Hannon and Beach, 1994; 
Hirai et al., 1995; Serrano et al., 1993; Sherr and Roberts, 1999) and the Cip/Kip 
family that inhibits mainly G1 and S phase cyclin-CDK complexes (el-Deiry et al., 
1994; Harper et al., 1993; Polyak et al., 1994a; Polyak et al., 1994b; Toyoshima 
and Hunter, 1994; Xiong et al., 1993). INK4 proteins make heterodimers with 
CDK4/6 and force the CDK to assume a conformation where it can no longer 
bind the cyclin and hence becomes inactive (Brotherton et al., 1998; Russo et al., 
1998). Cip/Kip family of CKIs can engage both the cyclin and the CDK subunit 
(Chen et al., 1995; Luo et al., 1995; Nakanishi et al., 1995) to bring about 
effective inhibition. In fact the crystal structure of mammalian cyclin A-CDK2 with 
the CKI p27Kip showed that p27 engaged the cyclin A hydrophobic patch region 
by presenting a LFG motif and the CDK active site was engaged by a region in 
p27 that mimicked the interactions of the ATP (Russo et al., 1996). A member of 
the same family, p21, has been shown to inhibit cyclinB-CDK1 under 
special circumstances (Charrier-Savournin et al., 2004; Satyanarayana et al., 
2008). 
 
In budding yeast there are three known CDK1 inhibitors, which regulate different 
stages of the cell cycle. One of them, Sic1, inhibits mainly S phase cyclin Clb5/6-
CDK1 complexes and regulates the commitment step of the cell cycle (Yang et 
al., 2013) (discussed above) and another one, Cdc6, likely inhibits mitotic cyclin-
CDK1 complexes when overexpressed and helps regulate mitotic exit 
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(Archambault et al., 2003; Bueno and Russell, 1992; Calzada et al., 2001; 
Elsasser et al., 1996). A third CKI in budding yeast, Far1, is mainly involved in 
regulating the mating pathway and is important for pheromone-induced arrest of 
cell cycle at G1 (Chang and Herskowitz, 1990). Far1 inhibits the Cln1/2-CDK1 
complexes (Peter and Herskowitz, 1994) but not others (Chapter 4).  
 
Focus of this dissertation 
 
This dissertation focuses on the mechanism of the substrate specificity of 
budding yeast G1/S cyclin-CDK complexes, the Cln1/2-CDK1 complexes. In 
Chapter 2, we will present evidence that several CDK1 substrates contain a 
particular type of docking motif that can only bind to Cln1/2 and not other yeast 
cyclins. This results in high cyclin specificity during the early cell cycle. One can 
switch the cyclin specificity simply by switching the docking motif. In Chapter 3, 
we show that Cln2 contains a highly conserved substrate-docking motif, which is 
close to, but in a different region than, the hydrophobic patch region found in 
most B-type cyclins. Mutating this patch in Cln2 has a variety of negative effects 
on cell cycle progression, the major effect being the significant increase in cell 
size at the time of commitment to a new cell cycle (Whi5 export, budding and 
DNA replication). In Chapter 4, we will elucidate the mechanism of action of the 
CKI Far1. Our results indicate that Far1 inhibits Cln2-CDK1 complex partially by 
inhibiting Cln2’s substrate binding and partially by inhibiting the activity of the 
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complex. In Chapter 5, we show that this method of substrate recognition is 
highly conserved in G1 cyclins of several fungal species as distant as molds and 
mushrooms and that some of this fungal cyclins have evolved to have unusually 
high potency, which may give them ability to regulate cell cycle events differently.  
  
  
37 
CHAPTER II 
Cyclin-specific docking motifs promote phosphorylation of 
yeast signaling proteins by G1/S CDK complexes 
 
 
The following Chapter contains the manuscript: 
 
Bhaduri, S. & Pryciak, P. M. (2011). Cyclin-specific docking motifs promote 
phosphorylation of yeast signaling proteins by G1/S CDK complexes. Current 
Biology, 21(19), 1615-1623 (selected amongst the top 25 Hottest Articles in 
Current Biology between October to December 2011) [PMID: 23817205] 
 
 
I solely performed all experiments presented. The manuscript was prepared by 
myself and Dr. Peter Pryciak. 
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Abstract 
 
The eukaryotic cell cycle begins with a burst of CDK phosphorylation.  In budding 
yeast, several CDK substrates are preferentially phosphorylated at the G1/S 
transition rather than later in the cell cycle when CDK activity levels are high.  
These early CDK substrates include signaling proteins in the pheromone 
response pathway.  Two such proteins, Ste5 and Ste20, are phosphorylated only 
when CDK is associated with the G1/S cyclins Cln1 and Cln2, and not G1, S, or 
M cyclins.  The basis of this cyclin specificity is unknown.   
Here we show that Ste5 and Ste20 have recognition sequences, or “docking” 
sites, for the G1/S cyclins.  These docking sites, which are distinct from 
Clb5/cyclin A-binding “RxL” motifs, bind preferentially to Cln2 and Cln1.  They 
strongly enhance Cln2-driven phosphorylation of each substrate in vivo, and 
function largely independent of position and distance to the CDK sites.  We 
exploited this functional independence to re-wire a CDK regulatory circuit in a 
way that changes the target of CDK inhibition in the pheromone response 
pathway.  Furthermore, we uncover functionally active Cln2 docking motifs in 
several other CDK substrates.  The docking motifs drive cyclin-specific 
phosphorylation, and the cyclin preference can be switched by using a distinct 
motif. 
Our findings indicate that some CDK substrates are intrinsically capable of being 
phosphorylated by several different cyclin-CDK forms, but they are inefficiently 
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phosphorylated in vivo without a cyclin-specific docking site.  Docking 
interactions may play a prevalent but previously unappreciated role in driving 
phosphorylation of select CDK substrates preferentially at the G1/S transition. 
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INTRODUCTION 
 
Cyclin-dependent kinases (CDKs) are central regulatory enzymes of the 
eukaryotic cell cycle (Morgan, 2007).  In most eukaryotes, different CDK forms 
are specialized for driving distinct events in the cell cycle.  In metazoans, these 
forms can differ in both the cyclin subunit and the CDK enzyme.  In simpler 
eukaryotes such as yeasts, a single CDK enzyme associates with multiple 
different cyclins, which impart different functional properties to the cyclin-CDK 
complex.  The ways in which the cyclin affects these properties are understood 
partly though still incompletely.  For example, cyclins can affect the specific 
activity of the CDK enzyme, the interaction with particular substrates, or the 
targeting to distinct subcellular locations (Bloom and Cross, 2007; Ubersax and 
Ferrell, 2007). 
 
In the budding yeast Saccharomyces cerevisiae, a single CDK protein 
(Cdc28) associates with nine different cyclins (Bloom and Cross, 2007; Enserink 
and Kolodner, 2010).  Six B-type cyclins (Clb1-Clb6) drive DNA synthesis and 
mitosis (S and M phases), whereas the transition from G1 to S phase is driven by 
the G1 cyclin Cln3 and the G1/S cyclins Cln1 and Cln2.  Although there is 
functional overlap, these various cyclins are clearly specialized for optimum 
performance of discrete tasks.  Even the three semi-redundant Cln proteins show 
functional distinctions, as cln3∆ and cln1∆ cln2∆ cells each display unique 
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phenotypic defects (Cross, 1988; Moffat and Andrews, 2004; Nash et al., 1988; 
Skotheim et al., 2008).  Interestingly, there are several CDK substrates whose 
phosphorylation peaks during maximum expression of Cln1/2 (McCusker et al., 
2007; Oehlen and Cross, 1998; Strickfaden et al., 2007; Wu et al., 1998), and it 
is not clear why later cyclins are less effective; e.g., despite the fact that the M-
phase cyclin Clb2 confers especially strong CDK activity (Loog and Morgan, 
2005), some substrates are phosphorylated more readily by Cln2-Cdc28 than by 
Clb2-Cdc28.  To date, no molecular mechanism explains why any particular 
substrate is preferentially phosphorylated in a Cln1/2-specific manner. 
 
Cln1/2-specific substrates include proteins in the pheromone response 
pathway.  This signaling pathway triggers a G1 phase arrest that synchronizes 
cells prior to mating (Bardwell, 2005; Dohlman and Thorner, 2001).  In cells that 
have already begun the cell cycle, this pathway is transiently inactivated so that 
cell division can conclude (Oehlen and Cross, 1994; Wassmann and Ammerer, 
1997).  Three proteins in this pathway are phosphorylated at the G1/S transition: 
Far1 (a CDK inhibitor protein), Ste20 (a PAK-family kinase), and Ste5 (a MAP 
kinase cascade scaffold protein) (McKinney et al., 1993; Oehlen and Cross, 
1998; Strickfaden et al., 2007; Wu et al., 1998).  While the role of Ste20 
phosphorylation remains unknown (Oda et al., 1999), CDK phosphorylation of 
Far1 and Ste5 inactivates the cell cycle arrest and signal transduction functions 
of the pheromone pathway, respectively (Henchoz et al., 1997; McKinney et al., 
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1993; Strickfaden et al., 2007).  Notably, Ste20 and Ste5 are Cln1/2-specific 
substrates (Oehlen and Cross, 1998; Strickfaden et al., 2007; Wu et al., 1998), 
but the mechanistic basis of this specificity is unknown. S-phase cyclins such as 
mammalian cyclin A and yeast Clb5 have a “hydrophobic patch” that allows them 
to recognize specific “RxL” motifs in some substrates (Cheng et al., 2006; 
Schulman et al., 1998; Wilmes et al., 2004).  Some related examples exist for 
other cyclins (Dowdy et al., 1993; Kelly et al., 1998), but not for the yeast G1 or 
G1/S cyclins. Moreover, as with many CDK substrates, Ste20 and Ste5 are each 
phosphorylated at a large number of sites, and this can be important for proper 
regulation (Strickfaden et al., 2007). 
 
In this study we probe the molecular basis of cyclin specificity during G1/S 
CDK phosphorylation in vivo.  We find that both Ste5 and Ste20 have specific 
recognition sequences, or “docking” sites, that interact preferentially with the 
cyclin Cln2.  In each protein, the docking sites promote efficient phosphorylation 
of CDK sites, and they do so in a cyclin-specific manner.  Furthermore, these 
docking sites function largely irrespective of distance or orientation relative to the 
phosphorylation sites, and they are interchangeable between substrates.  We 
identify functionally similar behavior for motifs in several other CDK substrates, 
suggesting that these docking sites may represent the first of many previously 
unrecognized recognition sequences for the G1 or G1/S cyclins in yeast. 
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RESULTS 
 
Cyclin-specific phosphorylation of Ste5 and Ste20.   
Pheromone responsiveness rises and falls in opposition to the periodic 
fluctuations in Cln1/2 levels (Oehlen and Cross, 1994; Wassmann and Ammerer, 
1997).  Similarly, both Ste20 and Ste5 are phosphorylated in a periodic pattern 
dependent on Cln1/2 cyclins (Oehlen and Cross, 1998; Strickfaden et al., 2007; 
Wu et al., 1998).  To investigate the basis of this cyclin specificity, we asked if it 
is an intrinsic feature of the CDK phosphorylation sites themselves or if it involves 
other structural or functional features of each substrate protein.  Ste5 and Ste20 
are large, multi-domain proteins (>900 residues) that can be roughly divided into 
N-terminal regulatory/localization regions and C-terminal catalytic/signaling 
regions (Figure 2.1A).  In each case the CDK sites are concentrated in the N-
terminal regions.  Using N-terminal fragments of each protein (Ste51-370, Ste51-337, 
Ste2080-590) as substrates, we found that cyclin specificity was maintained.  First, 
their phosphorylation in synchronous cultures peaked at the G1/S boundary (bud 
emergence; Figure 2.1B) instead of at times when the M-phase cyclin Clb2 was 
maximal.  Second, when using the inducible GAL1 promoter (PGAL1) to drive 
expression of various cyclins, phosphorylation of the Ste5 and Ste20 fragments 
was observed only with Cln1 and Cln2, and not with Cln3, Clb5, or Clb2 (Figure 
2.1C).  (Although unequal levels of cyclins could contribute to these differences, 
Clb2 was able to drive phosphorylation of the CDK substrate Swe1 [Figure 2.1C] 
(Harvey et al., 2005), and later results will show activity for both Clb5 and Clb2 in  
  
44 
Figure 2.1.  Cyclin specific phosphorylation of Ste5 and Ste20 regulatory 
domains 
(A) Domain structures of Ste5 and Ste20.  Red circles indicate CDK sites (Oda et 
al., 1999; Strickfaden et al., 2007); in Ste20, only the 13 confirmed sites (of 23 
possible) are shown. 
(B) Phosphorylation of Ste5 and Ste20 fragments in synchronous cdc15-2 
cultures, after release from M phase arrest.  Full-length Ste20 is shown for 
comparison; its phosphorylation behavior was described previously (Oehlen and 
Cross, 1998; Wu et al., 1998). Cell cycle progression was monitored by anti-Clb2 
immunoblot and by budding; representative examples are shown. 
(C) HA-tagged Ste5 or V5-tagged Ste20 fragments, expressed from native 
promoters, were monitored after galactose-induced expression of GST-tagged 
cyclins.  Reduced electrophoretic mobility signifies phosphorylation, as confirmed 
by phosphatase treatment (Appendix Figure 1).  For comparison, V5-tagged 
Swe1 demonstrates activity for Clb2.  The relative expression levels for GST-
cyclins were highly reproducible; one representative example is shown.  A variant 
of Cln3 lacking ten CDK sites (Cln310A) was used to increase its stability.  Results 
were similar in sic1∆ cells (Appendix Figure 2), in which the Clb-CDK inhibitor 
Sic1 is absent.  
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Figure 2.1.  Cyclin specific phosphorylation of Ste5 and Ste20 regulatory 
domains               
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similar assays). Thus, stage-specific and cyclin-specific phosphorylation of Ste5 
and Ste20 does not require their signaling functions, and the determinants of 
specificity must lie within their N-terminal fragments.  
 
A distal recognition sequence promotes CDK phosphorylation of the Ste5 
N-terminus.   
We used the Ste51-337 fragment to study the requirements for phosphorylation by 
Cln2-Cdc28.  As expected, phosphorylation required the same 8 CDK sites 
shown previously to regulate full-length Ste5 (Figure 2.2B) (Strickfaden et al., 
2007).  Nevertheless, these sites were not sufficient to ensure efficient 
phosphorylation.  By making further truncations, we discovered that 
phosphorylation required a short stretch of sequence (276-283) far away from the 
CDK sites (Figure 2.2B).  Similarly, alanine replacement of four residues within 
this region (LLPP) also disrupted phosphorylation (Figure 2.2B).  In contrast, 
internal deletions showed that several other large segments of the Ste5 N-
terminus were dispensable (Figure 2.2B).  We conclude that efficient Cln2-Cdc28 
phosphorylation of Ste5 requires specific sequences that are separate from the 
phosphorylation sites themselves.  For now we tentatively refer to this required 
region as a Cln2 docking site. 
This putative Cln2 docking site lies within a larger inter-domain region of Ste5 
with several notable features (Figure 2.3A), including: (i) a MAPK binding site; (ii) 
four MAPK phosphorylation sites, which possibly could also act as CDK sites due 
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Figure 2.2.  A distal docking motif promotes Cln2-Cdc28 phosphorylation of 
Ste5 
(A) Locations of key Ste5 features and mutations.  Residues 275-283 contain the 
putative Cln2 docking motif required for efficient phosphorylation of the N-
terminal CDK sites.  Mutations used in later panels are indicated; see Figure 
2.3A for details. 
(B) Phosphorylation of the Ste5 N-terminus (Ste51-337) requires both the CDK 
sites and a distal LLPP motif between residues 275 and 283. Phosphorylation 
was triggered by galactose-induced expression of a PGAL1-CLN2 construct (+) or 
a vector control (-). 
(C) The role of the LLPP motif is independent of MAPKs (fus3∆ kss1∆), the 
phosphatase Ptc1 (ptc1∆), and the MAPK binding site (ND mutant).  Results 
show the Ste51-337 fragment except as indicated otherwise. The fus3∆ kss1∆ 
strain (PPY1173) was tested in parallel with a congenic wild-type strain 
(PPY640).  LLPP function also does not require the MAPK phosphorylation sites, 
but non-phosphorylatable mutations at these sites (4AV) mildly reduce the extent 
of Cln2-Cdc28 phosphorylation.  Also see Figure 2.3B,C. 
(D) Cln2-driven phosphorylation of full-length Ste5 (V5-tagged) requires the 
LLPP motif.  For the 8A lanes, a longer exposure (of the same blot) is shown to 
compensate for imperfect loading. 
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(E) Mutation of the LLPP motif disrupts the ability of Cln2 to inhibit pheromone 
signaling. Fus3 phosphorylation was monitored in ste5∆ fus3∆ kss1∆ strains (± 
PGAL1-CLN2) harboring STE5 variants and wild-type FUS3 on plasmids. 
(F) The LLPP motif mediates regulation by Cln2 in the absence of Fus3-Ste5 
binding (Ste5 ND mutant) and Fus3 kinase activity (fus3-K42R mutant). Strains 
(as in panel D) harbored plasmids with the indicated forms of STE5 and FUS3. 
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Figure 2.2.  A distal docking motif promotes Cln2-Cdc28 phosphorylation of 
Ste5 
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 to similar target sequences (i.e., SP/TP); and (iii) a binding site for the 
phosphatase Ptc1 (Bhattacharyya et al., 2006; Malleshaiah et al., 2010).  None 
of these features seemed crucial for docking site function.  MAPK binding played 
no evident role, as the results were unaffected by deleting MAPK genes (fus3∆ 
kss1∆) or by mutating the MAPK binding site (ND mutant) (Figure 2.2C, 2.3B).  
At the MAPK phosphorylation sites, phospho-mimetic mutations (4E) had no 
effect (Figure 2.2C), but non-phosphorylatable mutations (4AV) caused a mild 
reduction; thus, phosphorylation at one or more of these sites (e.g., by a MAPK 
or CDK) may enhance further CDK phosphorylation elsewhere, or the mutations 
may mildly disrupt recognition of the docking motif.  (All four MAPK sites cannot 
be required, because the shorter Ste51-283 fragment retains only two sites yet 
remains a good substrate; Figure 2.2B,C).  Finally, although the required LLPP 
motif overlaps a binding site for Ptc1 (Malleshaiah et al., 2010), it promoted CDK 
phosphorylation identically in ptc1∆ cells (Figure 2.2C, 2.3C).  Altogether, these 
data show that recognition of the putative Cln2 docking site can be separated 
from MAPK and Ptc1 binding, though it may be affected by either the sequence 
or phosphorylation status of adjacent SP/TP sites.  Furthermore, as with the N-
terminal fragments, the LLPP motif was also required for CDK phosphorylation of 
full-length Ste5 (Figure 2.2D). 
 
Next, we tested if the Cln2 docking site is required for CDK inhibition of Ste5 
signaling (Strickfaden et al., 2007).  Indeed, as with mutation of the CDK sites 
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Figure 2.3.  The Cln2 docking region in Ste5, and requirements for CDK 
phosphorylation and regulation 
(A) Expansion of Ste5 residues 258-337, highlighting the following features: (i) a 
MAPK binding site (denoted “K” in the schematic above); (ii) four MAPK 
phosphorylation sites; and (iii) a Ptc1 binding site.  Note that the putative Cln2 
docking motif identified in this study (LLPP) overlaps the sequence previously 
implicated in Ptc1 binding (Malleshaiah et al., 2010).  Also indicated are the 
mutations used in Figure 2.2.  The ND mutation disrupts MAPK binding 
(Bhattacharyya et al., 2006), while 4AV and 4E are non-phosphorylatable and 
phospho-mimetic mutations that also have opposing effects on MAPK binding 
(Malleshaiah et al., 2010). 
(B) The ND and ND/LLPP mutant results from Figure 2.2C are shown here in an 
expanded form that includes additional controls (wt and LLPP) run alongside on 
the same gel.  Also included on this gel were the wt vs. 8A mutant results that 
are shown in Figure 2.2B. 
(C) The results using the ptc1∆ mutant strain that are shown in Figure 2.2C are 
shown here in parallel with the same fragments analyzed in a wild type strain, 
conducted in parallel.  Note that both wild type and ptc1∆ strains show the same 
effects of both truncations (e.g., compare 1-315 vs. 1-275) and point mutations 
(e.g., compare wt vs. LLPP versions of 1-283).  Thus, despite its overlap with the 
Ptc1 binding site, the LLPP motif controls Cln2-Cdc28 phoshorylation 
independent of Ptc1. 
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(D) The ability of PGAL1-CLN2 to inhibit pheromone response is disrupted in a 
synergistic way by Ste5 mutations in the LLPP motif and the MAPK binding site 
(ND). These experiments are related to Figure 2.2E-F, but here pheromone 
response was measured using a transcriptional reporter (FUS1-lacZ) in either 
FUS3 KSS1 strains or fus3∆ kss1∆ strains with a FUS3-wt plasmid (as in Figure 
2.2E-F).  Bars, mean ± SD (n = 8 [top] or 3 [others]).  As shown in Figure 2.2F, 
when the kinase activity of Fus3 is eliminated, the ability of Cln2 to inhibit 
pheromone response is fully dependent on the LLPP motif.  But when Fus3 is 
active the behavior is more complex. This is likely because the LLPP motif also 
binds Ptc1, which antagonizes Ste5-Fus3 association and limits Fus3 mediated 
negative feedback (Malleshaiah et al., 2010). Consequently, while the LLPP 
mutation disrupts inhibition by Cln2, it simultaneously increases Fus3-Ste5 
binding and inhibition, which may have a compensatory effect. Hence, the impact 
of the LLPP mutation on regulation by Cln2 is most clearly revealed in three 
distinct settings: (i) immediately after pheromone stimulation, before negative 
feedback kicks in (Figure 2.2E); (ii) when using a kinase-dead form of Fus3 
(Figure 2.2F); and (iii) when using the ND mutation to disrupt Fus3-Ste5 binding 
(Figure 2.2F and this Figure).  Finally, because the LLPP mutation seems more 
effective at restoring Fus3 phosphorylation than transcriptional induction, the 
transcriptional response may require sustained signaling or it may have a non-
linear dependence on Fus3 activation. 
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Figure 2.3.  The Cln2 docking region in Ste5, and requirements for CDK 
phosphorylation and regulation              
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(8A), mutation of the LLPP motif restored the ability of pheromone to activate the 
MAPK Fus3 in PGAL1-CLN2 cells (Figure 2.2E).  However, this restored activation 
was unusually transient, and the transcriptional response was only partially 
restored (Figure 2.3D).  This complex behavior likely reflects the additional role of 
the LLPP region in binding to Ptc1, which antagonizes the ability of Fus3 to bind 
Ste5 and down-regulate signaling (Malleshaiah et al., 2010).  That is, although 
the LLPP mutation disrupts Cln2 docking, it simultaneously leads to excessive 
binding and inhibition by Fus3, which may have a compensatory effect.  To 
eliminate contributions from Fus3, we used the Ste5 ND mutation to disrupt Fus3 
binding (Bhattacharyya et al., 2006), or a kinase-inactive form of Fus3 (K42R).  In 
these contexts, the LLPP mutation clearly blocked the inhibitory effect of Cln2 
(Figures 2.2F, 2.3D).  Therefore, the LLPP motif can mediate CDK inhibition in 
the absence of both Fus3 binding and kinase activity, whereas excess Fus3 
activity may obscure this role.  Although the overlap between Cln2 and Ptc1 sites 
creates an added layer of complexity, overall these results establish that CDK 
regulation of Ste5 involves both CDK phosphorylation sites and a separate Cln2 
docking motif. 
 
Cyclin-specific binding sites in Ste20 and Ste5. 
Efforts to test if Ste5 binds Cln2 were hampered by technical issues (e.g., non-
specific precipitation), but binding of Ste20 to Cln2 is readily detectable in cell 
extracts (Archambault et al., 2004; Oda et al., 1999). Therefore, we searched for 
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the responsible sequences in Ste20 using GST-Ste20 and Cln2-myc13 fusions.  
An N-terminal fragment (Ste201-333) was sufficient to bind Cln2, and this required 
residues 73-119 (Figure 2.4B).  The C-terminal end of this fragment, which 
harbors a membrane-binding “basic-rich” (BR) domain, was not required but it did 
enhance binding (Figure 2.5B); hence, further analyses kept the C-terminus fixed 
at position 333.  The required region (73-119) includes a conserved block of ~20 
residues (Figure 2.5C), and mutating consecutive sets of residues in this region 
revealed that an eight-residue stretch (SLDDPIQF) was critical for binding to 
Cln2 (Figure 2.4Ci).  We then asked if the role of this Ste20 motif could be 
replaced with a small fragment from Ste5 that harbors its putative Cln2 docking 
site.  Indeed, the Ste5 site mediated Cln2 binding, and this required the same 
LLPP sequence that promotes Ste5 phosphorylation (Figure 2.4Cii).  
Furthermore, each sequence preferentially bound to Cln2 over other cyclins 
(Figure 2.4D), and weakly to Cln1.  Collectively, these experiments identify 
docking sites in both Ste20 and Ste5 that can discriminate among different 
cyclins to mediate specific binding.  The two sites are not highly similar but each 
contains the motif LxxPΦxΦ (where Φ is hydrophobic), raising the possibility that 
a degenerate pattern of hydrophobic side chains forms the Cln2 recognition 
motif. 
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Figure 2.4.  Cyclin-specific binding by docking motifs in Ste20 and Ste5 
(A) The diagram indicates endpoints used for mapping the Cln2-binding region in 
Ste20, which is outlined in red. 
(B) Cells co-expressing GST fusions to Ste20 fragments and Cln2-myc13 were 
lysed, and complexes were recovered using glutathione sepharose.  Input (5%) 
and bound proteins were analyzed by anti-myc and anti-GST blots. 
(C) Starting with a Ste2072-333 fragment, alanine substitutions were made at 
blocks of residues in the 72-118 region (see Figure 2.5C; numbering starts at 2 
because additional flanking mutations were used in other assays). Cln2 binding 
was tested as in panel B. Separately, the required Ste20 region was replaced by 
a Ste5263-335 fragment (ii), in both wt and LLPP mutant forms, to test the ability of 
this Ste5 sequence to mediate Cln2 binding. 
(D) Ste20 and Ste5 docking sites show cyclin-specific binding. GST alone (-) or 
GST fusions (+) were used to co-precipitate myc13-tagged cyclins (expressed 
from the CYC1 promoter) in yeast lysates.  The GST fusions were to Ste201-333 
(Ste20 motif) or to the Ste5263-335-Ste20120-333 chimera used in panel Cii (Ste5 
motif).  Cln310A showed varying levels of non-specific precipitation but no 
reproducible binding to either GST fusion. 
(E) Cln2-induced phosphorylation was assayed for V5-tagged forms of full-length 
Ste20 (1-939) or N-terminal fragments (80-590, 80-500), with or without 
mutations in the docking site (mut3) or the 13 confirmed CDK sites (CDK*). 
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(F) The Cln2 docking site from Ste20 can drive phosphorylation of a 
heterologous substrate.  Phosphorylation was analyzed using Ste51-283 (i), Ste51-
260 (ii), and wt or mut3 versions of the Ste20 docking site (residues 80-115) fused 
to Ste51-260 (iii). 
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Figure 2.4.  Cyclin-specific binding by docking motifs in Ste20 and Ste5 
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The Cln2 docking site in Ste20 enhances phosphorylation. 
Ste20 contains 23 potential CDK sites, of which at least 13 are used in vivo (Oda 
et al., 1999).  To test if Cln2 docking affects Ste20 phosphorylation, we 
compared mutations in either the docking site (mut3) or the 13 confirmed CDK 
sites (CDK*), using full-length Ste20 and several N-terminal fragments (Figure 
2.4E).  In full-length Ste20 (1-939), the docking site mutation reduced the 
magnitude of the Cln2-induced mobility shift, but did not eliminate it (i.e., unlike 
the CDK* mutation).  This partial phenotype could signify less efficient use of all 
sites, or a specific defect at particular sites due to their position or sequence 
context; in this regard, it is noteworthy that 9 of the 13 confirmed CDK sites are 
“minimal” sites (S/T-P) whereas only 4 are “consensus” sites (S/T-P-x-K/R).  The 
docking site mutation again caused a partial phenotype for the largest N-terminal 
fragment (80-590), but it caused a strong disruptive phenotype for smaller 
fragments such as 80-500 (Figure 2.4E) and 80-333 (Appendix Figure 3).  While 
we did not parse these differences further, we note that the two smaller 
fragments retain only one consensus CDK site, raising the possibility that 
docking is especially important for phosphorylating minimal sites.  As a separate 
test of the activity of the Ste20 docking motif, we asked if it could substitute for 
the analogous site in Ste5.  Indeed, the Ste20 motif restored strong 
phosphorylation to the Ste51-260 fragment, and this activity was blocked by 
mutations that disrupt Cln2 binding (Figure 2.4Fiii).  Thus, the Ste20 docking 
motif can stimulate Cln2- Cdc28 phosphorylation of native sites in Ste20 or sites  
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Figure 2.5.  Ste20-Cln2 binding and conservation of the Cln2 docking site 
 
(A) Diagram of Ste20 showing the location of the Cln2 docking site outlined in 
red. 
(B) Effect of the Ste20 BR domain on binding between GST-Ste20 fragments 
and Cln2-myc13.  Binding assays were conducted as in Figure 2.4B.  The Ste201-
254 fragment lacks the BR domain, whereas the BR* derivative has mutations at 
eight basic residues that provide membrane affinity (Takahashi and Pryciak, 
2007).  Though the BR domain was not required for Cln2 binding, it did enhance 
both total binding and capture of the slowest migrating Cln2 species.  This could 
imply some subcellular segregation of different Cln2 phosphoisoforms, or that the 
polybasic BR domain contributes extra affinity for poly-phosphorylated forms of 
Cln2.  Hence, for simplicity, subsequent analyses kept the C-terminus fixed at 
position 333. 
(C) Conservation of sequences encompassing the Cln2 docking site.  The S. 
cerevisiae Ste20 sequence (at top) was aligned to orthologs from ten other 
yeasts.  Red and blue highlights indicate the most conserved residues.  At 
bottom are residues 80-109 (S. cerevisiae) with brackets indicating blocks of 
residues replaced with alanines, as used in Figures 2.4C and 2.6C. 
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Figure 2.5.  Ste20-Cln2 binding and conservation of the Cln2 docking site 
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in a heterologous substrate. 
 
Re-wiring a CDK regulatory circuit via a Ste20Ste5PM chimera. 
CDK phosphorylation of Ste5 serves to inhibit pheromone response at the G1/S 
transition (Strickfaden et al., 2007).  We wished to explore whether the 
responsible regulatory mechanism could be moved to other proteins, and 
whether such synthetic approaches (Lim, 2010; Pryciak, 2009) could help further 
probe the factors controlling CDK regulation.  Therefore, we attempted to transfer 
the regulatory effects of CDK phosphorylation from Ste5 onto Ste20.  Our 
rationale stems from the fact that each protein requires a short membrane-
binding motif for its plasma membrane localization and signaling activity 
(Takahashi and Pryciak, 2007; Winters et al., 2005), and the function of the Ste5 
motif, termed the PM domain, is inhibited by phosphorylation at adjacent CDK 
sites (Strickfaden et al., 2007).  Thus, we replaced the membrane-binding (BR) 
motif in Ste20 with Ste5 fragments that contain both the PM domain and its 
flanking CDK sites (Figure 2.6A), and then asked if Ste20 now could be inhibited 
by CDK phosphorylation.   
 
The Ste5 PM domain was a highly effective substitute for the Ste20 BR 
domain (Figure 2.6B), irrespective of the precise size of the transferred Ste5 
fragment.  As hypothesized, the function of these Ste20Ste5PM chimeras in the 
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Figure 2.6.  Re-wiring a CDK regulatory circuit with a Ste20Ste5PM chimera 
(A) The Ste20Ste5PM chimeras.  Ste20 residues 124-311, containing the 
membrane-binding BR domain, were replaced with three fragments from Ste5 
that include its membrane-binding PM domain plus 7 or 8 flanking CDK sites. 
(B) Pheromone signaling by Ste20Ste5PM chimeras is inhibited by Cln2.  Because 
Cln2-CDK normally inhibits signaling via Ste5, these tests used cells with a non-
phosphorylatable Ste5 variant (ste20∆ STE5-8A).  Wild-type Ste20 (wt) or 
Ste20Ste5PM chimeras (from panel A) were introduced on plasmids, and 
pheromone response was measured using a transcriptional reporter (FUS1-
lacZ).  Signaling by all three chimeras (#A, #B, #C) was inhibited by Cln2, but this 
was blocked by mutations in the CDK phosphorylation sites (7A, 8A).  Deletions 
of the Ste20 N-terminus, made in the #A chimera, show that residues 87-119 are 
required for regulation by Cln2.  Bars, mean ± SD (n = 3). 
(C) Sequences required for regulation by Cln2 were analyzed using a chimera 
similar to #A, containing only Ste20 residues 80-109 upstream of Ste5 1-85 (see 
Figure 2.7C).  Alanine mutations replaced eight blocks of residues (left) or 
individual residues in the SLDDPIQF motif (right).  These were compared to an 
un-mutated sequence (wt) and a chimera that lacks the sequence entirely (-).  
Signaling was assayed as in panel B.  Bars, mean ± SD (n = 3). 
(D) Docking sites from Ste20 (80-115) or Ste5 (257-330) were inserted at 
different positions (i-iv) into a variant of chimera #A that lacks residues 87-119 
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(see panel B).  Insertions at position ii also removed residues 1-86.  Signaling 
was assayed as above. Bars, mean ± SD (n = 3). 
(E) Bud tip localization of Ste20Ste5PM chimera in cycling cells is inhibited via the 
CDK sites (7A) and the Cln2 docking site (mut3).  Strain BY4741 harbored GFP-
Ste20 plasmids.  Representative images show unfixed cells (left); localization 
was quantified after formaldehyde fixation (right).  Bars, mean ± SD (n = 3 
experiments; >150 cells per allele per experiment). 
(F) The growth function of Ste20 is inhibited in the Ste20Ste5PM chimera, if CDK 
and docking sites are intact. Serial (1/5x) dilutions of strain KBY211 harboring the 
indicated Ste20 plasmids were spotted onto plates, and incubated at 25˚ or 36˚ C 
for 4 days. As a control, the ∆BR allele removes the BR domain in full-length 
Ste20 (Takahashi and Pryciak, 2007). 
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Figure 2.6.  Re-wiring a CDK regulatory circuit with a Ste20Ste5PM chimera 
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pheromone response pathway was inhibited by expression of Cln2 (Figure 2.6B). 
(Because Cln2 ordinarily inhibits pheromone response via Ste5, these assays 
used cells harboring a CDK-resistant derivative, Ste5-8A.)  Importantly, this 
inhibition specifically required intact CDK sites flanking the PM domain (Figure 
2.6B), despite the presence of other CDK sites elsewhere in Ste20.  Moreover, 
the inhibition was cyclin-specific and was not accompanied by any reduction in 
protein levels (Figures 2.7A,B).  Thus, these experiments show that the CDK 
regulatory target in the pheromone pathway can be switched to a different 
protein, and that the CDK-inhibited domain from Ste5 constitutes a portable 
regulatory module.  Furthermore, inhibition of the Ste20Ste5PM chimera required 
the region of Ste20 (residues 87-119) that contains its Cln2 docking site (Figure 
2.6B, right).  This finding establishes two further points: (i) the mere presence of 
CDK sites in the transferred Ste5 fragment is insufficient to make it an effective 
target of CDK down-regulation; and (ii) the Cln2 docking site in Ste20 can control 
functional regulation via CDK phosphorylation.   
 
We used the Ste20Ste5PM chimera to dissect which docking site residues were 
required for regulatory activity.  This function was fully contained in a 30-residue 
region (80-109) spanning the conserved stretch noted earlier (Figure 2.7C), and 
it required the same 8-residue motif involved in Cln2 binding (SLDDPIQF) (Figure 
2.6C, left).  Notably, no single residue in this motif was absolutely required, 
though partial phenotypes were seen for mutations at the L, P, and F residues 
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Figure 2.7.  Ste20Ste5PM chimeras: cyclin specificity, protein levels, and 
minimal motif 
(A) Inhibition of Ste20Ste5PM signaling is cyclin specific.  A ste20∆ STE5-8A strain 
(PPY2142) was co-transformed with plasmids expressing a Ste20Ste5PM chimera 
(see Figure 2.6A) and a galactose inducible cyclin construct (or a vector control).  
Pheromone response was assayed as in Figure 2.6B.  Signaling was inhibited 
strongly by Cln2 and partially by Cln1, each of which was blocked by mutating 
the CDK sites (7A).  Signaling was unaffected by Cln310A or Clb5.  Expression of 
Clb2 inhibited signaling regardless of the CDK sites, and hence this is most likely 
due to pleiotropic effects on cell physiology resulting from prolonged high levels 
of Clb2 produced by this construct (which is eventually lethal).  Bars, mean ± SD 
(n = 4). 
(B) Protein levels of Ste20Ste5PM chimeras are not affected under conditions in 
which pheromone signaling is inhibited.  Top, the same strains, plasmids, and 
treatment conditions used to analyze signaling in Figure 2.6B were used to 
prepare cell extracts for protein analysis by immunoblotting.  Equal amounts of 
protein were loaded in each case (20 µg/lane).  Note that in no case does PGAL1-
CLN2 cause a reduction in protein levels.  Also note that in the absence of the 
PM-proximal CDK sites (7A), the chimera is still phosphorylated at native sites in 
Ste20 and yet signaling is not inhibited (see Figure 2.6B); this demonstrates that 
down-regulation is not achieved by phosphorylation elsewhere in the protein but 
instead specifically requires that phosphates are added adjacent to the PM 
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domain.  Bottom, a similar analysis was performed using myc13-tagged chimeras, 
showing results analogous to the GFP-tagged chimeras. 
(C) Deletions and truncations were used to show that Ste20 residues 80-109 
constitute a minimal motif sufficient to mediate Cln2 inhibition of the chimeras.  
Signaling was assayed as in Figure 2.6B. Bars, mean ± SD (n = 3-4).  
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Figure 2.7.  Ste20Ste5PM chimeras: cyclin specificity, protein levels, and 
minimal motif 
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(Figure 2.6C, right).  Thus, Cln2 docking may involve contacts distributed 
throughout the motif.  We also found that docking site function is highly flexible, 
as it remained active when placed on either side of the PM domain and up to 
~280 residues from the nearest CDK site (Figure 2.6D).  Moreover, the docking 
site from Ste5 could also function in the chimera (Figure 2.6D, right).  Finally, 
additional tests showed that the CDK regulation conferred upon the Ste20Ste5PM 
chimera is not limited to pheromone response or to over-expressed Cln2.  
Specifically, Ste20 performs additional functions in cycling cells, and its ability to 
localize to growing bud tips, or to sustain viability in the absence of the related 
PAK Cla4, requires plasma membrane contact (Leberer et al., 1997; Peter et al., 
1996; Takahashi and Pryciak, 2007).  These abilities were inhibited in the 
Ste20Ste5PM chimera in a manner that required both docking and CDK sites 
(Figure 2.6E, F).  Hence, the chimera converts Ste20 from a multi-functional 
kinase into a form that is restricted to functioning in non-cycling cells.  Altogether, 
the results clearly reveal the feasibility of creating new CDK regulatory circuits via 
a combination of Cln2 docking and CDK phosphorylation sites, and they 
establish the Ste20Ste5PM chimera as a functionally flexible platform with which to 
assay docking site activity. 
 
Functional Cln2 docking sites in other CDK substrates. 
To assess whether the Cln2 docking behavior seen with Ste5 and Ste20 might 
be more widespread, we searched for similar sites in other CDK substrates.  
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Matches to the LxxPΦxΦ motif or the core Ste5 site (LLPP) were too numerous 
for a proteome-wide analysis.  Nevertheless, we scanned the sequences of 
known Cln1/2-Cdc28 targets and Cln2 binding partners, plus Cdc28 substrates 
found in large-scale screens (Archambault et al., 2004; Enserink and Kolodner, 
2010; Holt et al., 2009; Ubersax et al., 2003), for Leu/Pro-rich sequence motifs 
that are conserved among fungal orthologs and that lie outside of known or 
predicted structural domains. Although not comprehensive, as an initial test case 
we chose seven such sequences (from Sic1, Whi5, Srl3, Bem3, Tus1, Exo84, 
and Pea2; see Figure 2.9), including one recently implicated in Cln2-Cdc28 
phosphorylation of Sic1 (Koivomagi et al., 2011b).  We then tested these 
sequences for their ability to functionally substitute for the Ste5/Ste20 docking 
sites, using two experimental settings: (i) Cln2 inhibition of signaling by the 
Ste20Ste5PM chimera; and (ii) Cln2-driven phosphorylation of the Ste5 N-terminus.   
 
Remarkably, the majority of these sequences had measurable activity.  In the 
signaling assays (Figure 2.8A), they mediated Cln2 inhibition to varying degrees, 
from strong (Sic1, Whi5, Exo84) to moderate (Tus1, Pea2) to weak (Bem3); only 
the Srl3 sequence was ineffective.  Importantly, their inhibitory effects were a 
specific response to Cln2 expression, and no non-specific effects were seen.  
The three most potent sequences contain exact matches to the Ste5 LLPP motif 
(Figure 2.9B), though it is notable that each was in fact more potent than the 
Ste5 sequence in these assays (Figure 2.8A); thus, additional context features 
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Figure 2.8.  Identification of additional candidate Cln2 docking sites 
(A) Candidate Cln2 docking sites from seven CDK substrates (see Figure 2.9) 
were inserted into a Ste20Ste5PM chimera lacking the endogenous docking site. 
These derivatives were compared to chimeras containing the Ste5 or Ste20 
docking sites inserted at the same position, or no docking site (none). Cln2 
inhibition of pheromone response was assayed as in Figure 2.6. Bars, mean ± 
SD (n = 5). 
(B) The same candidate docking sites used in panel A were inserted at the end 
of a Ste5 fragment (Ste51-260) that lacks its endogenous docking site, and Cln2-
driven phosphorylation was assayed. See Figure 2.9C for additional repetitions. 
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Figure 2.8.  Identification of additional candidate Cln2 docking sites 
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likely influence the efficacy of this motif.  Similarly, the Pea2 sequence closely 
resembles the motif in Ste20, and yet was less potent.  The phosphorylation 
assays yielded similar overall results, with a range of activity (Figures 2.8B and 
2.9C).  The relative activities in the two assays were generally correlated, but 
there were some discrepancies; for example, the Whi5 and Pea2 sequences 
were each weaker in the phosphorylation assay than the sequences with which 
they showed comparable potency in the signaling assay.  Together, these results 
clearly establish the utility of each assay for their ability to rapidly evaluate 
multiple candidate Cln2 docking sites, and to compare efficacy in parallel.  
Overall, given the large fraction of sequences that were effective, the findings 
suggest that Cln2 recognition sites of various strengths may be quite prevalent 
among Cln-CDK targets.   
 
The phosphorylation role of docking sites is cyclin-specific 
Finally, we tested whether the Cln2 docking sites enhance phosphorylation by all 
forms of cyclin-CDK or only by specific forms.  We used the Ste51-260 fragment as 
a starting substrate, and monitored its phosphorylation by inducing expression of 
different cyclins in asynchronous cells (Figure 2.10A).  In the absence of any 
docking site, none of the cyclins drove appreciable phosphorylation.  When Cln2 
docking sites from Ste5, Ste20, or Exo84 were appended to this substrate, 
phosphorylation was enhanced in a manner that was clearly cyclin-specific.  Cln2 
was generally most effective, followed by Cln1.  (With the Ste20 site, Clb2 could 
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Figure 2.9.  Sources of candidate Cln2 docking sites from other CDK 
substrates 
(A) For each protein, its structural or functional domains, possible CDK 
phosphorylation sites, and candidate Cln2 docking motifs are diagrammed.  
Sequence alignments show the extent of conservation (among fungal orthologs) 
of the tested regions.  Note that Srl3, which is a Cln2 binding protein 
(Archambault et al., 2004), is a paralog of Whi5; but because the candidate Cln2 
docking site in Whi5 is less well conserved in Srl3, we tested a Leu/Pro-rich 
sequence further downstream.  Also note that there are several Cln1/2-Cdc28 
targets involved in cell polarization (Rga1, Rga2, Bem2, Bem3, Tus1, Cdc24, 
Boi1, Boi2) (Archambault et al., 2004; Breitkreutz et al., 2010; Knaus et al., 2007; 
Kono et al., 2008; McCusker et al., 2007; Sopko et al., 2007; Wai et al., 2009), 
which we considered good candidates for harboring possible Cln2 docking sites.  
The large size of some of these proteins made it difficult to identify candidate 
sequences for our initial survey; hence, we chose two examples (Bem3 and 
Tus1) in which single regions stood out.  Subsequent studies will 
comprehensively test multiple sequences from such proteins. 
(B) Sequences chosen to test for Cln2 docking activity (in Figure 2.8), with red 
highlighting of the motifs that are most similar to those characterized in Ste5 and 
Ste20. 
(C) Two additional repetitions of the experiments shown in Figure 2.8B are 
shown here alongside those presented in Figure 2.8B (shown here as repeat #3).  
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Note the consistency in the extent of phosphorylation, indicating that the relative 
efficacy of each site is a reproducible feature.  Some of the weaker sites (Bem3, 
Pea2) gave effects that were more detectable in some repeats than others, 
whereas the Srl3 site was ineffective in all cases. 
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Figure 2.9.  Sources of candidate Cln2 docking sites from other CDK 
substrates 
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drive some weak phosphorylation detectable in longer exposures.)  As a further 
test, we fused the same substrate to a different type of docking site: namely, a 
short sequence containing an “RxL” motif from Fin1, a CDK substrate that is 
normally preferred by Clb5 (Loog and Morgan, 2005).  This motif switched the 
cyclin preference and caused phosphorylation to be driven strongly by Clb5, plus 
moderately by Clb2 (Figure 2.10A, bottom).  (It is noteworthy that the band 
patterns were not identical, suggesting different extent or distribution of 
phosphorylation events.)  These results clearly indicate that CDK sites in the 
Ste5 N-terminus are intrinsically capable of being phosphorylated by several 
different cyclin-CDK forms, but they are not effectively phosphorylated in vivo in 
the absence of cyclin-specific docking sites, and hence this provides specificity to 
the CDK phosphorylation. 
  
  
79 
Figure 2.10.  Docking sites drive cyclin-specific phosphorylation 
(A) Phosphorylation of a single substrate (Ste51-260) was monitored with and 
without the addition of the indicated docking sites, in cells expressing different 
PGAL1-induced cyclins.  Docking sites from Ste5, Ste20, and Exo84 preferentially 
enhance phosphorylation by Cln1/2-Cdc28, whereas an RxL-containing fragment 
from Fin1 converts the substrate into one that is preferred by Clb5 and Clb2. 
(B) Schematic comparison of different cyclin-CDK complexes, with a general 
model for how cyclin-specific docking interactions can selectively enhance 
substrate phosphorylation by individual forms of cyclin-CDK. 
  
  
80 
Figure 2.10.  Docking sites drive cyclin-specific phosphorylation 
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DISCUSSION 
 
In this study we identified docking sites for the yeast G1/S cyclins in several CDK 
substrates.  These sites bind preferentially to Cln2 and enhance phosphorylation 
of CDK substrates in a cyclin-specific manner in vivo.  They are also functionally 
modular, in that they can promote phosphorylation at a variety of distances and 
positions relative to the CDK sites, and the cyclin specificity of phosphorylation 
can be switched by exchanging docking sites.  We exploited this functional 
modularity to re-wire a CDK regulatory circuit so as to change the target of Cln2-
Cdc28 regulation in the pheromone response pathway, and to identify candidate 
Cln2 docking sites in several other CDK substrates.  The relative ease with which 
these other sites were found suggests that there may be numerous examples of 
such sites for the G1 or G1/S cyclins in yeast.  Indeed, recent studies from 
another group show that the Sic1 sequence which we used to drive Cln2-Cdc28 
phosphorylation of heterologous substrates does in fact promote phosphorylation 
of Sic1 itself and can also act as a competitive inhibitor of other Cln2-Cdc28 
substrates (Koivomagi et al., 2011b).  Collectively, these findings suggest that 
docking interactions play a prevalent but previously unappreciated role in driving 
phosphorylation of G1/S CDK substrates. 
 
 The use of separate docking and phosphorylation sites offers functional 
and regulatory flexibility.  At one extreme, it can allow different kinases to 
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phosphorylate the same sites, as we observed by replacing a Cln2 docking site 
with an RxL motif favored by B-type cyclins.  It may also allow the sequence 
requirements at phosphorylation sites to be relaxed.  While most kinases favor 
certain residues flanking the phosphorylation site (Mok et al., 2010; Ubersax and 
Ferrell, 2007), this ideal context may not be present or tolerated in all relevant 
substrates.  Indeed, proteome-wide analysis (Holt et al., 2009) suggests that 
roughly two thirds of CDK sites in yeast are not “consensus” sites (S/T-P-x-K/R).  
In Ste5, none of the 8 N-terminal CDK sites matches this consensus.  The 
presence of a Cln2 docking site converts the Ste5 N-terminus from a weak 
substrate into a better substrate, but only for Cln1/2-Cdc28.  This enhancement 
may compensate for poor sequence context, which in turn could minimize use by 
other cyclin-CDKs, thus providing a regulatory benefit.  Other possible benefits of 
cyclin docking interactions include: (i) they may enhance CDK phosphorylation 
even for substrates that are not cyclin specific; (ii) they may help drive multi-site 
phosphorylation of CDK substrates (Salazar et al., 2010); and (iii) they may 
impart useful regulatory behavior by fostering interplay with competitors or other 
bound factors.  Indeed, the Cln2 docking site in Ste5 overlaps a binding site for 
the phosphatase Ptc1 (Malleshaiah et al., 2010), and these two factors may 
compete for access to Ste5 in vivo. Overlapping cyclin and phosphatase binding 
sites have also been found in the mammalian protein Rb (Hirschi et al., 2010), 
suggesting a common theme. 
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Differences in docking strength may impact the extent and/or timing of 
substrate phosphorylation (Salazar et al., 2010).  For example, the docking sites 
in Ste5 and Ste20 bind stronger to Cln2 than Cln1, and such differences could 
contribute to disparities in efficacy of these two cyclins (Chang and Herskowitz, 
1992; Oehlen and Cross, 1994; Queralt and Igual, 2004).  We also observed 
varying degrees of potency for different Cln2 docking sites, though the 
responsible sequence features remain uncertain.  The Ste5 and Ste20 sites 
share an LxxPΦxΦ motif and an overall enrichment in Leu, Pro, and/or 
hydrophobic residues, which was used as a criterion to identify additional sites.  
An LLPP motif is shared by several of the strong sites, but the docking site in 
Ste20 does not match this motif and yet is very potent.  Thus, deducing the key 
sequence features of Cln2 docking sites will require subsequent study, as will 
determination of whether they bind directly to the cyclin versus the cyclin-CDK 
complex. 
 
 Subcellular localization can also contribute to functional specialization of 
cyclins (Draviam et al., 2001; Edgington and Futcher, 2001; Miller and Cross, 
2000).  Hence, in addition to driving phosphorylation in cis, some cyclin docking 
sites may help localize cyclins and/or promote phosphorylation in trans of other 
proteins in the same complex or subcellular locale (Pascreau et al., 2011).  In 
fact, prior to our discovery that it binds Cln2, we originally found that the Cln2 
docking site in Ste20 could trigger hyperpolarized growth when over-expressed 
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and membrane-localized (Takahashi and Pryciak, 2007); in retrospect, this 
phenotype could result from the generation of excess cortical binding sites for 
Cln2, which promotes apical polarized growth (Lew and Reed, 1993). Several 
Cln1/2-Cdc28 substrates are involved in cell polarity (Enserink and Kolodner, 
2010) (see Figure 2.9 legend), so it will be of interest to determine whether they 
each contain Cln1/2 docking sites or if docking sites in some can serve a 
scaffolding role that promotes CDK phosphorylation of co-bound or co-localized 
substrates.  Synthetic approaches, such as those described here, can be used to 
discover these docking sites as well as to characterize their functional properties 
and activities in a standardized setting, which ultimately can illuminate how the 
regulatory behavior of native proteins and pathways arises from the combined 
properties of individual motifs. 
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Materials and Methods 
 
 
Yeast Strains and Plasmids 
Standard procedures were used for growth and genetic manipulation of yeast 
(Rothstein, 1991; Sherman, 2002). Cells were grown at 30°C in yeast 
extract/peptone medium with 2% glucose (YPD) or galactose (YPGal), or in 
synthetic (SC) medium with 2% glucose and/or raffinose. Strains and plasmids 
are listed in the tables below. 
 
Protein analysis in whole yeast cell lysates 
Except for GST co-precipitation assays, protein analysis used whole cell lysates 
prepared by glass-bead lysis of frozen cell pellets directly in trichloroacetic acid 
(TCA) solution, as described previously (Lee and Dohlman, 2008), which 
provides good preservation of protein phosphorylation state.  Ten mL of culture 
(OD660 ~ 0.7) was collected by centrifugation, and cell pellets were frozen in liquid 
nitrogen and stored at -80°C.  Frozen pellets were thawed by adding 300 µL of 
TCA buffer (10 mM Tris.HCl, pH 8.0, 10% TCA, 25 mM ammonium acetate, 1 
mM Na2EDTA), transferred to a microcentrifuge tube, lysed by vortexing with 
glass beads (five 1-min cycles, with chilling on ice for 3 min between cycles).  
The cell lysate was transferred to a new tube and centrifuged (16,000 x g, 10 min 
at 4˚C). The pellet was resuspended in 150 uL of solution R (0.1 M Tris.HCl, pH 
11.0, 3% SDS), boiled for 5 min, cooled to room temperature, and re-centrifuged 
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for 30 sec.  Then, 120 µL of supernatant was transferred to a fresh tube.  
Aliquots were reserved to determine protein concentration using a detergent-
compatible (bicinchoninic acid) assay (Thermo Scientific # 23225), and the 
remainder was combined with 2x SDS-PAGE sample buffer and boiled for 5 min. 
 
Phosphorylation Gel Shift Assays 
Cultures harboring HA3- or V53-tagged proteins, plus a PGAL1-GST-cyclin 
construct or a vector control, were grown in 2% raffinose media and induced with 
2% galactose for 3 hr.  Alternatively, to reduce toxic effects of Clb2 expression, 
the experiments comparing all five PGAL1-GST-cyclins in parallel used only 1 hr 
galactose induction.  Wild-type strain BY4741 was used except where noted 
otherwise.  Using samples prepared by the TCA method described above, 
equivalent amounts of protein (20 µg/lane) were separated by SDS-PAGE, and 
transferred to PVDF membranes (Immobilon-P; Millipore) using a submerged 
transfer apparatus.  Blots were probed with mouse anti-HA (1:1000, Covance 
#MMS-101R), anti-V5 (1:5000, Invitrogen #46-0705), or anti-GST (1:1000, Santa 
Cruz Biotechnologies #sc-138) antibodies, and detected using HRP-conjugated 
goat anti-mouse antibodies (1:3000, BioRad #170-6516) and Pierce SuperSignal 
West Pico (#34080) chemilluminescent reagent.  To follow phosphorylation in 
synchronous cultures, cdc15-2 strain PPY1762 harboring tagged proteins was 
grown overnight at 25°C, arrested at 37°C for 3 hr, and then released at 25°C.  
Aliquots were taken at 20 min intervals, then chilled on ice for 5 min, pelleted, 
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and frozen in liquid nitrogen.  Cell extracts were prepared and analyzed as 
described above.  In parallel, cells at each time point were fixed with 5% 
formaldehyde and scored for small buds by microscopy.  Clb2 was detected with 
rabbit anti-Clb2 (1:1000, Santa Cruz Biotechnologies #sc-9071) and AP-
conjugated goat anti-rabbit (1:3000, BioRad #170-6518) antibodies, with Immun-
Star-AP substrate (BioRad #170-5018). 
Most SDS-PAGE analysis used standard (Laemmli) methods, in which 
separating gels included 8% acrylamide [37.5:1 acryl:bis] with 0.1 % SDS.  
However, to better separate phosphorlyated forms of large proteins (i.e., full-
length Ste5 and Swe1), a higher acrylamide:bis ratio was used and SDS was 
omitted from the gel (i.e., separating gel: 0.375 M Tris-HCl pH 8.8, 7.5 % 
acrylamide [43.4:1 acryl:bis]; stacking gel: 0.125 M Tris-HCl pH 6.8, 5 % 
acrylamide [37.5:1 acryl:bis]; running buffer: 0.05 M TRIZMA base, 0.38 M 
glycine, 0.1 % SDS; electrophoresis: 20 mA for roughly 5 hr). 
 
Signaling Assays 
To measure effects of PGAL1-CLN2 on pheromone response, cells were grown in 
2% raffinose selective media, induced with 2% galactose, and then treated with α 
factor.  (i) For assays of transcriptional response, 1 hr galactose induction was 
followed by 2 hr treatment with 5 µM α factor; then, FUS1-lacZ expression was 
measured by β-galactosidase assay as described previously (Lamson et al., 
2002; Strickfaden et al., 2007).  (ii) For assays of MAPK phosphorylation, 75 min. 
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galactose induction was followed by 0-60 min. treatment with 1 µM α factor. 
Phosphorylated Fus3 was detected with rabbit anti-phospho-p44/42 (1:1000, Cell 
Signaling Technology #9101) and HRP-conjugated goat anti-rabbit (1:3000, 
Jackson ImmunoResearch #111-035-144) antibodies; then, blots were stripped 
(Thermo Scientific #21059) and probed with goat anti-Fus3 (1:2000, Santa Cruz 
Biotechnologies #sc-6773) and HRP-conjugated donkey anti-goat (1:3000, Santa 
Cruz Biotechnologies #sc-2020) antibodies. (Pierce SuperSignal West Pico 
reagent was used for each.)  (iii) For assaying the levels of Ste20Ste5PM chimera 
proteins, epitope-tagged forms were detected with mouse anti-GFP (1:1000, 
Clontech #JL-8) and HRP-conjugated goat anti-mouse (1:3000, BioRad #170-
6516) antibodies, or rabbit anti-myc (1:200, Santa Cruz Biotechnologies #sc-789) 
and HRP-conjugated goat anti-rabbit (1:3000, Jackson ImmunoResearch #111-
035-144) antibodies (with Pierce SuperSignal West Pico reagent). 
 
GST Binding Assays 
Cultures (25 ml) of strain BY4741 harboring PGAL1-GST-tagged Ste20 or 
Ste20Ste5 chimeric fragments, with or without cyclin-myc13 constructs, were 
induced with 2% galactose for 3 hr, harvested, and stored at -80°C. Extracts 
were prepared by glass bead lysis in a non-ionic detergent buffer as described 
previously (Lamson et al., 2002). Aliquots were reserved to assess input levels. 
GST fusions were collected by binding to glutathione-sepharose beads (GE 
Healthcare #17-0756-01) and detected with anti-GST antibodies described above 
  
89 
and AP-conjugated goat anti-mouse antibodies (1:3000, BioRad #170-6520) and 
Immun-Star-AP substrate. Cyclin-myc13 proteins were detected using rabbit anti-
myc (1:200, Santa Cruz Biotechnologies #sc-789) and HRP-conjugated goat 
anti-rabbit (1:3000, Jackson ImmunoResearch #111-035-144) antibodies, and 
Pierce SuperSignal West Pico (#34080) reagent. 
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Table 2.1: Yeast strains used in Chapter II 
Yeast strains used in this study 
bkg
nd* 
strain name genotype source §  
    
(a) BY4741 MATa  his3∆1  leu2∆0  ura3∆0  met15∆0 (1) 
(a) BY4741 ptc1∆ MATa  his3∆1  leu2∆0  ura3∆0  met15∆0  ptc1∆::kanR (2) 
(a) BY4741 sic1∆ MATa  his3∆1  leu2∆0  ura3∆0  met15∆0  sic1∆::kanR (2) 
(a) PPY2285 MATa  his3∆1  leu2∆0  ura3∆0  met15∆0  SWE1-3xV5::kanR this study 
    
(b) PPY640 MATa  FUS1::FUS1-lacZ::LEU2 (3) 
(b) PPY858 MATa  FUS1::FUS1-lacZ::LEU2  ste5::ADE2 (3) 
(b) PPY1173 MATa  FUS1::FUS1-lacZ::LEU2  fus3::LEU2  kss1::ura3FOA (4) 
(b) PPY1665 MATa  FUS1::FUS1-lacZ::LEU2  fus3::LEU2  kss1::ura3FOA  ste5::ADE2 this study 
(b) PPY1695 MATa  FUS1::FUS1-lacZ::LEU2  ste5::ADE2  HIS3::PGAL1-CLN2 (5) 
(b) PPY1762 MATa  ade1  cdc15-2  ste5::ADE2 (5) 
(b) PPY2142 MATa  FUS1::FUS1-lacZ::LEU2  STE5-8A  ste20∆::kanR this study 
(b) PPY2143 MATa  FUS1::FUS1-lacZ::LEU2  STE5-8A  ste20∆::kanR  HIS3::2x(PGAL1-CLN2) this study 
(b) PPY2281 MATa  FUS1::FUS1-lacZ::LEU2  fus3::LEU2  kss1::ura3FOA  ste5::ADE2  HIS3::PGAL1-CLN2 this study 
(b) KBY211 MATα  ste20::ADE2  cla4::LEU2  +  YCpTRP1-cla4-75ts (6) 
    
* strain background:   
(a) S288c  (his3∆1  leu2∆0  ura3∆0  met15∆0) 
(b) W303  (ade2-1  his3-11,15  leu2-3,112  trp1-1  ura3-1  can1) 
 
§ source:  (1) (Brachmann et al., 1998); (2) (Winzeler et al., 1999); (3) (Pryciak and Huntress, 1998); (4) (Winters et al., 2005); (5) 
(Strickfaden et al., 2007); (6) (Holly and Blumer, 1999). 
 
 
 
 
 
 
Table 2.2.   Plasmids used in Chapter II 
 
Plasmids used in this study 
name alias description ** source § 
pPP538 pRL116 CEN URA3 PSTE20-GFP-STE20 WT   1 
pPP681 pRS316 CEN URA3 vector 2 
pPP1843 pUG-GST-GFP 2µm URA3 PGAL1-GST-GFP vector   3 
pPP1919 pUG-GST-F20-WT 2µm URA3 PGAL1-GST-GFP-STE20-WT (full-length)  this study 
pPP1927 pT-F3-myc CEN TRP1 FUS3-myc13  TCYC1 this study 
pPP2036 pUG-GST-F20L 2µm URA3 PGAL1-GST-GFP-ste20(72-333)   4 
pPP2037 pUG-GST-F20M 2µm URA3 PGAL1-GST-GFP-ste20(120-333)   4 
pPP2038 pUG-GST-F20FM+ 2µm URA3 PGAL1-GST-GFP-ste20(1-254)   4 
pPP2040 pUG-GST-F20AM+ 2µm URA3 PGAL1-GST-GFP-ste20(1-333)  4 
pPP2041 pUG-GST-F20ABR-M+ 2µm URA3 PGAL1-GST-GFP-ste20(1-333)/BR* 4 
pPP2154 pHG-GST CEN HIS3 PGAL1-GST vector   this study 
pPP2163 pHGT-S20A CEN HIS3 PGAL1-GST-ste20(1-333)    4 
pPP2177 pEHG-GST 2µm HIS3 PGAL1-GST vector  this study 
pPP2271 pT-F3K42R-myc CEN TRP1 fus3(K42R)-myc13  TCYC1 this study 
pPP2318 pRL116∆BR CEN URA3 PSTE20-GFP-ste20(∆285-311) 4 
pPP2816 pRS413-TEFpr  CEN HIS3 PTEF2 vector 5 
pPP2927 pRL116myc   CEN URA3 PSTE20-myc13-STE20 4 
pPP2929 pRL116myc∆BR    CEN URA3 PSTE20-myc13-ste20(∆285-311) 4 
pPP3066 pRL116-A5N    CEN URA3 PSTE20-GFP-[(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3071 pRL116-XA5N    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-85)-(Ste20 312-939)]   this study 
pPP3072 pRL116-XA5N8A    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-85/8A)-(Ste20 312-939)] this study 
pPP3077 pTEFpr-CLN2-myc    CEN URA3 PTEF2-CLN2-myc13 TCYC1 this study 
pPP3102 pRL116-XA5N∆2-72   CEN URA3 PSTE20-GFP-[(Ste20 73-123)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3103 pRL116-XA5N∆87-119    CEN URA3 PSTE20-GFP-[(Ste20 1-86)-(Ste5 1-85)-(Ste20 312-939)]    this study 
pPP3104 pRL116-XA5N-Ala5 CEN URA3 PSTE20-GFP-[(Ste20 1-123/mut3)-(Ste5 1-85)-(Ste20 312-939)]   this study 
pPP3118 pRL116-XB5N    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-125)-(Ste20 312-939)] this study 
pPP3119 pRL116-XB5N-8A    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-125/8A)-(Ste20 312-939)] this study 
pPP3120 pRL116-XC5N    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-176)-(Ste20 312-939)]    this study 
pPP3121 pRL116-XC5N-8A    CEN URA3 PSTE20-GFP-[(Ste20 1-123)-(Ste5 1-176/8A)-(Ste20 312-939)] this study 
pPP3125 pRL116myc-XA5N    CEN URA3 PSTE20-myc13-[(Ste20 1-123)-(Ste5 1-85)-(Ste20 312-939)]  this study 
pPP3127 pRL116myc-XA5N-8A    CEN URA3 PSTE20-myc13-[(Ste20 1-123)-(Ste5 1-85/8A)-(Ste20 312-939)] this study 
pPP3133 pRL116myc-XA5N-Ala5  CEN URA3 PSTE20-myc13-[(Ste20 1-123/mut3)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3152 pH-TEFpr-CLN2-myc    CEN HIS3 PTEF2-CLN2-myc13 TCYC1 this study 
  
91 
pPP3153 pCYC1-CLN1-myc     CEN URA3 PCYC1-CLN1-myc13 TCYC1 this study 
pPP3154 pCYC1-CLB5-myc     CEN URA3 PCYC1-CLB5-myc13 TCYC1 this study 
pPP3155 pCYC1-CLB2-myc     CEN URA3 PCYC1-CLB2-myc13 TCYC1 this study 
pPP3203 pCYC1-CLN2-myc    CEN URA3 PCYC1-CLN2-myc13 TCYC1 this study 
pPP3218 pM20-BXA5N-U    CEN URA3 PSTE20-myc13-[(Ste20 80-109)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3219 pM20-BXA5N-V    CEN URA3 PSTE20-myc13-[(Ste20 80-115)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3239 pRL116myc-NA5N    CEN URA3 PSTE20-myc13-[(Ste20 1-284)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3267 pRL116V5    CEN URA3 PSTE20-3xV5-STE20 this study 
pPP3270 pM20-BXA5N-∆87-119 CEN URA3 PSTE20-myc13-[(Ste20 1-86)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3272 pM20-BXA5N-U-CSM1 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut1)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3273 pM20-BXA5N-U-CSM2 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut2)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3274 pM20-BXA5N-U-CSM3 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut3)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3275 pM20-BXA5N-U-CSM4 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut4)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3276 pM20-BXA5N-U-CSM5 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut5)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3277 pM20-BXA5N-U-CSM6 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut6)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3278 pM20-BXA5N-U-CSM7 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut7)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3279 pM20-BXA5N-U-CSM8 CEN URA3 PSTE20-myc13-[(Ste20 80-109/mut8)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3281 pM20-BXA5N-U-CSM3a CEN URA3 PSTE20-myc13-[(Ste20 80-109/S87A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3301 pM20-BXA5N-U-CSM3b CEN URA3 PSTE20-myc13-[(Ste20 80-109/L88A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3302 pM20-BXA5N-U-CSM3c CEN URA3 PSTE20-myc13-[(Ste20 80-109/D89A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3303 pM20-BXA5N-U-CSM3d CEN URA3 PSTE20-myc13-[(Ste20 80-109/D90A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3304 pM20-BXA5N-U-CSM3e CEN URA3 PSTE20-myc13-[(Ste20 80-109/P91A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3305 pM20-BXA5N-U-CSM4a CEN URA3 PSTE20-myc13-[(Ste20 80-109/I92A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3306 pM20-BXA5N-U-CSM4b CEN URA3 PSTE20-myc13-[(Ste20 80-109/Q93A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3307 pM20-BXA5N-U-CSM4c CEN URA3 PSTE20-myc13-[(Ste20 80-109/F94A)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3311 pM20-BXA5N-∆87-119-
MCSM 
CEN URA3 PSTE20-myc13-[(Ste20 1-86)-(Ste5 1-85)-(Ste20-80-115)-(Ste20 
312-939)] 
this study 
pPP3312 pM20-BXA5N-∆87-119-
SgCSM 
CEN URA3 PSTE20-myc13-[(Ste20 1-86)-(Ste5 1-85)-(Ste20 312-567)-(Ste20-
80-115)-(Ste20 568-939)] 
this study 
pPP3313 pM20-BXA5N-∆87-119-
NXCSM 
CEN URA3 PSTE20-(Ste20 80-115)- myc13-[(Ste20 1-86)-(Ste5 1-85)-(Ste20 
312-939)]  
this study 
pPP3367 pV20-80-590/A13 CEN URA3 PSTE20-3xV5-(Ste20 80-590/CDK*) this study 
pPP3368 pRL116V5-Ala5 CEN URA3 PSTE20-3xV5-(Ste20 1-939/mut3) this study 
pPP3369 pRL116V5-Ala13 CEN URA3 PSTE20-3xV5-(Ste20 1-939/CDK*) this study 
pPP3370 pV20-80-590/WT CEN URA3 PSTE20-3xV5-(Ste20 80-590/wt) this study 
pPP3373 pM20-BXA5N-5CDS   CEN URA3 PSTE20-myc13-[(Ste5 257-335)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3374 pM20-BXA5N-∆87-119-
M5CDS 
CEN URA3 PSTE20-myc13-[(Ste20 1-86)-(Ste5 1-85)-(Ste5 257-335)-(Ste20 
312-939)] 
this study 
pPP3415 pS5kHA-1-370   CEN URA3 PSTE5-ste5 1-370- 3xHA  TCYC1 this study 
pPP3433 pS5kHA-1-262   CEN URA3 PSTE5-ste5 1-262- 3xHA  TCYC1 this study 
pPP3434 pS5kHA-1-315   CEN URA3 PSTE5-ste5 1-315- 3xHA  TCYC1 this study 
pPP3435 pS5kHA-1-337   CEN URA3 PSTE5-ste5 1-337- 3xHA  TCYC1 this study 
pPP3454 pS5kHA-1-337-8A   CEN URA3 PSTE5-ste5 1-337 (8A)- 3xHA  TCYC1  this study 
pPP3501 pS5kHA-1-283   CEN URA3 PSTE5-ste5 1-283- 3xHA  TCYC1 this study 
pPP3502 pS5kHA-1-300   CEN URA3 PSTE5-ste5 1-300- 3xHA  TCYC1 this study 
pPP3503 pS5kHA-1-260   CEN URA3 PSTE5-ste5 1-260- 3xHA  TCYC1 this study 
pPP3509 pH5n-1-337-wt   CEN URA3 PSTE5-ste5 1-337-(wt)- 3xHA  TCYC1 this study 
pPP3510 pH5n-1-337-3AV   CEN URA3 PSTE5-ste5 1-337-(4AV)- 3xHA  TCYC1 this study 
pPP3513 pH5n-1-337-ND   CEN URA3 PSTE5-ste5 1-337-(ND)- 3xHA  TCYC1 this study 
pPP3546 pH5n-1-337-4E   CEN URA3 PSTE5-ste5 1-337-(4E)- 3xHA  TCYC1 this study 
pPP3547 pH5n-1-260-S20CSM   CEN URA3 PSTE5-ste5 1-260-(S20 80-115wt)- 3xHA  TCYC1 this study 
pPP3548 pH5n-1-260-S20CSMmut  CEN URA3 PSTE5-ste5 1-260-(S20 80-115mut3) -3xHA  TCYC1 this study 
pPP3550 pS5kHA-1-275   CEN URA3 PSTE5-ste5 1-275- 3xHA  TCYC1 this study 
pPP3571 pH5n-1-260-fRXL   CEN URA3 PSTE5-ste5 1-260-(Fin1 190-208) -3xHA  TCYC1 this study 
pPP3572 pt-HGT-CLN2-F   CEN HIS3 PGAL1-GST-CLN2  TCYC1 this study 
pPP3610 pS5kHA-1-283-P4   CEN URA3 PSTE5-ste5 1-283-(LLPP)- 3xHA  TCYC1 this study 
pPP3701 pS5kHA-1-337∆RING    CEN URA3 PSTE5-ste5 1-337 [∆177-229]- 3xHA  TCYC1 this study 
pPP3702 pS5kHA-1-337∆124-151   CEN URA3 PSTE5-ste5 1-337 [∆124-151]- 3xHA  TCYC1 this study 
pPP3703 pS5kHA-1-337∆152-173    CEN URA3 PSTE5-ste5 1-337 [∆152-173]- 3xHA  TCYC1 this study 
pPP3704 pS5kHA-1-337∆239-256    CEN URA3 PSTE5-ste5 1-337 [∆239-256]- 3xHA  TCYC1 this study 
pPP3714 pH5n-1-337-P4   CEN URA3 PSTE5-ste5 1-337-(LLPP)- 3xHA  TCYC1 this study 
pPP3715 pH5n-1-337-P4,3AV   CEN URA3 PSTE5-ste5 1-337-(LLPP/4AV)- 3xHA  TCYC1 this study 
pPP3716 pH5n-1-337-P4,4E   CEN URA3 PSTE5-ste5 1-337-(LLPP/4E)- 3xHA  TCYC1 this study 
pPP3717 pH5n-1-337-P4,ND   CEN URA3 PSTE5-ste5 1-337-(LLPP/ND)- 3xHA  TCYC1 this study 
pPP3724 pV20-80-590-A5b   CEN URA3 PSTE20- 3xV5- (ste20 80-590/mut3) this study 
pPP3738 pS5kmyc-Nhe-wtb   CEN URA3 PSTE5-ste5 full length-(wt)-myc13  TCYC1 this study 
pPP3739 pS5kmyc-Nhe-P4   CEN URA3 PSTE5-ste5 full length-(LLPP)-myc13  TCYC1 this study 
pPP3744 pS5kmyc-Nhe-ND   CEN URA3 PSTE5-ste5 full length-(ND)-myc13  TCYC1 this study 
pPP3745 pS5kmyc-Nhe-P4,ND   CEN URA3 PSTE5-ste5 full length-(LLPP/ND)-myc13  TCYC1 this study 
pPP3749 pt-HGT-CLN1   CEN HIS3 PGAL1-GST-CLN1  TCYC1 this study 
pPP3755 pCYC1-CLN3-10A-myc CEN URA3 PCYC1-CLN3(10A)- myc13  TCYC1 this study 
pPP3757 pV20-80-500-wt CEN URA3 PSTE20- 3xV5- (ste20 80-500/wt) this study 
pPP3758 pV20-80-500-A5 CEN URA3 PSTE20- 3xV5- (ste20 80-500/mut3) this study 
pPP3759 pV20-80-500Ala6 CEN URA3 PSTE20- 3xV5- (ste20 80-500/CDK*) this study 
pPP3760 pS5kV5-Nhe-wt  CEN URA3 PSTE5-STE5 full length-(wt)-3xV5  TCYC1 this study 
pPP3761 pS5kV5-Nhe-P4  CEN URA3 PSTE5-ste5 full length-(LLPP)-3xV5  TCYC1 this study 
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pPP3771 pUG-GST-F20M-5CSM-wt 2µm URA3 PGAL1-GST-GFP-[(ste5 263-335)-(ste20 120-333)]  this study 
pPP3772 pUG-GST-F20M-5CSM-P4 2µm URA3 PGAL1-GST-GFP-[(ste5 263-335/LLPP)-(ste20 120-333)] this study 
pPP3802 pH5n-1-260-dSic1   CEN URA3 PSTE5-ste5 1-260-(Sic1 121-150) 3xHA  TCYC1 this study 
pPP3803 pH5n-1-260-dWhi5   CEN URA3 PSTE5-ste5 1-260-(Whi5 121-150) 3xHA  TCYC1 this study 
pPP3804 pH5n-1-260-dSrl3   CEN URA3 PSTE5-ste5 1-260-(Srl3 135-164) 3xHA  TCYC1 this study 
pPP3805 pH5n-1-260-dBem3   CEN URA3 PSTE5-ste5 1-260-(Bem3 98-131) 3xHA  TCYC1 this study 
pPP3806 pH5n-1-260-dTus1   CEN URA3 PSTE5-ste5 1-260-(Tus1 21-50) 3xHA  TCYC1 this study 
pPP3807 pH5n-1-260-dExo84   CEN URA3 PSTE5-ste5 1-260-(Exo84 281-311) 3xHA  TCYC1 this study 
pPP3808 pH5n-1-260-dPea2   CEN URA3 PSTE5-ste5 1-260-(Pea2 187-216) 3xHA  TCYC1 this study 
pPP3809 pM20-BXA5N-dSic1   CEN URA3 PSTE20-myc13-[(Sic1 121-150)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3810 pM20-BXA5N-dWhi5   CEN URA3 PSTE20-myc13-[(Whi5 121-150)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3811 pM20-BXA5N-dSrl3   CEN URA3 PSTE20-myc13-[(Srl3 135-164)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3812 pM20-BXA5N-dTus1   CEN URA3 PSTE20-myc13-[(Tus1 21-50)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3813 pM20-BXA5N-dExo84   CEN URA3 PSTE20-myc13-[(Exo84 281-311)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3814 pM20-BXA5N-dPea2   CEN URA3 PSTE20-myc13-[(Pea2 187-216)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3815 pM20-BXA5N-dBem3   CEN URA3 PSTE20-myc13-[(Bem3 98-131)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP3820 pHG-GST-S20L-CSM-wt   CEN HIS3 PGAL1-GST-[(ste20 72-118)-(ste20 120-333)]   this study 
pPP3821 pHG-GST-S20L-CSM2   CEN HIS3 PGAL1-GST-[(ste20 72-118/mut2)-(ste20 120-333)] this study 
pPP3822 pHG-GST-S20L-CSM3   CEN HIS3 PGAL1-GST-[(ste20 72-118/mut3)-(ste20 120-333)]  this study 
pPP3823 pHG-GST-S20L-CSM4   CEN HIS3 PGAL1-GST-[(ste20 72-118/mut4)-(ste20 120-333)]   this study 
pPP3824 pHG-GST-S20L-CSM5   CEN HIS3 PGAL1-GST-[(ste20 72-118/mut5)-(ste20 120-333)] this study 
pPP3827 pt-HGT-CLN3-10A   CEN HIS3 PGAL1-GST-CLN3(10A)  TCYC1 this study 
pPP3828 pt-HGT-CLB5   CEN HIS3 PGAL1-GST-CLB5  TCYC1 this study 
pPP3829 pt-HGT-CLB2   CEN HIS3 PGAL1-GST-CLB2  TCYC1 this study 
pPP3853 pEHGT-S20M-5CSM-wt   2µm HIS3 PGAL1-GST-[(ste5 263-335)-(ste20 120-333)] this study 
pPP3865 pS5kV5-Nhe-ND  CEN URA3 PSTE5-ste5 full length-(ND)-3xV5  TCYC1 this study 
pPP3866 pS5kV5-Nhe-P4,ND  CEN URA3 PSTE5-ste5 full length-(LLPP/ND)-3xV5  TCYC1 this study 
pPP3867 pS5kV5-Nhe-8A  CEN URA3 PSTE5-ste5 full length-(8A)-3xV5  TCYC1 this study 
pPP3871 pS5kmyc-Nhe-8A CEN URA3 PSTE5-ste5 full length-(8A)-myc13  TCYC1 this study 
    
 
§ Source: (1) (Leberer et al., 1997); (2) (Sikorski and Hieter, 1989); (3) (Winters et al., 2005); (4) (Takahashi and Pryciak, 2007); (5) 
(Mumberg et al., 1995) 
 
** mutations denoted by abbreviated names: 
 
Ste5 8A:  T4A, S11A, T29A, S43A, S69A, S71A, S81A, T102A 
Ste5 LLPP: L278A, L279A, P280A, P281A 
Ste5 ND:  Q292A, I294A, Y295A, L307A, P310A, N315A 
Ste5 4AV: T267A, S276A, T287V, S329A 
Ste5 4E:  T267E, S276E, T287E, S329E 
 
Ste20 BR*: K285N, K286N, R287G, K288A, R297A, M298G, K299A, K310N, R311G 
Ste20 CDK*: T203A, T218A, S269A, S418A, T423A, S492A, S502A, T512A, S517A, S547A, T555A, S562A, T573A 
Ste20 mut1: D80A, D81A, D82A 
Ste20 mut2: N83A, N84A, V85A, V86A 
Ste20 mut3: S87A, L88A, D89A, D90A, P91A 
Ste20 mut4: I92A, Q93A, F94A 
Ste20 mut5: T95A, R96A, V97A 
Ste20 mut6: S98A, S99A, S100A, S101A 
Ste20 mut7: V102A, I103A, S104A, G105A 
Ste20 mut8: M106A, S107A, S108A, S109A 
 
Cln3 10A:  T420A, S449A, T455A, S462A, S464A, S468A, T478A, S514A, T517A, T520A 
  
  
93 
CHAPTER III 
A conserved docking interface in the cyclin Cln2 controls multi-
site substrate phosphorylation and ensures timely entry into the 
cell cycle 
 
The following Chapter contains the manuscript: 
 
Bhaduri, S., Valk, E., Winters, M.J., Gruessner B., Loog, M., Pryciak, P.M. 
(2014). A conserved docking interface in the cyclin Cln2 controls multi-site 
substrate phosphorylation and ensures timely entry into the cell cycle [Manuscript 
under preparation] 
 
 
The study has been devised and results have been interpreted by myself and Dr. 
Pryciak. All experiments, except for the ones listed below, have been performed 
by myself and the manuscript has been prepared by myself and Dr. Pryciak. 
Figure 3.5 has been contributed by Brian Gruessner under my guidance. 
Figure 3.6 and Figure 3.8D have been contributed by E. Valk and M. Loog. 
M.J. Winters has constructed several plasmids used in the study and helped with 
different experiments. 
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Abstract 
Eukaryotic cell division is driven by cyclin-dependent kinases (CDKs).  Distinct 
cyclin-CDK complexes are specialized to drive different cell cycle events, though 
the molecular bases for these specializations are only partly understood.  In 
budding yeast, the decision to begin a new cell cycle is regulated by three G1 
phase (Cln) cyclins.  Recent studies revealed that some CDK substrates contain 
a novel docking motif that is recognized by Cln1 and Cln2 but not by Cln3 or later 
S- or M-phase cyclins.  Here, to explore the role of this new docking mechanism 
in the cell cycle, we first show that it is conserved in a distinct cyclin subtype, the 
fungal Ccn1 group, and then use phylogenetic variation to identify cyclin 
mutations that disrupt docking.  These mutations disrupt binding to multiple 
substrates as well as the ability to use docking sites to promote efficient, multi-
site phosphorylation of substrates in vitro. In cells in which the Cln2 docking 
function is blocked, we observed reductions in the polarized morphogenesis of 
daughter buds and reduced ability to fully phosphorylate the G1/S transcriptional 
repressor Whi5.  Furthermore, disruption of Cln2 docking perturbs the 
coordination between cell size and the G1/S transition such that DNA synthesis 
and budding are delayed until cells reach a larger size.  The findings point to a 
novel substrate interaction interface on cyclins and indicate that efficient, 
docking-dependent substrate phosphorylation contributes to punctual cell cycle 
entry. 
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Introduction 
 
Cyclin-dependent kinases (CDKs) are central regulators of cell division in 
eukaryotes (Morgan, 2007).  The cyclin subunit has a critical role in triggering 
CDK kinase activity, but it can also play important regulatory roles by controlling 
subcellular localization and substrate selection (Bloom and Cross, 2007).  
Eukaryotic cells invariably have several distinct cyclin-CDK forms that are 
specialized for particular cell cycle stages.  In yeasts, multiple cyclins associate 
with a single CDK molecule, whereas animal cells have multiple cyclins as well 
as multiple CDKs.  Generally, these different cyclin-CDK forms fall into two broad 
functional classes: those that control the biochemical events of DNA synthesis 
and mitosis (in S and M phases), and those that control the decision to begin a 
new division cycle (in G1 phase).  To understand how sequential cell cycle 
events are properly orchestrated, it is necessary to determine the molecular 
mechanisms by which distinct cyclin-CDK forms differ functionally from each 
other.  For example, how do early forms of cyclin-CDK, which act in G1 phase to 
drive cell cycle entry, trigger some events without triggering other events that 
should occur later in S and M phases?  One general class of explanation is that 
early cell cycle events may rely on cyclin-CDK complexes with low activity but 
strong substrate selectivity (Koivomagi et al., 2011b; Levine et al., 1996).  This 
study pursues recent discoveries regarding substrate selection by early cyclins. 
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 In the budding yeast S. cerevisiae, S and M phases are driven by six B-
type cyclins (Clb1-6), whereas the decision to enter a new cell cycle is controlled 
by three G1 cyclins, Cln1-3 (Bloom and Cross, 2007; Morgan, 2007).  The G1 
phase constitutes a critical assessment period in which cells determine whether 
conditions are appropriate to begin a new round of division, and this decision is 
responsive to both internal and external cues such as nutrient availability, cell 
size, and inhibitory signals.  Ultimately these signals affect the function of Cln1-3, 
which then drive the CDK phosphorylation events that commit cells to cell cycle 
entry in a step known as “Start”, followed by the transition from G1 to S phase 
(Cross, 1995b; Johnson and Skotheim, 2013; Jorgensen and Tyers, 2004).  Key 
CDK substrates in this period are inhibitors of cell cycle entry such as Whi5, a 
repressor of G1/S transcription (Costanzo et al., 2004; de Bruin et al., 2004), as 
well as Cdh1 and Sic1, which prevent the expression and activity of Clb cyclins, 
respectively (Morgan, 2007).  Notably, each of these substrates has multiple 
CDK phosphorylation sites (Nash et al., 2001; Wagner et al., 2009; Zachariae et 
al., 1998), which may place unique demands on the cyclin-CDK complex to 
ensure efficient and complete phosphorylation, and also dictate the threshold 
CDK levels required to trigger the regulatory effect (Koivomagi et al., 2013; 
Koivomagi et al., 2011a; Nash et al., 2001; Yang et al., 2013). 
 
 Despite some functional overlap among Cln1-3 in governing cell cycle 
entry, these three cyclins have functional distinctions (Bloom and Cross, 2007; 
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Levine et al., 1996) that contribute to a two-stage commitment process: Cln3 
plays an early priming role that initiates expression of Cln1 and Cln2, which 
further promote their own expression via a positive feedback loop, resulting in a 
sharp increase in Cln1/2 activity that triggers a decisive entry into the cell cycle 
(Cross and Tinkelenberg, 1991; Dirick and Nasmyth, 1991; Skotheim et al., 
2008).  The distinctions between Cln3 and Cln1/2 include different subcellular 
distributions (Edgington and Futcher, 2001; Miller and Cross, 2000).  In addition, 
recent studies revealed that the Cln1/2 cyclins recognize specific docking motifs 
in select CDK substrates (Figure 3.1A).  These Cln1/2-specific “LP-type” docking 
motifs (enriched in Leu and Pro residues) are not recognized by either Cln3 or 
Clb1-6, and hence they promote phosphorylation preferentially by Cln1/2-CDK 
(Bhaduri and Pryciak, 2011; Koivomagi et al., 2011b).  This mechanism is 
analogous to recognition of RxL motifs by S-phase cyclins such as yeast Clb5 or 
mammalian CycA (Archambault et al., 2005), but the motifs are unrelated and 
are not cross-recognized (Bhaduri and Pryciak, 2011; Koivomagi et al., 2011b).  
Currently, it is unknown what part of the Cln1/2 protein recognizes the LP motifs, 
or why other cyclins do not recognize them.  It is also unknown what cell cycle 
events depend on docking by Cln1/2.  To address these issues, in this study we 
identify and characterize a docking-defective Cln2 mutant.  Our findings uncover 
a novel substrate-docking interface that is conserved among distinct cyclin sub-
groups, and demonstrate that this docking function promotes multi-site 
phosphorylation of substrates and punctual entry into the cell cycle. 
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Results 
 
Strategic framework for localizing the docking interface in Cln2 
Before screening for a Cln2 mutant that is defective at docking, we needed a 
strategy to distinguish mutants with specific defects in docking from those with 
more general defects in CDK activation.  Our solution was to compare a CDK 
substrate harboring a native LP docking site with one that instead uses a leucine 
zipper to promote cyclin-substrate interaction, expecting that the desired class of 
mutant would only show defects in phosphorylating the former substrate (Figure 
3.1B). Indeed, this predicted behavior is exemplified by Cln3, which can 
phosphorylate a substrate harboring the leucine zipper but does not recognize 
LP docking sites (Figure 3.1C).  Hence, in principle we sought a Cln2 mutant that 
behaves more like Cln3 in this respect.  
 
 Because S-phase cyclins recognize RxL docking motifs via a hydrophobic 
patch (HP) on their surface, we considered a simple model that the different 
sequence composition of this region in Cln1/2 cyclins might allow them to 
recognize LP rather than RxL motifs.  But mutations in this part of Cln2 did not 
confer a specific defect in LP docking, and instead they caused a general mild 
reduction in all phosphorylation activity, including auto-phosphorylation of the 
Cln2 C-terminus (Figure 3.1D).  Hence, we concluded that LP recognition is 
encoded elsewhere on Cln2, thus necessitating a broad interrogation of  
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Figure 3.1. Sequence constraints and evolutionary conservation of docking 
function. 
 
(A) Interaction of Cln1/2 with “LP” docking sites promotes CDK substrate 
phosphorylation. 
(B) Expected phenotype of a docking-defective Cln1/2 mutant.  Defects in 
docking vs. CDK activity can be discerned by comparing substrates with a 
docking site vs. a leucine zipper. 
(C) Cln3 exemplifies non-docking behavior. Cyclins were expressed as fusions to 
GST plus a half leucine zipper (GST-[lz]), along with a substrate harboring 
either the partner half leucine zipper or an LP docking site (see Figure 3.2A). 
Reduced gel mobility indicates substrate phosphorylation. 
(D) Mutations in the hydrophobic patch region of Cln2 (hpm1, 3; see Figure 3.2B) 
do not confer specific docking defects but rather a mild general reduction in 
phosphorylation activity. 
(E) The C-terminal tail of Cln2 is dispensable for docking. Full-length Cln2 (1-545) 
and truncated forms were tested for substrate phosphorylation (as in C-D). 
Truncation endpoints are shown relative to regulatory phosphorylation sites 
(P-sites) and tandem cyclin box folds (CBF1, 2) predicted for Cln2 (see Figure 
3.2C). Lower abundance was observed consistently for the 1-352 fragment. 
(F) Conservation of LP docking in Cln1/2 and Ccn1 cyclins. Top, phylogenetic 
tree of six yeasts, and their G1 cyclins. Some species have two Cln1/2 
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paralogs, due to whole genome duplication (WGD); where only one is 
present, it is denoted as Cln12.  The Ccn1 group is related but distinct from 
Cln3 and Cln1/2 groups. Bottom, cyclins from different yeasts were tested in 
S. cerevisiae as GST-(lz) fusions for substrate phosphorylation in vivo.  All 
cyclins were truncated to remove their C-terminal tails (see Figure 3.2C). 
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Figure 3.1. Sequence constraints and evolutionary conservation of docking 
function. 
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candidate sequences.  To help constrain the search, we tested truncations of the 
Cln2 C-terminus, and found that we could dispense with roughly one-third of the 
protein (the C-terminal regulatory tail) and retain LP recognition, whereas 
truncations that perturb the predicted globular cyclin box fold domains (CBF1, 2) 
eliminated all activity (Figure 3.1E).  Thus, all positions within the roughly 370-
residue core of Cln2 remained potential candidates. 
 
 The contrasting docking ability of Cln1/2 versus Cln3 must arise from 
sequence differences, but they were too extensive to explore comprehensively, 
and chimeras were non-functional and hence uninformative (unpublished 
observations).  Therefore, we devised a strategy to exploit natural sequence 
variation among fungal G1 cyclins.  Namely, by expressing cyclins from other 
yeasts in S. cerevisiae, we found that recognition of LP docking sites was 
conserved in other Cln1/2 members and lacking among Cln3 members (Figure 
3.1F).  Moreover, this led us to test a distinct class of G1 cyclin, the Ccn1 group, 
which is absent from S. cerevisiae but present in other yeasts such as C. 
albicans (Figure 3.1F, top), where it promotes hyphal morphogenesis (Loeb et 
al., 1999).  Remarkably, we found that Ccn1 members are proficient at using an 
LP docking motif to drive substrate phosphorylation (Figure 3.1F).  This revealed 
that LP docking exists for a class of cyclin other than Cln1/2, and offered a way 
to further constrain the possible residues involved in docking. 
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Figure 3.2. Leucine zippers, hydrophobic patch, and cyclin domains. 
 
(A) Cln2 was fused to a half leucine zipper (lz) at its N-terminus (lz-Cln2) or C-
teminus (Cln2-lz), or to no zipper (wt). These were co-expressed with a CDK 
substrate (Ste5 1-260) harboring no docking site, an LP docking site, or three 
variants of the partner half leucine zipper (E34[I], E34[V], or E34[N]) that 
range in binding affinity from 6 to 800 nM (Acharya et al., 2002; Bashor et al., 
2008). Reduced gel mobility indicates substrate phosphorylation. The leucine 
zipper worked best at the Cln2 N-terminus (lz-Cln2) but did not require strong 
affinity. Hence, all further experiments used the weakest affinity version 
(E34[N]). 
(B) Hydrophobic patch mutations. In S-phase cyclins such as mammalian CycA 
or yeast Clb5, recognition of RxL docking motifs is mediated by a hydrophobic 
patch (HP) formed largely by helix α1 (the “MRAIL” motif), and mutation of 
residues in blue disrupts RxL recognition (Loog and Morgan, 2005; Schulman 
et al., 1998; Wilmes et al., 2004). To test if the different helix α1 sequence in 
Cln2 leads to recognition of distinct LP-type docking motifs, we mutated the 
analogous positions (hpm1) as well as nearby residues (hpm3); see Figure 
3.1D.  The hpm1 mutations were also tested by other assays in a previous 
study (Miller et al., 2005). 
(C) Yeast cyclin fragments analyzed in Figure 3.1F. Each diagram shows 
predicted α helices (as boxes) and a plot of protein disorder (highest at top), 
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obtained using PSIPRED v3.3 and DISOPRED3, respectively (Buchan et al., 
2013). Truncation endpoints are shown in text and by red arrows. Helix boxes 
are colored red and blue (as in panel B) to denote regions predicted to 
correspond to CBF1 and CBF2 globular domains. These general domain 
boundaries also agree with separate multiple sequence alignments of over 75 
fungal G1 cyclins together and with cyclins of known structure (available on 
request), as well as with 3D structure prediction results for 8 of the 11 cyclins 
shown here using I-TASSER (Roy et al., 2010). 
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Figure 3.2. Leucine zippers, hydrophobic patch, and cyclin domains 
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Identification of a docking defective Cln2 mutant 
 
By performing sequence alignments with multiple members of the Cln1/2, Cln3, 
and Ccn1 groups, we found that there were many positions where Ccn1 and 
Cln3 residues were identical (or nearly so), and hence we excluded these from 
consideration as key residues in LP docking.  Then, we scrutinized those 
positions that correlated with docking ability; i.e., similar in Cln1/2 and Ccn1, but 
different in Cln3.  Based primarily (though not exclusively) on these 
considerations, twelve Cln2 mutants were designed (Figures 3.3A, 3.4). 
 
 These mutants were tested for their ability to phosphorylate substrates 
with two distinct LP-type docking sites or the control leucine zipper (Figure 3.3B). 
In addition, because they were initially tested in the context of full-length Cln2, we 
also monitored their ability to auto-phosphorylate the C-terminus.  Several 
mutants (m1, m2, m5, m6, m9) showed non-specific reduction in phosphorylation 
of all substrates including the leucine zipper control (note the drop in the upper-
most forms), while two mutants (m8, m10) had no detectable activity and no 
auto-phosphorylation, suggesting severe impairment in CDK activity.  By 
contrast, one mutant, cln2-m4, displayed the desired phenotype, as it showed a 
specific defect with LP-containing substrates but normal phosphorylation of the 
control substrate (Figure 3.3B).  To explore the generality of this phenotype, we 
compared the analogous m4 mutation in four distinct cyclins – two Cln1/2  
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Figure 3.3. Identification of a docking-defective Cln2 mutant. 
 
(A) Twelve regions of Cln2 were mutated, emphasizing residues conserved in 
Cln1/2 and Ccn1 groups but not in Cln3 (see Figure 3.4). One example (m4) 
is illustrated by the sequence alignment, with mutated positions marked by 
asterisks. 
(B) Cln2 mutants were expressed as GST-(lz) fusions to test phosphorylation in 
vivo of substrates with either of two LP docking sites (from Ste5 or Ste20) or 
the leucine zipper. 
(C) Left, the m4 mutation was tested in four different cyclins (two Cln1/2 and two 
Ccn1) for effects on docking-dependent phosphorylation. Right, analysis of 
single mutations at each of the three residues mutated in the m4 mutant. 
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Figure 3.3. Identification of a docking-defective Cln2 mutant. 
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Figure 3.4. Site-directed mutations in Cln2. 
 
(A) List of specific residue changes in Cln2 mutants m1-m12. 
(B) Comparison of Cln1/2, Cln3, and Ccn1 sequences at positions mutated in 
cln2 m1-m12. Sequence alignments, created using Clustal Omega (Sievers et 
al., 2011), compare representatives of each cyclin group in regions 
encompassing the mutated residues, which are marked with asterisks (or by 
brackets for large deletions). The top line is S. cerevisiae Cln2. The 
mutational strategy prioritized residues conserved in Cln1/2 and Ccn1 groups 
but not in Cln3, but also considered some regions where Cln1/2 and Cln3 
differ without requiring clear conservation in Ccn1. 
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Figure 3.4. Site-directed mutations in Cln2 
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members and two Ccn1 members (Figure 3.3C, left).  Each showed the same 
behavior, in which the m4 mutant was defective at using a native LP dock but 
fully competent to use the leucine zipper.  We also tested each of the single 
residue changes in the original m4 triple mutant, and found that one of the 
changes, L112A, was largely responsible for the defect (Figure 3.3C, right); 
however, the L112A single mutant was not quite as defective as the m4 triple 
mutant.  We also observed mild defects in each of the other two single mutants 
(R109A and R113A), and hence we used the original m4 triple mutant for further 
analyses. Collectively, these findings argue that the m4 mutation disrupts a 
region of the cyclin with a specific role in utilizing LP docking sites. 
 
Cln2 docking function is required for interaction with multiple substrates 
 
To verify that cln2-m4 was defective at docking interactions, we assayed 
substrate binding.  First, we compared several of the initial Cln2 mutants, 
expressed as GST fusions, for their ability to co-precipitate Ste5, a Cln2 
substrate with an LP docking motif (Bhaduri and Pryciak, 2011).  As predicted for 
a docking mutant, cln2-m4 showed reduced binding to Ste5 but normal binding to 
its partner CDK molecule, Cdc28 (Figure 3.5A).  The specific nature of this 
binding phenotype was reinforced by comparison to other mutants: namely, (i) 
cln2-m3 showed no binding defects, consistent with it being fully functional in 
phosphorylation assays; (ii) cln2-m5 showed reduced binding to both Ste5 and 
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Cdc28, suggesting a non-specific general defect that agrees with its reduced 
activity against all substrates; and, (iii) the cln2-m8 and cln2-m10 mutants were 
defective at binding Cdc28 but bound Ste5 normally, which agrees with their 
complete inactivity in phosphorylation assays while separately indicating that 
binding Cdc28 is not required for binding substrates. 
 
 We also conducted reciprocal assays in which GST-substrate fusions 
were used to co-precipitate V5-tagged Cln2 (Figures 3.5B, C), and found that 
cln2-m4 showed substantially reduced binding to most substrates tested (i.e., 
Ste20, Ste5, Sic1, Whi5, Rga1, Tus1).  The sole exception was Srl3, which binds 
Cln2 especially strongly; this might indicate a distinct mode of binding or that the 
reduction in binding is too mild to register in this assay.  As a further control, we 
tested binding to Grr1, an F-box protein that promotes Cln2 ubiquitination; this 
binding was unaffected by the m4 mutation (Figure 3.5B), consistent with the fact 
that Grr1 recognizes the phosphorylated C-terminus of Cln2 rather than the 
globular CBF domains (Berset et al., 2002; Landry et al., 2012).  Finally, we also 
assayed the effect of the m4 mutation on substrate binding by one of the Ccn1 
family members, from K. waltii (Figure 3.5D).  This cyclin bound only a subset of 
the substrates that bind Cln2, indicating some divergence in docking motif 
recognition (to be pursued as part of a separate study), but each of the 
detectable interactions was disrupted by the ccn1-m4 mutation. 
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Figure 3.5. Docking-defective Cln2 and Ccn1 mutants shows reduced 
binding to multiple partners. 
 
(A) Cells (far1∆) co-expressed a galactose-inducible GST-cyclin (or vector) with 
V5-tagged Ste5.  After galactose induction, GST fusions and co-bound 
proteins were captured with glutathione-Sepharose.  Bound and input 
proteins were analyzed by immunoblots. 
(B) The m4 mutation disrupts Cln2 binding to multiple partners.  Cells (far1∆) 
expressed V5-tagged Cln2 (wt or m4) and galactose-inducible GST fusions to 
full-length proteins or N-terminal fragments. Ste5* is a hybrid fragment 
(Bhaduri and Pryciak, 2011; Pope et al., 2014), in which the Cln2-docking site 
in the Ste20 N-terminus is replaced with one from Ste5. Grr1∆F lacks its F-
box, to prevent it from driving degradation of Cln2 (Landry et al., 2012). 
(C) Binding of V5-tagged Cln2 (wt or m4) to GST fusions in a FAR1 strain, in 
which binding of Cln2 to some substrates is noticeably weaker than in far1∆ 
cells (Pope et al., 2014).  As in Figure 3.5B, the cln2-m4 mutant shows 
reduced binding for some substrates (Ste20 N-terminus and full-length Whi5), 
yet Srl3 binding is not detectably altered. 
(D) Binding of V5-tagged K. waltii Ccn1 (wt and m4) to the same set of GST 
fusion proteins as tested as Figure 3.5B for Cln2 binding.  Ccn1 binds only a 
subset of the proteins bound by Cln2, but in cases where binding is 
detectable it is disrupted by the m4 mutation.  Note that these Ccn1 
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fragments (1-379) lack the C-terminal tail and the phosphorylation sites 
therein, explaining why they do not bind Grr1∆F (Berset et al., 2002; Landry 
et al., 2012). 
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Figure 3.5. Docking-defective Cln2 and Ccn1 mutants shows reduced 
binding to multiple partners. 
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In vitro kinase assays confirm a specific defect in docking function 
 
To probe the biochemical defects of the cln2-m4 mutant in vitro, we purified wt 
and m4 versions of the Cln2-Cdc28 complex from yeast cells.  cln2-m4 co-
purified with normal amounts of Cdc28 and, when using a generic CDK 
substrate, histone H1, the wt and m4 complexes showed indistinguishable kinase 
activity.  In contrast, however, the cln2-m4 complex showed defects in activity 
against other substrates in a manner that indicated a specific failure in LP 
docking function.  Namely, for several substrates (Sic1, Sic1∆C, Whi5, Stb1), the 
activity of the cln2-m4 complex was reduced to a level comparable to that seen 
when the wt complex was incubated with a competitor LP peptide (Figure 3.6Ai, 
3.6B).  The competitor peptide had negligible effect on the ability of cln2-m4 
complex to phosphorylate docking dependent substrates, indicating that its 
reduced activity specifically reflects an inability to recognize the LP docking site 
to enhance phosphorylation.  Similarly, mutating the LP docking site on Sic1 
(Sic1-vllpp) reduced phosphorylation by the wt complex, but did not affect 
phosphorylation by the m4 complex (Figure 3.6Ai, 3.6B). 
 
 To further assess the defects of the cln2-m4 mutant, the products of these 
kinase reactions were analyzed on Phos-tag gels, which can resolve substrate 
isoforms that differ in the number of phosphate groups added.  The cln2-m4  
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Figure 3.6. Docking promotes multi-site phosphorylation of substrates in 
vitro. 
 
(A) Cln2-Cdc28 complexes containing either wt or m4 Cln2 were purified from 
yeast cells and assayed for substrate phosphorylation in vitro, both with and 
without a competitor LP peptide. (i) Total 32P incorporation into substrates. (ii) 
Reaction products were separated on Phos-tag gels to assess the multiplicity 
of phosphorylation.  
(B) Quantification of 32P incorporation from assays as in panel Ai. 
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Figure 3.6. Docking promotes multi-site phosphorylation of substrates in 
vitro. 
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complex was defective at generating multiply-phosphorylated products of several 
substrates, and instead yielded products modified on few sites.  This behavior is 
similar to that seen when the competitor LP peptide is included, or when the LP 
docking site is lacking from the substrate (Figure 3.6Aii).  Collectively, these in 
vitro findings show that the cln2-m4 mutant has a specific defect in utilizing LP 
docking sites to drive substrate phosphorylation extensively at multiple sites. 
 
Cln2-substrate docking helps coordinate the G1/S transition with cell size  
 
To begin assessing how docking contributes to the cellular functions of Cln2, we 
first asked if cln2-m4 can support cell growth when expressed from the native 
CLN2 promoter.  Indeed, the mutant permitted growth when provided as the only 
G1 cyclin (Figure 3.7A), as well as under conditions where CLN3 was not 
sufficient (i.e., cln1∆ cln2∆ pcl1∆ pcl2∆; Figure 3.7B).  These results confirm that 
cln2-m4 remains generally active, and indicate that docking is not the only 
function that discriminates Cln1/2 from Cln3. 
Because G1 phase is a period of growth before division, defects in the control of 
cell cycle entry can lead to alterations in cell size (Jorgensen and Tyers, 2004; 
Turner et al., 2012).  When we measured cell volumes in asynchronous cultures 
(using cln1∆ strains to eliminate redundancy between Cln1 and Cln2), we found 
that cln2-m4 cultures were shifted toward mildly larger cells (Figure 3.8A, top &  
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Figure 3.7. Effect of the cln2-m4 mutation on viability and cell size. 
 
(A) Spot growth tests of cyclin plasmids in a cln1∆ cln2∆ cln3∆ background.  
Strain PPY2407 (cln1∆ cln2∆ cln3∆ PMET3-CLN2) was transformed with 
plasmids expressing the indicated CLN2 alleles from the native CLN2 
promoter (or a vector control).  Cultures were first kept alive by propagation in 
–Met medium to allow expression of the integrated PMET3-CLN2 allele.  Then, 
serial dilutions were spotted onto medium with or without methionine (to 
repress PMET3-CLN2). 
(B) Spot growth tests of cyclin plasmids in a cln1∆ cln2∆ pcl1∆ pcl2∆ background. 
Strain BY2287A (cln1∆ cln2∆ pcl1∆ PGAL1-PCL2) was transformed with the 
indicated CLN2 or CLN3 plasmids, or a vector control.  Cultures were first 
kept alive by propagation in selective medium with raffinose and galactose.  
Then, serial dilutions were spotted onto solid media either with raffinose + 
galactose or with glucose (to repress PGAL1-PCL2).  
(C) The increases in cell volume caused by the cln2-m4 allele were analyzed as 
in Figure 3.8A, but verified in independent strains. Note that all strains are 
cln1∆. Solid and dashed lines show mean ± SEM (n = 3, in YPD). 
(D) The increases in diameters of mother and unbudded cells caused by the cln2-
m4 allele were analyzed as in Figure 3.8B, but verified using independent 
strains (all of which are far1∆ cln1∆).  Lines denote the mean ± SD. 
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(E) The cln2-m4 allele does not cause an accumulation of 1C or unbudded cells 
in asynchronous, log-phase cultures (grown in YPD).  The graphs plot mean ± 
SEM (n = 9; left), or mean ± range (n = 2; right). 
(F) The cln2-m4 allele and nutrient source affect cell size independently.  
Cultures growing in YP or SC media with different carbon source (glucose, 
galactose, or raffinose) were analyzed.  Graphs plot the mean of duplicate 
measurements for each strain and condition. 
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Figure 3.7. Effect of the cln2-m4 mutation on viability and cell size. 
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Figure 3.8.  cln2-m4 alters the critical cell size for cell cycle entry. 
 
(A) Cell volume is increased in cln2-m4 strains. Note that all strains are cln1∆. 
Solid and dashed lines show mean ± SEM (n = 6, in YPD).  Results were 
similar in independent strains; see Figure 3.7C. 
(B) Increased diameters of mother and unbudded cells in cln2-m4 strains 
compared to CLN2-wt, in far1∆ cln1∆ background. Cells were grown in 
SC/raffinose. Lines denote mean ± SD. Results were similar in independent 
strains; see Figure 3.7D. 
(C) cln2-m4 alters critical size. Small G1 daughter cells (in far1∆ cln1∆ 
background) were isolated by centrifugal elutriation and inoculated in fresh 
medium (note, cln2-m4 cells were born larger than wt cells); samples were 
collected at 15-min. intervals to assay cell volume, budding, and DNA 
replication. For each strain, we assayed two elutriator fractions (denoted by 
open and closed symbols) with distinct starting median cell volumes (17 and 
23 fL for CLN2 wt, or 27 and 30 fL for cln2-m4), to confirm that the 
phenotypes relate to size rather than incubation time. Findings were similar in 
independent strains (not shown). 
(D) Time-lapse microscopy was used to monitor the size (diameter) of cells at the 
times of Whi5 nuclear exit and bud emergence (left), as well as the time 
intervals separating Whi5 exit from Sic1 degradation and budding (right).  
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Only the first G1 of newly born daughter cells was monitored.  Lines show 
mean ± SD. 
(E) cln2-m4 does not alter rate of growth. Median cell volumes from experiment 
described in Figure 3.8C were plotted against time and slope and R2 values 
were calculated for each series.  
     Cln2-wt: Slope = 0.1129 & 0.1374; cln2-m4: Slope= 0.1665 & 0.1637,      
     Cln2-wt: R2 = 0.9718 & 0.9944; cln2-m4: R2= 0.9758 & 0.9963. 
(F) Summary of phenotypes.  In cln2-m4 cells, Whi5 exit is delayed and Start 
occurs at a larger cell size.  After the delayed Start, subsequent events (DNA 
replication, bud emergence) occur with relatively normal timing. 
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Figure 3.8.  cln2-m4 alters the critical cell size for cell cycle entry. 
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3.7C top: represents two independently derived strains), consistent with a 
previously documented role for Cln1/2 in setting critical cell size (Dirick et al., 
1995; Ferrezuelo et al., 2012; Skotheim et al., 2008).  Remarkably, this 
difference between CLN2 and cln2-m4 cultures was amplified in cells lacking the 
CDK inhibitor protein Far1 (Figures 3.8A, 3.7C: represents two independently 
derived strains).  We were primed to consider such an effect by our recent finding 
that Far1 competitively interferes with Cln2-substrate docking (Pope et al., 2014 
& Chapter 4). This effect raised the possibility that mutations in the docking 
interface of Cln2 could simultaneously impair Far1 interaction, so that the 
resulting defects in positive functions of Cln2 are partly counteracted by reduced 
inhibition from Far1 (see Discussion).  Hence, to avoid differential inhibition, 
further analysis was conducted using far1∆ strains. 
 
 When examined microscopically, mother cells and unbudded cells in cln2-
m4 cultures had significantly larger diameters than those in wt cultures (Figures 
3.8B, 3.7D: represents two independently derived strains), suggesting that the 
mutant cells did not begin dividing until they reached a larger size.  Indeed, when 
small daughter G1 cells were isolated by centrifugal elutriation (Figure 3.8C), we 
observed a clear delay in the G1/S transition such that cln2-m4 cells did not 
begin budding and DNA synthesis until they reached a roughly one-third greater 
volume than wt cells (i.e., ~ 40 vs. 30 fL).  The m4 cultures started at larger sizes 
than wt cultures but rate of growth of both wt and m4 cells were very similar 
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(Figure 3.8E). Thus, disruption of the docking function of Cln2 skews the 
calibration between cell size and cell cycle entry.  To pinpoint the defect, we 
conducted time-lapse microscopy with fluorescent forms of two critical G1/S 
regulators, the transcriptional repressor Whi5 and the CDK inhibitor Sic1. The 
cln2-m4 cells delayed the nuclear exit of Whi5 until cells were larger, whereas 
the subsequent degradation of Sic1 and budding occurred with relatively normal 
timing thereafter (Figure 3.8D).  Thus, the predominant effect of cln2-m4 is to 
delay Start (Figure 3.8F), which coincides with Whi5 exit and the initiation of 
G1/S transcription (Doncic et al., 2011; Skotheim et al., 2008).  It is notable that 
this delay does not cause an accumulation of excess 1C or unbudded cells in 
asynchronous cultures (Figure 3.7E), likely because cells that bud at a larger size 
also produce larger daughters (i.e., with a larger birth size), and hence the time 
from birth to budding remains comparable.  The size threshold for division is also 
regulated by the availability of nutrients such as carbon source (Jorgensen and 
Tyers, 2004; Turner et al., 2012), but the cell size effect of the cln2-m4 allele is 
independent of nutrient regulation, as the mutant cells still shifted to smaller sizes 
in poor carbon media and were always larger than wt regardless of nutrient 
conditions (Figure 3.7F).  Therefore, nutrient regulation remains intact, but the 
eventual execution of Start is delayed in cln2-m4 cells. 
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Docking promotes Whi5 phosphorylation and bud polarization 
 
To compare the potency of cyclins at driving Whi5 phosphorylation in vivo, 
we used conditions in which any delays in achieving critical cell size were first 
eliminated.  For this, we synchronized cells by a prolonged G1 arrest using 
mating pheromone.  Cells arrested in G1 continue to grow (Goranov et al., 2009; 
Moore, 1983), and so upon release can begin cell cycle entry without further 
growth delay (Schwob and Nasmyth, 1993), much as large mother cells do not 
rely on size and instead use a timer to govern Start (Di Talia et al., 2007).  To 
further equalize initial conditions, and permit comparisons of Cln2 variants both 
with and without Cln3, we used cells with a separate PMET3-CLN2  
construct (Dirick et al., 1995; Skotheim et al., 2008) that was expressed only 
during initial propagation and then repressed during the experiment. 
 
 Using these conditions, we monitored Whi5 gel mobility (Figure 3.9A), 
which is slowed upon CDK phosphorylation (Costanzo et al., 2004; de Bruin et 
al., 2004; Wagner et al., 2009).  V5-tagged Whi5 was resolved into three species; 
one in G1 arrested cells, plus two higher forms that appeared after release 
(Figure 3.9Ai-ii).  Notably, in CLN2-wt cells the highest form eventually became 
the predominant species, whereas this never occurred in cln2-m4 cells and 
instead the middle form was predominant.  This pattern suggests that cln2-m4 
cannot drive Whi5 phosphorylation as extensively as wt, in agreement with the in  
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Figure 3.9.  Whi5 phosphorylation and bud polarization depend on Cln2 
docking. 
 
(A) CLN3 cln1∆ cln2∆ PMET3-CLN2 and cln3∆ cln1∆ cln2∆ PMET3-CLN2 cells 
harbored a CLN2 plasmid (wt or m4; native promoter) or empty vector. Cells 
were arrested in G1 phase with α factor (plus methionine to repress PMET3-
CLN2), and then released; aliquots were harvested at times shown.  Whi5 
phosphorylation was monitored by immunoblotting for Whi5-V5 (i, ii) or Whi5-
GFP (iii); Cln2-V5 levels and a loading control (G6PDH) are shown for set (iii). 
(B) mRNAs levels were measured, in the cln3∆ background, using conditions as 
in panel (A).  Graphs plot mean ± SEM (n = 5), and asterisks indicate p < 0.05 
(t-test) for wt vs. m4. 
(C) The cln2-m4 protein shows reduced turnover. Cells harboring a CLN2-V5 
plasmid (wt or m4; as in panel Diii), growing in +Met medium, were treated 
with 50 µg/mL cycloheximide (CHX). Cln2-V5 and G6PDH levels were 
measured at times indicated. The graph plots the fraction of protein remaining 
(mean ± SD; n = 4) with exponential trendlines; half-lives (t1/2) were calculated 
by fitting to an exponential decay (in Prism 7). 
(D) cln2-m4 is deficient at driving polarized bud growth. Cells harboring a PGAL1-
CLN2 plasmid (wt or m4) were induced with galactose for 1.5 or 3 hr. Images 
are from 1.5 hr. Plots show individual bud lengths with mean ± SD (n > 150); 
p = 10-29 (1.5 hr) or 10-33 (3 hr) by two-tailed t-test. 
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(E) Cells harboring PGAL1-CLN2 or PGAL1-CCN1 plasmids (as in Figure 3.3C) were 
induced with galactose for 3.5 hr. Plots show bud lengths with mean ± SD (n 
> 50); for all pair-wise comparisons of wt versus m4, p < 10-4 (two-tailed t-
test).  Also see Figure 3.10B. 
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Figure 3.9.  Whi5 phosphorylation and bud polarization depend on Cln2 
docking. 
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vitro assays.  GFP-tagged Whi5 was resolved into only two species (Figure 
3.9Aiii), but again we observed less of the uppermost form in cln2-m4 cells.  This 
reduced phosphorylation of Whi5 was associated with mildly reduced G1/S 
transcription (Figure 3.9B) and budding (Figure 3.10A), whereas DNA synthesis 
was unaffected (Figure 3.10A), consistent with prior findings that Cln1/2 have a 
more unique role in bud emergence whereas expression of Clb5/6 is sufficient to 
trigger DNA synthesis (Dirick et al., 1995; Moffat and Andrews, 2004; Schwob 
and Nasmyth, 1993).  Furthermore, it is particularly noteworthy that in the 
absence of Cln2 (i.e., empty vector), phosphorylation of Whi5 by Cln3 was barely 
detectable (Figure 3.9Aii-iii), despite prior evidence that Cln3 triggers its initial 
inactivation (de Bruin et al., 2004; Skotheim et al., 2008).  This raises the 
interesting possibility that Cln3-CDK phosphorylates Whi5 on only a fraction of its 
twelve CDK sites and that Cln1/2-CDK follow with more complete multi-site 
phosphorylation (see Discussion).  Altogether, these findings indicate that cln2-
m4 is not entirely defective but is deficient at driving full modification of 
substrates. 
 
 Interestingly, in these synchronous cultures, the cln2-m4 protein was 
initially expressed on schedule but then persisted long after the wt protein 
declined (Figure 3.9Aiii), suggesting that it might have a reduced turnover rate.  
Indeed, using a cycloheximide chase assay, the half-life was roughly doubled for 
the mutant protein (Figure 3.9C).  Hence, Cln2 turnover might be governed by 
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docking interactions with specific partner proteins (see Discussion).  This 
stabilization is also noteworthy because the increased protein levels or duration 
in the mutant might partially counteract its defects. 
 
 Finally, we analyzed how docking contributes to function of Cln2 in 
polarized bud growth. Early in the cell cycle, Cln1 and Cln2 have a special role in 
driving bud emergence as well as highly polarized apical growth of the new buds, 
which then shifts to an isotropic pattern as Cln1/2 levels decline and Clb1-6 
cyclins take their place (Lew and Reed, 1993).  If Cln2 is expressed continuously 
from a foreign promoter (e.g., PGAL1), it can drive incessant apical growth and 
lead to hyperpolarized buds (Lew and Reed, 1993).  We found that the ability to 
drive hyperpolarized growth was greatly diminished for the docking mutant, cln2-
m4 (Figure 3.9D).  Furthermore, the hyperpolarized phenotype was also 
observed upon expression of other members of the Cln1/2 and Ccn1 subgroups 
(Figures 3.9E, 3.10B), and in each case this was disrupted by the m4 mutation.  
Thus, docking helps each of these cyclins drive directionally persistent bud 
growth, which may be of particular importance in fungi that form hyphal filaments 
(see Discussion). 
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Figure 3.10. Analysis of synchronous cultures and cell polarization  
 
(A) Budding and DNA replication, in both CLN3 and cln3∆ backgrounds, were 
measured following the G1 arrest and release, as in Figure 3.9A.  Graphs, 
mean ± SEM (n = 3-6). 
(B) The effect of m4 mutations on the ability of Cln1/2 and Ccn1 cyclins to 
drive polarized bud growth. The same experiment shown in Figure 3.9E 
was performed here using only 1.5 hr galactose induction. The graphs plot 
individual bud lengths with the mean ± SD (n > 50); p < 10-4, by two-tailed 
t-test, for all pair-wise comparisons of wt versus m4. 
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Figure 3.10. Analysis of synchronous cultures and cell polarization 
(related to Figure 3.9). 
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Discussion 
 
In this study we have identified a mutant form of the yeast cyclin Cln2 that is 
deficient in recognition of LP-type docking sites on CDK substrates.  The 
detection of key residues in Cln2 was aided by the discovery that recognition of 
LP docking motifs is conserved in the distinct Ccn1 group.  Mutation of these 
residues disrupts docking interactions with multiple CDK substrates, and disrupts 
multi-site phosphorylation of substrates in vitro.  In vivo, these defects hamper 
the ability of Cln2 to drive polarized bud morphogenesis and to fully 
phosphorylate a key G1/S regulator.  Moreover, disruption of docking by Cln2 
alters the calibration of Start to cell size, such that cells delay entry into the cell 
cycle until they are larger than normal. 
 
 Conservation of LP docking in both Cln1/2 and Ccn1 groups attests to a 
selectively advantageous function. Of note, Cln3 and Cln1/2 groups likely 
diverged from each other after they split from the Ccn1 group (N. Buchler, 
personal communication), implying that LP docking existed in the prior common 
ancestor but was then lost in Cln3.  Indeed, most non-yeast fungi (dikarya) 
harbor only one G1 cyclin, and initial studies suggest that they can recognize LP 
motifs (S. B. and P.M.P., unpublished observations). Still, LP docking may not be 
identical in each case, as Ccn1 bound some but not all of the same substrates as 
Cln1/2 (Figure 3.5D), and we have observed parallel differences in 
phosphorylation assays (S. B. and P.M.P., unpublished observations).  Thus, as 
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the cyclin groups diverged, they may have developed distinct preferences for LP 
motif composition.  Future elucidation of these specificity determinants can 
illuminate the evolution of these docking networks. 
 
 LP docking motifs are functionally distinct from RxL motifs (Bhaduri and 
Pryciak, 2011; Koivomagi et al., 2011b), which bind a hydrophobic patch (HP) on 
S-phase cyclins (Loog and Morgan, 2005; Schulman et al., 1998; Wilmes et al., 
2004). A comparison of the HP and m4 regions, using bona-fide structures or 
models, suggests that they are close but separated (Figure 3.11A, B). The m4 
residues begin at a ridge bordering the HP cleft and then proceed along the edge 
of an adjacent plateau.  The non-polar Leu112 residue that is most critical in Cln2 
is predicted to be solvent-exposed, and thus is well suited to mediate 
energetically favorable interactions with Leu/Pro-rich LP motifs.  Interestingly, 
although RxL peptides from CDK substrates do not encroach upon the m4 
plateau (Cheng et al., 2006; Lowe et al., 2002), the inhibitor protein p27, which 
binds cyclin A-CDK2 over a broad interface (Russo et al., 1996), does make 
contacts in this region as it traverses from the HP cleft toward the CDK (Figure 
3.11A).  Hence, it is conceivable that LP docking originated from an earlier role in 
assisting contact with CDK inhibitors, and then evolved an independent function.  
Indeed, fungal Cln proteins are thought to have evolved from a B-type cyclin 
precursor (N. Buchler, personal communication). Reconstruction of ancestral 
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Figure 3.11. Docking interfaces and models. 
 
(A) Structures of a mammalian cyclin A-CDK2 complex, with and without the 
inhibitor protein p27 (PDB IDs: 1H26, 1JSU), compared to models for S. 
cerevisiae Cln2 and K. waltii Ccn1 generated by the I-TASSER algorithm 
(Roy et al., 2010). The hydrophobic patch (HP, yellow) and residues altered in 
the m4 mutants (red) are highlighted. 
(B) Close-up of the boundary between HP and m4 regions in the predicted 
models, with mutated residues labeled. 
(C) General schematic model for accumulation of Cln1/2-CDK activity and 
substrate phosphorylation in late G1 phase.  See text for discussion. 
(D) Disruption of Cln2 docking may simultaneously disrupt both positive output  
      and negative regulation.  See text for discussion. 
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Figure 3.11. Docking interfaces and models 
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cyclins might reveal if any intermediate forms recognized both RxL and LP 
motifs.  
In vitro, the docking function of Cln2 was required for the extensive 
phosphorylation of substrates at multiple sites, which occurs via processive 
catalysis involving binding of initial phospho-peptides to the Cks1 subunit of the 
cyclin-CDK-Cks1 complex (Koivomagi et al., 2013; McGrath et al., 2013).  Thus, 
in vivo, cell cycle events that require substrates to become highly phosphorylated 
are likely to be especially dependent on docking, and this may underlie some 
functional distinctions between different G1 cyclins. In this regard, the Whi5 
phosphorylation behavior that we observed in vivo is especially noteworthy.  
Although Cln3 initiates the inactivation of Whi5 (de Bruin et al., 2004; Skotheim et 
al., 2008), our analysis of Whi5 gel mobility suggests that Cln3 is not as proficient 
as Cln2 at triggering extensive modification of Whi5 in vivo, and this more potent 
activity of Cln2 depends at least in part on docking.  A superior ability to drive full 
Whi5 phosphorylation could explain why Cln1/2 accelerate the pace of Whi5 
chromatin dissociation and nuclear exit, after being initiated by Cln3 (de Bruin et 
al., 2004; Skotheim et al., 2008). A two-stage relay, in which Whi5 is 
phosphorylated partially by Cln3 and then more completely by Cln1/2, would be 
remarkably analogous to recent findings on Rb phosphorylation by cyclin D and 
cyclin E in animal cells (Narasimha et al., 2014), and to the sequential 
phosphorylation of Sic1 by Cln1/2 and Clb5 in yeast (Koivomagi et al., 2011a; 
Yang et al., 2013). 
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 We found that substrate docking by Cln2 is important for initiating the cell 
cycle at the proper size.  According to current views on cell size control in yeast, 
Cln1/2 are not expected to be involved in the size sensing mechanism per se but 
rather in the robust execution of molecular events that drive cell cycle entry once 
the sensing mechanism is satisfied (Jorgensen and Tyers, 2004; Turner et al., 
2012).  Thus, the commitment point at Start represents a brief interval in which 
Cln1/2-CDK activity rapidly accumulates (Figure 3.11C).  Accordingly, the 
docking function of Cln1/2 likely contributes to a sharp and speedy transition by 
ensuring that full phosphorylation of substrates occurs promptly once the cyclins 
start to be expressed.  Indeed, many key regulators of the G1/S transition are 
proteins with multiple CDK sites whose complete phosphorylation would benefit 
from docking, including not only Whi5 but also Sic1 and Cdh1 (Nash et al., 2001; 
Zachariae et al., 1998), whose inactivation permits the rise in Clb-CDK activity 
needed for DNA synthesis.  Notably, the cln2-m4 mutant showed reduced 
interactions with some of these key regulators (Figure 3.5). Thus, our results 
support the view that substrate docking by Cln1/2 helps ensure that the 
commitment step governing cell cycle entry occurs rapidly and decisively. 
 
 It is noteworthy that the cln2-m4 phenotypes were subtler in G1 
arrest/release experiments than in the first cycle of new daughter cells. A similar 
phenomenon was observed previously, in which ectopic Clb5 expression 
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triggered S phase much more readily in cells that had undergone prolonged G1 
arrest than in early G1 daughters (Schwob and Nasmyth, 1993). Because 
arrested cells continue to grow, they can be past the critical size at the time of 
release, and this may alter the threshold level of cyclin-CDK activity required to 
pass Start (Di Talia et al., 2007). 
 
 Our observation that Cln2 docking contributes to bud formation and 
polarized morphogenesis fits with prior findings that Cln2 substrates include 
several proteins involved in cell polarization such as GEFs and GAPs for Rho 
GTPases (reviewed in (Enserink and Kolodner, 2010; Wang, 2009)), some 
examples of which (i.e., Rga1, Tus1) showed reduced binding to cln2-m4.  
Relatedly, G1 cyclins drive persistent polarized growth in filamentous fungi such 
as Ashbya gossypii (Hungerbuehler et al., 2007) and Candida albicans (Loeb et 
al., 1999; Zheng and Wang, 2004), where they phosphorylate secretory proteins 
and septins (Bishop et al., 2010; Sinha et al., 2007; Zheng et al., 2007).  
Substrate docking by the Cln1/2 and Ccn1 groups could help maintain high levels 
of substrate phosphorylation in a localized subcellular domain, and conceivably 
could co-localize the cyclin with substrates at sites of polarized growth. 
 
 Two sources of indirect evidence suggest that the docking interface on 
Cln2 promotes not only positive functions but also regulation by antagonists 
(Figure 3.11D).  First, the cln2-m4 protein shows reduced turnover, suggesting 
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that the docking interface might interact with degradation machinery.  A likely 
participant in this process is Cdc48, which binds Cln2 and stimulates its turnover 
(Archambault et al., 2004); unfortunately, we have not yet obtained sufficiently 
strong binding with Cdc48 to test if it is disrupted by the m4 mutation.  Second, 
some phenotypic differences between wt and cln2-m4 alleles were greater in 
far1∆ cells. This raises the possibility that, when comparing Cln2-wt and cln2-m4 
in FAR1 cells, the defects in positive functions of cln2-m4 are partly suppressed 
by reduced inhibition from Far1. Of note, Far1 blocks Cln2-substrate docking 
(Pope et al., 2014 & Chapter 4), and hence it may engage the docking interface 
on Cln2.  Indeed, in a recently developed in vitro assay for Far1 inhibition (E.V. 
and M.L., in preparation), the cln2-m4 mutation increased the Ki of Far1 by 
roughly ten-fold.  There are precedents for a single docking region binding both 
positive and negative factors, including in cyclin-CDK complexes (Lowe et al., 
2002; Russo et al., 1996; Schulman et al., 1998) and MAP kinases (Remenyi et 
al., 2005). Competition among substrates and regulators for a common docking 
interface may provide a simple mechanism to integrate multiple factors. 
 
 In conclusion, our findings uncover a novel substrate-docking interface, 
conserved among distinct G1 cyclin sub-groups, that contributes to efficient, 
multi-site phosphorylation of substrates and to the punctual entry into the cell 
cycle.  The patterns of conservation among different G1 cyclins could illuminate 
further studies into the evolution of docking interfaces, and they also raise the 
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question of whether the Cln3 group lacks docking entirely or if it has docking 
interactions that remain to be discovered.  In addition, it will be of interest to 
study the requirement for LP docking by G1 cyclins in filamentous fungi where 
polarized growth at hyphal tips shows high directional persistence.  Finally, these 
findings provide a useful launch point for future studies into understanding how 
robust substrate phosphorylation promoted by cyclin-substrate docking 
interactions influences cell-to-cell variability of Start (Di Talia et al., 2007; 
Ferrezuelo et al., 2012) and the temporal coherence of distinct events at the 
G1/S transition (Skotheim et al., 2008). 
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Materials and Methods 
 
Yeast Strains and Plasmids 
Standard procedures were used for growth and genetic manipulation of yeast 
(Rothstein, 1991; Sherman, 2002). Cells were grown at 30°C in yeast 
extract/peptone medium with 2% glucose (YPD) or galactose (YPGal), or in 
synthetic (SC) medium with 2% glucose and/or raffinose. Strains and plasmids 
are listed in the tables below. The cln2-m4 allele was introduced at the native 
CLN2 locus by two-step (pop-in/pop-out) allele replacement (Rothstein, 1991), 
using plasmid pPP4121. PCR-mediated methods (Longtine et al., 1998) were 
used for gene deletion and tagging endogenous gene loci. 
 
In vivo CDK Phosphorylation Assays 
As described previously (Bhaduri and Pryciak, 2011; Pope et al., 2014), cells 
harboring PGAL1-GST-cyclin constructs and HA-tagged CDK substrates were 
grown in synthetic raffinose media, and then induced with 2% galactose (for 2.5 
hr) to drive cyclin expression; substrates were based on the Ste5 N-terminus, 
with or without docking sites as indicated. Whole cell extracts were prepared, and 
substrate phosphorylation was assessed by SDS-PAGE and immunoblotting. 
 
Protein Preparation, Binding, and Immunoblotting 
Whole cell extracts were prepared by lysis in trichloroacetic acid as described 
previously (Pope et al., 2014), using 5 or 2 mL cultures (OD660 ~ 0.6); total 
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protein concentrations were measured by BCA assay, and equal amounts 
(usually 20 µg) were loaded per lane. 
 GST co-precipitation binding assays were performed as described (Pope 
et al., 2014).  Briefly, 10 mL cultures were treated with 2% galactose (1.5 hr) to 
express GST fusion proteins. Extracts were prepared by glass bead lysis, and 
GST fusions and co-bound proteins were collected using glutathione-sepharose 
beads. 
 For immunoblotting, proteins were resolved by SDS-PAGE and 
transferred to PVDF in a submerged tank. Primary antibodies were mouse anti-
V5 (1:5000, Invitrogen #46-0705), anti-HA (1:1000, Covance #MMS101R), anti-
GFP (1:200, Clontech # 632381) or anti-GST (1:1000, Santa Cruz 
Biotechnologies #sc-138), rabbit anti-G6PDH (1:1000, Sigma #A9521), and goat 
anti-Cdc28 (1:200 Santa Cruz #sc-6709). HRP-conjugated secondary antibodies 
were goat anti-mouse (1:3000, BioRad #170-6516), goat anti-rabbit (1:3000, 
Jackson ImmunoResearch #111-035-144), or donkey anti-goat (1:3000 Santa 
Cruz #sc-2020). Enhanced chemiluminescent detection used a BioRad Clarity kit 
(#170-5060). 
 
Synchronous Cultures 
Small G1 cells were purified by centrifugal elutriation as described previously 
(Strickfaden et al., 2007). Initial cultures (0.7-1 L) were grown in synthetic 
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raffinose medium.  Elutriated cells were resuspended in YPD and then incubated 
at 30˚C. 
 For synchronization by G1 arrest/release, CLN3 cln1∆ cln2∆ PMET3-CLN2 
and cln3∆ cln1∆ cln2∆ PMET3-CLN2 cells harbored a CLN2 plasmid (wt or m4; 
native promoter) or empty vector. Cells were grown in –Met medium, then 
arrested in G1 phase by transfer to +Met medium (to repress PMET3-CLN2) 
containing α factor (0.1 µM, 150 min), then released by washing twice and 
incubating in +Met medium without α factor. 
 
Flow Cytometry and Budding Assays 
DNA content was measured by flow cytometry using Sytox Green as described 
previously (Pope and Pryciak, 2013).  Budding status was assayed using 
formaldehyde-fixed cells as described previously (Pope and Pryciak, 2013); 200 
cells were counted per condition. 
 
mRNA Preparation and RT-qPCR Analysis 
RNA was prepared as described previously (Pope and Pryciak, 2013), and cDNA 
was synthesized from ~1 µg of RNA with a QuantaBio qScript kit (#95048-025); 
products were diluted to 5 ng/µL.  Quantitative real-time PCR was performed 
using KAPA Biosystems SYBR FAST qPCR Master Mix (#KK4601). Reaction 
mixtures (10 µL) contained 5 µL of SYBR Green mix, 1.3 µL of primer mix (0.4 
µM each primer), 1 µL of cDNA (5 ng), and 2.7 µL of water.  Reactions were 
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performed in 96-well plates, in duplicate, using a BioRad CFX96 instrument; 
ACT1 mRNA served as the internal control. Data were normalized to the average 
maximum wt level. 
 
Cell Size Measurements 
Cell volume was measured using a Beckman Coulter Multisizer 3 (Beckman 
Coulter). Log-phase cultures were briefly sonicated, and then 10 µL was diluted 
into 10 mL of Isoton II diluent (Beckman Coulter #8546719), and 30,000 cells 
were sized per sample.  Particles below 3 µm in diameter were excluded to 
ignore dead cells. 
 Cell diameters and bud lengths were measured microscopically. Images of 
multiple fields of live cells were captured, and then all relevant cells were 
analyzed in Image J software. Mother cell diameter was defined by a line starting 
at the midpoint of the bud neck, bisecting the mother. Unbudded cells were 
measured using the longest axis evident.  Bud lengths were measured from neck 
to tip. 
 
In Vitro Kinase Assays 
HA3-tagged Cln2-Cdc28 complexes were purified from yeast (PPY2443, 
PPY2444) using previous immunoaffinity methods (Koivomagi et al., 2013; 
Koivomagi et al., 2011b). 
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Time-Lapse Microscopy 
Cells expressing Whi5-mCherry and Sic1-GFP, growing in SC medium, were 
entrapped in a CellASIC microfluidic device, as in previous studies (Doncic et al., 
2011). Images were acquired every 3 min., and multiple fields were followed 
simultaneously.  Using pre-existing software (Doncic et al., 2011; Yang et al., 
2013), fluorescence data were analyzed to determine the midpoint times of Whi5 
nuclear exit and Sic1 degradation.  Phase-contrast images were inspected 
manually to determine the time of bud emergence, and Image J software was 
used to measure cell diameters at the midpoint of Whi5 exit and the onset of 
budding. 
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     Table 3.1.   Yeast strains used in Chapter III 
Yeast strains used in this study. 
Name Background* Relevant Genotype Source† 
    
BY2287 (a) MATa cln1∆::TRP1  cln2Δ::LEU2  pcl1Δ::HIS3  kanMX6-PGAL1-3HA-PCL2 (1) 
BY4741 (b) MATa (2) 
PPY2322 (b) MATa bar1∆::hphMX6  (3) 
PPY2326 (b) MATa bar1∆::hphMX6 far1Δ::kanMX6 (3) 
PPY2327 (b) MATa bar1∆::hphMX6 STE5-8A far1Δ::kanMX6 (3) 
PPY2330 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-S87A (3) 
PPY2406 (c) MATa bar1∆::hphMX6  TRP1::PMET3-CLN2  WHI5-GFP::kanR  HTB2-
mCherry::spHIS5 cln1::HIS3  cln2∆ 
§ 
PPY2407 (c) MATa bar1∆:hphMX6  TRP1::PMET3-CLN2  WHI5-GFP::kanR  HTB2-
mCherry::spHIS5 cln1::HIS3  cln2∆  cln3::LEU2 
§ 
PPY2431 (c) MATa bar1∆::hphMX6  TRP1::PMET3-CLN2  WHI5-3xV5::natMX6  HTB2-
mCherry::spHIS5 cln1::HIS3  cln2∆ 
§ 
PPY2432 (c) MATa bar1∆:hphMX6  TRP1::PMET3-CLN2  WHI5-3xV5::natMX6  HTB2-
mCherry::spHIS5 cln1::HIS3  cln2∆  cln3::LEU2 
§ 
PPY2433 (c) MATa bar1::hisG  SIC1-TAP::HIS3MX6  cln1∆::LEU2Cg ‡ 
PPY2438 (c) MATa bar1::hisG  sic1(vllpp)-TAP::HIS3MX6  cln1∆::LEU2Cg ‡ 
PPY2443 (c) MATa bar1∆  cln2::TRP1::PGAL1-HA3-CLN2 # 
PPY2444 (c) MATa bar1∆  cln2::TRP1::PGAL1-HA3-cln2-m4 # 
PPY2452 (c) MATa bar1::hisG  SIC1-TAP::HIS3MX6  cln1∆::LEU2Cg  cln2-m4 ‡ 
PPY2457 (c) MATa bar1::hisG  sic1(vllpp)-TAP::HIS3MX6  cln1∆::LEU2Cg  cln2-m4 ‡ 
PPY2472 (c) MATa ADE2 bar1::hisG  WHI5-mCherry::HIS3MX6  SIC1-GFP::kanMX6  
cln1∆::LEU2Cg 
# 
PPY2474 (c) MATa ADE2 bar1::hisG  WHI5-mCherry::HIS3MX6  SIC1-GFP::kanMX6  
cln1∆::LEU2Cg  cln2-m4 
# 
PPY2487 (c) MATa bar1::hisG  SIC1-TAP::HIS3MX6  cln1∆::LEU2Cg  far1∆::kanMX6 # 
PPY2488 (c) MATa bar1::hisG  SIC1-TAP::HIS3MX6  cln1∆::LEU2Cg  cln2-m4  
far1∆::kanMX6 
# 
PPY2490 (c) MATa ADE2  bar1::hisG  WHI5-mCherry::HIS3MX6  SIC1-GFP::kanMX6  
cln1∆::LEU2Cg  far1∆::kanMX6 
# 
PPY2492 (c) MATa ADE2  bar1::hisG  WHI5-mCherry::HIS3MX6  SIC1-GFP::kanMX6  
cln1∆::LEU2Cg  cln2-m4  far1∆::kanMX6 
# 
    
* Strain Background:  (a) S288C/BY263 (ade2-107 his3∆200 leu2-3,112 lys2-801 trp1∆63 ura3-52 ssd1-d); (b) 
BY4741 (his3∆1 leu2∆0 ura3∆0 met15∆0); (c) W303 (ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1). 
 
† Source:  (1) Moffat/Andrews; (2) Bachman/Boeke; (3) Pope/Bhaduri; (§) this study, derived from JS146-8C and 
JS146-16C (Doncic et al.); (‡) this study, derived from MK0158 and MK0311 (Koivomagi et al.; Koivomagi et al.); (#) 
this study. 
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Table 3.2.   Plasmids used in Chapter III 
Plasmids used in this study 
Name Alias Description Source 
pPP681 pRS316 CEN URA3 vector (1) 
pPP2154 pHG-GST CEN HIS3 PGAL1-GST vector  (2) 
pPP2163 pHGT-S20A CEN HIS3 PGAL1-GST-ste20(1-333)  (3) 
pPP3266 pS5kV5  CEN URA3 STE5-3xV5   TCYC1  (4) 
pPP3434 pS5kHA-1-315 CEN URA3 ste5 1-315- 3xHA   TCYC1 (2) 
pPP3503 pS5kHA-1-260  CEN URA3 ste5 1-260- 3xHA tag   TCYC1 (2) 
pPP3509 pH5n-1-337-wt CEN URA3 ste5 1-337-(wt)- 3xHA   TCYC1 (2) 
pPP3547 pH5n-1-260-S20CSM CEN URA3 ste5 1-260-(Ste20 80-115wt)- 3xHA   TCYC1 (2) 
pPP3714 pH5n-1-337-P4 CEN URA3 ste5 1-337-(LLPP-AAAA)- 3xHA   TCYC1 (2) 
pPP3807 pH5n-1-260-dExo84 CEN URA3 ste5 1-260-(Exo84 281-311)- 3xHA   TCYC1 (2) 
pPP3825 pHG-GST-S20M-5CSM-wt CEN HIS3 PGAL1-GST-ste5(263-335/WT)  + ste20(120-333)  (2) 
pPP3874 pt-HGTB-CLN2-F   CEN HIS3 PGAL1-GST-CLN2(1-545)  TCYC1 this study 
pPP3875 pS5kHA-1-260-E34(I)  CEN URA3 ste5(1-260)-[E34(I) zipper]-  3xHA   TCYC1 this study 
pPP3876 pS5kHA-1-260-E34(V)   CEN URA3 ste5(1-260)-[E34(V) zipper]-  3xHA   TCYC1 this study 
pPP3877 pS5kHA-1-260-E34(N)  CEN URA3 ste5(1-260)-[E34(N) zipper]-  3xHA    TCYC1 (4) 
pPP3903 pt-HGTB-CLN2-F-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545)   TCYC1 this study 
pPP3904 pt-HGTB-CLN2-F-R34dn  CEN HIS3 PGAL1-GST-CLN2(1-545)-[R34 zipper]   TCYC1 this study 
pPP3916 pt-HGT-CLN2-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-372)   TCYC1 (4) 
pPP3917 pt-HGTB-CLN2-hpm1-Rup CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /hpm1)  TCYC1 this study 
pPP3918 pt-HGTB-CLN2-hpm3-Rupb CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /hpm3)  TCYC1 this study 
pPP3919 pt-HGT-Rup-Sklu-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Sklu CLN1/2(1-364)  TCYC1 this study 
pPP3920 pt-HGT-Rup-Kwal-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CLN1/2(1-363)  TCYC1 this study 
pPP3921 pt-HGT-Rup-Agos-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Agos CLN1/2(1-364)  TCYC1 this study 
pPP3922 pt-HGT-Rup-Cgla-CLN1 CEN HIS3 PGAL1-GST-[R34 zipper]-Cgla CLN1(1-362)  TCYC1 this study 
pPP3923 pt-HGT-Rup-Cgla-CLN2 CEN HIS3 PGAL1-GST-[R34 zipper]-Cgla CLN2(1-371)  TCYC1 this study 
pPP3929 pt-HGT-CLN1-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN1(1-388)  TCYC1 (4) 
pPP3954 pt-HGTE-CLN2-F-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545)  TCYC1  this study 
pPP3957 pt-HGT-Rup-Kwal-CCN1 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CCN1(1-379)  TCYC1 this study 
pPP3959 pt-HGT-Rup-Calb-CCN1-a CEN HIS3 PGAL1-GST-[R34 zipper]-Calb CCN1(1-469)  TCYC1  this study 
pPP3963 pt-HGT-Rup-Agos-CLN3 CEN HIS3 PGAL1-GST-[R34 zipper]-Agos CLN3(1-324)  TCYC1 this study 
pPP3964 pt-HGT-CLN3-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN3(1-395)  TCYC1 (4) 
pPP3965 pt-HGTE-Rup-CLN2-mut1 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m1)  TCYC1    this study 
pPP3966 pt-HGTE-Rup-CLN2-mut2 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m2)  TCYC1   this study 
pPP3967 pt-HGTE-Rup-CLN2-mut3 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m3)  TCYC1   this study 
pPP3968 pt-HGTE-Rup-CLN2-mut4 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m4)  TCYC1    this study 
pPP3969 pt-HGTE-Rup-CLN2-mut5 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m5)  TCYC1    this study 
pPP3970 pt-HGTE-Rup-CLN2-mut6 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m6)  TCYC1    this study 
pPP3971 pt-HGTE-Rup-CLN2-mut7 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m7)  TCYC1  this study 
pPP3972 pt-HGTE-Rup-CLN2-mut8 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m8)  TCYC1   this study 
pPP3973 pt-HGTE-Rup-CLN2-mut9 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m9)  TCYC1     this study 
pPP3974 pt-HGTE-Rup-CLN2-mut10 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m10)  TCYC1    this study 
pPP3975 pt-HGTE-Rup-CLN2-mut11 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m11)  TCYC1    this study 
pPP3976 pt-HGTE-Rup-CLN2-mut12 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /m12)  TCYC1    this study 
pPP4078 pHGT-Rga1-FL  CEN HIS3 PGAL1-GST-RGA1 (full length)  this study 
pPP4079 pHGT-Srl3-FL  CEN HIS3 PGAL1-GST-SRL3 (full length) this study 
pPP4080 pHGT-Tus1-1-300  CEN HIS3 PGAL1-GST-tus1(1-300)  this study 
pPP4111 pt-HGT-Rup-CLN2-t-mut4 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-372 /m4)  TCYC1 this study 
pPP4115 pCLN2pr-CLN2-V5-wt  CEN URA3 PCLN2-CLN2(1-545 /wt)-3xV5   TCYC1    this study 
pPP4116 pCLN2pr-CLN2-V5-mut4  CEN URA3 PCLN2-CLN2(1-545 /mut4)-3xV5   TCYC1     this study 
pPP4117 pCYC1-CLN2-V5-wt  CEN URA3 PCYC1-CLN2(1-545 /wt)-3xV5   TCYC1   this study 
pPP4118 pCYC1-CLN2-V5-mut4 CEN URA3 PCYC1-CLN2(1-545 /mut4)-3xV5   TCYC1     this study 
pPP4121 pIU-CLN2-mut4 integrating URA3 cln2-mut4 this study 
pPP4122 pt-HGT-Rup-Kwal-CCN1-mut4 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CCN1(1-379 /m4)  TCYC1 this study 
pPP4123 pt-HGT-Rup-Calb-CCN1-mut4 CEN HIS3 PGAL1-GST-[R34 zipper]-Calb CCN1(1-469 /m4)  TCYC1    this study 
pPP4124 pt-HGT-Rup-Kwal-CLN1/2-mut4 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CLN1/2(1-363 /m4)  TCYC1 this study 
pPP4125 pt-HGTE-Rup-CLN2-mut4f CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /R109A)  TCYC1    this study 
pPP4126 pt-HGTE-Rup-CLN2-mut4g  CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /L112A)  TCYC1  this study 
pPP4127 pt-HGTE-Rup-CLN2-mut4h  CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-545 /R113A)  TCYC1   this study 
pPP4140 pt-HGT-Rup-CLN2-1-362 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-362)  TCYC1 this study 
pPP4141 pt-HGT-Rup-CLN2-1-352 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-352)  TCYC1 this study 
pPP4142 pt-HGT-Rup-CLN2-1-342 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-342)  TCYC1 this study 
pPP4143 pt-HGT-Rup-CLN2-1-332 CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-332)  TCYC1 this study 
pPP4146 pHGT-Sic1-1-214  CEN HIS3 PGAL1-GST-sic1(1-214)   (4) 
pPP4147 pHGT-Whi5-FL  CEN HIS3 PGAL1-GST-WHI5 (full length) (4) 
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pPP4148 pCLN2pr-CLN2-myc-wt  CEN URA3 PCLN2-CLN2(1-545 /wt)-myc13   TCYC1    this study 
pPP4149 pCLN2pr-CLN2-myc-mut4  CEN URA3 PCLN2-CLN2(1-545 /m4)-myc13   TCYC1    this study 
pPP4152 pt-HGT-Whi5-1-172  CEN HIS3 PGAL1-GST-whi5(1-172)   (4) 
pPP4153 pCYC1-Kw-CCN1-V5-wt  CEN URA3 PCYC1-Kwal CCN1(1-379 /wt) 3xV5   TCYC1 this study 
pPP4154 pCYC1-Kw-CCN1-V5-mut4  CEN URA3 PCYC1-Kwal CCN1(1-379 /m4) 3xV5   TCYC1 this study 
pPP4157 pt-HGT-GRR1-dF  CEN HIS3 PGAL1-GST-grr1(ΔF)-Flag  TCYC1   this study 
pPP4158 pt-HGT-STE5-1-341  CEN HIS3 PGAL1-GST-GFP-ste5(1-341)   this study 
pPP4160 pCYC1-CLN3-t-V5  CEN URA3 PCYC1-CLN3(1-395)-3xV5   TCYC1 this study` 
* Source:  (1) (Sikorski and Hieter, 1989); (2) (Bhaduri and Pryciak, 2011); (3) (Takahashi and Pryciak, 2007); (4) (Pope et al., 
2014) 
 
 
 
 
 
Table 3.3    Oligonucleotide primers used for RT-qPCR analysis in Chapter III 
 
Oligonucleotide primers used for RT-qPCR analysis 
Primer Name Sequence (5’ to 3’) 
  
ACT1-fw1 TTCCAGCCTTCTACGTTTCC 
ACT1-rev1 CCAGCGTAAATTGGAACGAC 
CLB5-up2 GGATCTCCAAGGCAGATGAT 
CLB5-dn2 CCATTGCGCTTACGGTAGAT 
YOX1-up1 AAATAGGCGCTCATCCACAC 
YOX1-dn1 ACGTTTTCACGGGAGTCAAC 
NRM1-up2 GAAGTTGCAAATTCGTTTAC 
NRM1-dn2 CGCGACTTTGGAAGGCCTCG 
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CHAPTER IV 
Regulation of cyclin-substrate docking by a G1 arrest signaling 
pathway and the CDK inhibitor Far1 
 
 
 
The following Chapter contains the manuscript: 
 
Pope, P. A.,* Bhaduri, S.,* Pryciak, P. M. (2014). Regulation of cyclin-substrate 
docking by a G1 arrest signaling pathway and the CDK inhibitor Far1 (* Co-first 
authors). Current Biology, 24(12), 1390-1396 [PMID 24909323] 
 
 
The study has been devised by and all results have been interpreted by myself, 
Dr. Pope and Dr. Pryciak. 
Parts of Figures 4.4, 4.5, 4.6, 4.7 and 4.8 have been contributed by myself.  
All other Figures have been contributed by Dr. Pope. 
The manuscript had been prepared by myself, Dr. Pope and Dr. Pryciak. 
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Abstract 
 
 
Eukaryotic cell division is often regulated by extracellular signals. In budding 
yeast, signaling from mating pheromones arrests the cell cycle in G1 phase 
(Bardwell, 2005). This arrest requires the protein Far1 (Chang and Herskowitz, 
1990), which is thought to antagonize the G1/S transition by acting as a CDK 
inhibitor (CKI) (Peter et al., 1993; Peter and Herskowitz, 1994), although the 
mechanisms remain unresolved (Gartner et al., 1998).  Recent studies found that 
G1/S cyclins (Cln1 and Cln2) recognize CDK substrates via specific docking 
motifs, which promote substrate phosphorylation in vivo (Bhaduri and Pryciak, 
2011; Koivomagi et al., 2011b).  Here, we show that these docking interactions 
are inhibited by pheromone signaling, and that this inhibition requires Far1.  
Moreover, Far1 mutants that cannot inhibit docking are defective at cell cycle 
arrest.  Consistent with this arrest function, Far1 outcompetes substrates for 
association with G1/S cyclins in vivo, and it is present in large excess over G1/S 
cyclins during the pre-commitment period where pheromone can impose G1 
arrest.  Finally, a comparison of substrates that do and do not require docking 
suggests that Far1 acts as a multi-mode inhibitor that antagonizes both kinase 
activity and substrate recognition by Cln1/2-CDK complexes.  Our findings 
uncover a novel mechanism of CDK regulation by external signals, and shed new 
light on Far1 function to provide a revised view of cell cycle arrest in this model 
system. 
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Background and Results 
 
 
During cell cycle arrest by pheromone, Far1 is thought to act as a CDK inhibitor 
(CKI) that antagonizes cyclin-CDK complexes containing early cyclins (Cln1, 
Cln2, Cln3), which function in G1 to drive cell cycle entry (Figure 4.1A). Far1 
binds these CDK complexes in vivo (Tyers and Futcher, 1993) and appeared to 
inhibit Cln2-CDK activity in vitro (Peter and Herskowitz, 1994), but later studies 
failed to detect this inhibitory effect (Gartner et al., 1998) and others suggested 
that Far1 might inhibit Cln3-CDK or regulate Cln2 protein levels (Jeoung et al., 
1998; Valdivieso et al., 1993). Consequently, the precise effects of pheromone 
and Far1 on CDK function in vivo have remained unresolved.  Recent studies 
revealed that some Cln-CDK phosphorylation events require docking interactions 
between Cln1/Cln2 and specific motifs in substrate proteins, including 
components of the mating pathway (Ste5, Ste20) and regulators of the G1/S 
transition (Sic1, Whi5) (Bhaduri and Pryciak, 2011; Koivomagi et al., 2011b).  
Therefore, we asked if pheromone signaling and/or Far1 might disrupt these 
docking interactions, either in addition to or as an alternative to direct inhibition of 
CDK activity per se (Figure 4.1B). 
 
 To monitor docking, we used an assay in which a GST-substrate fusion 
and an epitope-tagged cyclin (Cln2) were co-expressed and co-precipitated 
(Bhaduri and Pryciak, 2011).  (Here, we took steps to prevent CLN2 expression 
and pheromone signaling from interfering with each other; see Experimental  
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Figure 4.1. Pheromone signaling disrupts Cln2-substrate interactions. 
(A) Mating pheromones signal through a MAP kinase cascade, leading to 
phosphorylation and increased expression of Far1, which is thought to induce 
G1 arrest by inhibiting Cln-CDK complexes. 
(B) Far1 could inhibit cyclin-substrate docking (left) or Cln-CDK kinase activity 
(right). 
(C) Cells harboring Cln2-myc (expressed from the CYC1 promoter; see Figure 
4.2) and a galactose-inducible GST fusion to the Ste20 N-terminus (Ste20*) 
were induced with galactose with or without pheromone (α factor) for varying 
times. Complexes were captured on glutathione-sepharose.  Bound and input 
samples were analyzed by anti-myc and anti-GST blots.  
(D) Binding of Cln2-myc to galactose-inducible GST-Ste20* or GST-Ste5*, 
induced with or without pheromone.  Note that pheromone disruption of Cln2-
substrate binding was lost in far1∆ cells. 
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Figure 4.1. Pheromone signaling disrupts Cln2-substrate interactions. 
 
 
 
    
C 
D 
Ste20* vector 
far1∆ 
Cln2-myc 
bound 
Cln2-myc 
total 
α factor: 
PGAL1-GST: 
- + - + - + - + - + - + 
Ste5* vector Ste5* vector 
GST 
- α factor + α factor 
0 15
 
30
 
60
 
12
0 
18
0 0 15
 
30
 
60
 
12
0 
18
0 minutes 
galactose: 
Cln2-myc 
bound 
Cln2-myc 
total 
PGAL1-GST- 
Ste20* 
A 
B 
G1 
P 
Far1 
S 
Ste5 
Ste7 
Fus3 
Ste11 
Cln-Cdk 
Cdk 
inhibitor 
FAR1 
mRNA 
Far1 Far1 or 
? 
? 
Cln-Cdk substrate 
  
158 
Figure 4.2. Effects of Cln2 and Far1 on pheromone response. 
Pheromone signaling is reduced by deleting FAR1 or expressing CLN2 from 
foreign, constitutively-active promoters (PCYC1 and PADH1). Strains with the 
indicated genotypes (PPY640, PPY892, PPY2075, PPY2076) harbored plasmids 
expressing CLN2 from the indicated promoters or a vector control (pPP681, 
pPP3203, pPP3079).  Cells were treated with α factor (5 µM, 2 hr).  Pheromone 
response was assayed using a transcriptional reporter (FUS1-lacZ); results 
(mean ± SD; n = 4) were normalized to the wild-type strain with vector.  Note that 
cells lacking Far1 (far1∆) have reduced signaling, and are sensitive to further 
reduction by extra CLN2.  These features are eliminated by the CDK-resistant 
STE5-8A allele (Strickfaden et al., 2007), such that the presence or absence of 
Far1 (or excess CLN2) no longer affects pheromone signaling.  Thus, by using 
STE5-8A strains, it is possible to compare the effect of Far1 on Cln2-substrate 
interactions without complicating secondary effects on pheromone signaling due 
to the presence or absence of Far1 and/or Cln2. 
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Figure 4.2. Effects of Cln2 and Far1 on pheromone response. 
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Procedures and Figure 4.2.)  First, we tested a GST fusion to a Cln2-binding 
fragment of Ste20 (residues 72-333, designated Ste20*)(Bhaduri and Pryciak, 
2011), expressed from an inducible promoter (PGAL1).  Without pheromone, we 
observed Cln2-myc binding as soon as GST-Ste20* expression was detected, 
but binding was strongly inhibited when pheromone was included (Figure 4.1C).  
(Note, total Cln2 levels were often reduced by prolonged pheromone treatments, 
as in earlier studies (Valdivieso et al., 1993), so we used short treatment times 
where possible to minimize this effect.)  Pheromone also inhibited Cln2-myc 
binding to another, similar GST fusion (GST-Ste5*), in which the Cln2 docking 
site from Ste20 was replaced with one from Ste5 (Figure 4.1D).  Remarkably, this 
inhibition was not observed in far1∆ cells (Figure 4.1D).  Therefore, pheromone 
signaling can disrupt Cln2-substrate binding interactions in a manner that 
depends on Far1. 
 
 Next, we tested the role of regulatory phosphorylation sites in Far1 (Figure 
4.3A): phosphorylation at residue T306 by the MAPK Fus3 promotes Far1 
function, whereas phosphorylation at residue S87 by CDK triggers its 
degradation (Gartner et al., 1998).  We introduced non-phosphorylatable Ala 
mutations at these sites, tested previously in an N-terminal fragment of Far1 
(Gartner et al., 1998), into full-length Far1 expressed from the native FAR1 locus.  
As expected, the T306A mutant was defective at pheromone arrest whereas the  
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Figure 4.3. Far1 inhibition of docking correlates with G1 arrest ability. 
(A) Pheromone triggers phosphorylation of Far1 at T306, which promotes G1 
arrest, whereas CDK phosphorylates Far1 at S87, which promotes its 
degradation (Gartner et al., 1998). 
(B) The indicated FAR1 strains were tested for pheromone arrest. Cell lawns 
were overlaid with disks containing 20 µL of α factor (20 or 100 µM), and 
incubated at 30˚C for 2 days. 
(C, D) Binding of Cln2-myc to GST-Ste20* or GST-Ste5* was analyzed (as in 
Figure 4.1) using strains with different FAR1 alleles, in the presence or 
absence of pheromone. 
(E) Far1 disrupts Cln2 binding to Sic1 and Whi5.  Sic1∆C (residues 1-214) lacks 
its CDK-inhibitor domain but includes its Cln1/2 docking site (Bhaduri and 
Pryciak, 2011; Koivomagi et al., 2011b). Pheromone was omitted from these 
assays because it affected GST-Whi5 levels.  Also see Figure 4.4A. 
(F) Far1 disrupts binding of GST-Cln2 to full-length Ste20. Strains harbored a 
PGAL1-GST-CLN2 plasmid or GST vector, plus V5-tagged Ste20. To reduce 
effects of pheromone on Cln2 levels, we used a truncated Cln2 (residues 1-
372), which lacks its destabilizing C-terminus (Lanker et al., 1996).  Cells 
were induced with galactose ± pheromone; bound complexes were captured 
and analyzed by anti-V5, anti-GST, and anti-Cdc28 blots.  Graphs quantify 
relative levels of Ste20 binding (mean ± SEM; n = 3). Also see Figure 4.4B-E. 
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Figure 4.3. Far1 inhibition of docking correlates with G1 arrest ability. 
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S87A mutant remained functional (Figure 4.3B); the S87A T306A double mutant 
showed an intermediate phenotype, indicating that T306 phosphorylation is not 
absolutely required if Far1 is stabilized by the S87A mutation. When we tested 
Cln2-substrate binding in these strains, we observed several notable features 
(Figures 4.3C, 4.3D).  First, the T306A mutation blocked the ability of pheromone 
to disrupt Cln2-substrate interactions, whereas the S87A mutation increased this 
disruptive effect.  Second, this increased potency of the Far1-S87A mutant was 
evident even in the absence of pheromone.  Third, the S87A mutation partially 
suppressed the defect of the T306A mutation, consistent with the arrest 
phenotypes.  (Note that the effect of pheromone in the S87A T306A double 
mutant cannot be due to Far1 activation by phosphorylation at T306, and instead 
it may reflect elevated FAR1 transcription (Chang and Herskowitz, 1990).) The 
ability of Far1-S87A to reduce Cln2-substrate binding even without pheromone 
was unanticipated, but it may imply that the unmodified wild-type protein is 
partially active (rather than inactive) and that this activity becomes more evident 
in the S87A mutant due to higher protein levels or presence in a greater fraction 
of cells (see below).  Overall, the binding results mirror the G1 arrest phenotypes, 
implying that interference with Cln2-substrate docking relates to the arrest 
function of Far1.  In further support of this view, we found that Far1 (especially 
Far1-S87A) also disrupted binding of Cln2 to the G1/S regulators Sic1 and Whi5 
(Figures 4.3E, 4.4A), which are CDK substrates with Cln1/2 docking sites similar 
to those in Ste5 and Ste20 (Bhaduri and Pryciak, 2011; Koivomagi et al., 2011b). 
  
164 
Figure 4.4. Effects of Far1 on Cln2-substrate binding interactions. 
 
(A) Far1 inhibits binding of Cln2 to GST-Whi5 fragments.  Strains (PPY2322, 
PPY2326, PPY2329) harbored Cln2-myc (pPP3203) plus GST fusions to 
Whi5 fragments (pPP4150, pPP4151, pPP4152) or GST alone (pPP2154).  
Binding was assayed by glutathione-sepharose capture followed by anti-myc 
and anti-GST blots.  Note that Far1-S87A inhibits Cln2 binding to all Whi5 
fragments, similar to results using full-length Whi5 (Figure 4.3E), and with all 
GST-Whi5 fusions a truncated product is also observed (marked by **).  
Phosphorylation of Whi5 by Cln2-CDK depends on docking (Koivomagi et al., 
2011b), and it has at least one docking motif in the 121-150 region (Bhaduri 
and Pryciak, 2011), but it could also have additional motifs that confer weak 
binding to the 1-125 fragment. 
(B, C) Binding of GST-Cln2 to full-length substrate proteins requires docking 
sites.  Galactose-inducible GST or GST-Cln2 (residues 1-372) was co-
expressed in far1∆ cells (PPY2327) with V5-tagged forms of full-length 
substrates (Ste20 or Ste5) expressed from their native promoters. Binding 
was assayed by glutathione-sepharose capture followed by anti-V5 and anti-
GST blots.  In each panel, the WT and mutant substrates were analyzed in 
parallel but were separated by additional lanes in the original gels.  Panel B 
shows binding to full-length Ste20-WT or a docking site mutant (mut3; 
(Bhaduri and Pryciak, 2011)). Plasmids were pPP2154, pPP3573, pPP3267, 
and pPP3368.  Panel C shows binding to full-length Ste5-WT or a docking 
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site mutant (LLPP to AAAA; (Bhaduri and Pryciak, 2011)).  Plasmids were 
pPP2154, pPP3573, pPP3266, and pPP3761. 
(D, E) Far1 inhibits binding of GST-Cln2 to full-length Ste20 and Ste5.  Strains 
with the indicated FAR1 genotype (PPY2327, PPY2330, PPY2340, PPY2358, 
PPY2359) harbored galactose-inducible GST (pPP2154) or GST-Cln2 
(pPP3573), plus V5-tagged Ste20 (pPP3267) or Ste5 (pPP3266).  Cells were 
induced with galactose ± pheromone for 90 minutes, and then bound 
complexes were captured and analyzed by anti-V5, anti-GST, and anti-Cdc28 
blots.  Graphs show the relative level of substrate binding (mean ± SEM) from 
three (D) or four (E) experiments.  Panel D is identical to Figure 4.3F and is 
repeated here for comparison to the other panels. 
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We confirmed these findings via reciprocal assays in which a GST-Cln2 
fusion was used to co-precipitate full-length substrates (Ste20 and Ste5). Binding 
of each substrate to GST-Cln2 required their docking sequences (Figures 4.4B, 
4.4C) and was strongest in far1∆ cells, weakest in FAR1-S87A cells, and 
intermediate in FAR1-WT cells (Figure 4.3F, 4.4).  This trend was seen even 
without pheromone treatment, further reinforcing the notion that unmodified Far1 
is partially active.  Importantly, Far1 did not affect binding of Cln2 to its partner 
CDK molecule, Cdc28 (Figures 4.3F, 4.4E).  The effect of pheromone was less 
evident in these experiments than when using the previous (reverse) procedure, 
perhaps because chronic Cln2 expression can induce Far1 degradation, 
counteracting its activation by pheromone.  Overall, however, the results confirm 
the disruptive effect of Far1 and argue that it blocks interactions between intact 
Cln2-CDK complexes and their substrates. 
 
 Because Far1 binds Cln-CDK complexes (Gartner et al., 1998; Peter et 
al., 1993; Tyers and Futcher, 1993), we asked if Far1 and substrates bind Cln2 
competitively, and if Far1 outcompetes substrates via higher concentration or 
affinity.  First, we compared their concentrations by marking Far1 and substrates 
with the same epitope tag (3xV5).  Far1 levels ranged between those of Ste20 
and Ste5, depending on whether it had been induced by pheromone or stabilized 
by the S87A mutation (Figure 4.5A).  Next, we used cells that simultaneously 
expressed V5-tagged forms of Far1 and Ste20 to compare their binding to Cln2 
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(Figure 4.5B).  The results suggest that Far1 binds Cln2 more favorably, as total 
Far1-WT was much less abundant than Ste20 and yet it bound Cln2 at equal or 
greater levels.  Similarly, Far1-S87A was comparably abundant to Ste20 yet 
showed disproportionally greater binding to Cln2.  When comparing WT and 
S87A forms of Far1, the increased Cln2 binding to the S87A mutant was 
accompanied by reduced binding to Ste20, implying that Far1 competes with 
Ste20.  Indeed, pheromone caused increased Cln2-Far1 binding and reduced 
Cln2-Ste20 binding. Collectively, these results suggest that Far1 binds Cln2 in a 
way that is mutually exclusive with Cln2-substrate docking, and that the 
preferential binding of Far1 allows it to outcompete substrates. 
 
 We reasoned that Far1 should be in excess of Cln2 in order to effectively 
outcompete Cln2-substrate interactions.  Therefore, we compared their levels as 
cells approached the critical point of cell cycle commitment, or “Start”.  Using 
synchronous cultures in which both Far1 and Cln2 had the same epitope tag, we 
monitored protein levels and the ability of cells to arrest in G1 in response to 
pheromone (Figures 4.5C, 4.6).  Far1 was generally in large excess over Cln2 as 
cells approached Start, and a sharp increase in Cln2 corresponded to the first 
appearance of committed cells. It did not seem that Cln2 must reach peak levels 
or exceed Far1 for cells to pass Start, but rather it only must begin to 
accumulate. This pattern fits previous findings that Start occurs simultaneous 
with CLN2 promoter firing (Doncic et al., 2011), and is reminiscent of the 
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Figure 4.5. Far1 outcompetes substrates for binding to Cln2. 
(A) Far1, Ste5, and Ste20 were tagged with the identical 3xV5 tag to compare 
protein levels. Far1 (WT or S87A) was expressed from its native genomic 
locus; Ste5 and Ste20 were expressed from their native promoters on low 
copy number plasmids. Whole cell extracts were prepared and equivalent 
amounts of total protein were analyzed by SDS-PAGE and anti-V5 blots. 
(B) Strains with V5-tagged Far1 or Far1-S87A harbored a V5-Ste20 plasmid plus 
galactose-inducible GST-Cln2 or GST vector.  Cells were induced with 
galactose with or without pheromone, and then binding of Far1 to GST-Cln2 
was assayed. 
(C) Strains with V5-tagged Far1 and Cln2 were synchronized by arrest in mitosis 
(using a cdc15-2 mutant).  At various times after release, aliquots were taken 
to assess protein levels and then treated with pheromone to assess whether 
they could still arrest in G1 or had passed Start (committed).  Signal levels in 
the two blots are directly comparable, as all steps were performed in parallel 
using equal protein loading.  Graphs show mean ± SEM (n = 4-6).  See 
Figure 4.6 for additional tests. 
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Figure 4.6. Far1 vs. Cln2 levels in synchronous cultures. 
Using strains in which Far1 and Cln2 are tagged with the identical 3xV5 tag, cells 
were synchronized by arrest in mitosis (using either cdc15-2 or PGAL1-CDC20), 
and then released.  At various times after release, aliquots were taken to assess 
protein levels and then were treated with pheromone to assess whether they 
could still arrest in G1 or had passed Start (committed).  In each column the blots 
are directly comparable, as the experiments were performed in parallel, the 
individual gels had the same amount of protein loaded per lane, and the blots 
were processed in parallel and exposed simultaneously to a single film.  For the 
same reasons, the four cdc15-2 blots are also directly comparable to each other.  
Results shown are representative of two or more independent experiments.  
Graphs show mean ± SEM (n = 4-6; left) or mean ± range (n = 2; middle and 
right).  Note that the degree of delay in commitment caused by the Far1-S87A 
mutant varied with experimental context; it also varied among independent 
isolates of BY4741 cdc15-2 strains, and so we combined results from two FAR1-
wt strains (PPY2393, PPY2394) and four FAR1-S87A strains (PPY2395, 
PPY2396, PPY2425, PPY2426).  The data at left are identical to Figure 4.5C and 
are repeated here to facilitate comparison. 
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mammalian cell restriction point occurring at very low levels of cyclin E (Ekholm 
et al., 2001; Martinsson et al., 2005). Thus, it may be necessary for Far1 to 
substantially exceed cyclin levels to prevent Start, whereas cyclin levels may not 
need to exceed Far1 to pass Start, perhaps because the positive feedback loop 
governing Cln1/2 expression (Skotheim et al., 2008) makes them destined to 
overwhelm Far1 once their expression begins.  In accord with recent work 
(Doncic et al., 2011), the Far1-S87A mutant caused mild delays in commitment 
and Cln2 expression, though to varying degrees (Figures 4.5C, 4.6).  Notably, 
the Far1-S87A protein was not strongly over-expressed compared to peak levels 
of Far1-WT, but it was present over a broader range of the cell cycle (Figures 
4.5C, 4.6).  Hence, the increased inhibitory activity of Far1-S87A seen in 
preceding experiments (using asynchronous cultures) may primarily reflect an 
increase in the fraction of cells expressing Far1 rather than in its concentration. 
 
 CDK phosphorylation of both Ste20 and Ste5 alters their electrophoretic 
mobility (Bhaduri and Pryciak, 2011; Oehlen and Cross, 1998; Strickfaden et al., 
2007; Wu et al., 1998).  By using extended electrophoresis to better resolve 
Ste20 forms, we found that pheromone and Far1 inhibited Cln2-driven 
phosphorylation (Figures 4.7A, 4.8A).  Specifically, Cln2 expression in far1∆ cells 
converted Ste20 to its slowest mobility, phosphorylated form.  Pheromone had no 
effect in far1∆ cells, but it reduced Ste20 phosphorylation in FAR1-WT cells.  In 
FAR1-S87A cells, Ste20 phosphorylation was reduced even without pheromone 
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Figure 4.7. Effects of Far1 and pheromone on CDK phosphorylation in vivo 
using substrates with native and artificial docking interactions. 
(A) Extracts of cells harboring V5-Ste20 and galactose-inducible GST-Cln2, as in 
Figure 4.3F, were analyzed by extended electrophoresis to resolve the extent 
of Ste20 phosphorylation triggered by Cln2 expression.  See Figure 4.8A for 
replicates. 
(B) CDK inhibition alone does not disrupt Cln2-Ste20 binding.  Strains with a 
drug-sensitive CDK (cdc28-as2) harbored V5-tagged Ste20 plus galactose-
inducible GST-Cln2 or GST vector.  Cells were induced with galactose either 
with or without the ATP analog 1-NM-PP1 (15 µM), and GST fusions were 
captured.  Total and bound Ste20 were analyzed by anti-V5 blots. 
(C) The indicated FAR1 strains harbored a plasmid expressing GST-Cln2 with an 
attached leucine half-zipper (lz), plus a plasmid expressing an HA-tagged 
CDK substrate with either the matching half-zipper or an LP-type Cln1/2 
docking site (see Figure 4.8Eii).  Cultures were pre-incubated for 2 hr ± α 
factor (0.1 µM), and then induced with galactose for 2 hr.  Substrate 
phosphorylation (Bhaduri and Pryciak, 2011) and GST-Cln2 expression was 
monitored by anti-HA and anti-GST blots, respectively.  Figure 4.8C shows 
that leucine zipper binding is resistant to pheromone and Far1. 
(D) FAR1-S87A and far1∆ strains co-expressing GST-(lz)-cyclins with an HA-
tagged substrate (Figure 4.8Eii) were induced with galactose for 2.5 hr.  
Levels of GST-(lz)-cyclins were monitored in each experiment; one 
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representative anti-GST blot is shown.  Note that, aside from effects of Far1, 
these results confirm that cyclin docking drives substrate use, because 
switching the docking site alters which cyclins are effective, as seen 
previously (Bhaduri and Pryciak, 2011). 
(E) GST-(lz)-cyclin plasmids were introduced into a strain with V5-tagged Far1-
S87A.  Cultures were induced with galactose for 1.5 hr and then association 
of Far1 with the GST-tagged cyclin was assayed. 
(F) Strains co-expressed GST-(lz)-Cln2 with HA-tagged substrates that each 
show only two mobility forms (see Figure 4.8Eiii), which makes it easier to 
quantify phosphorylation.  Cultures were pre-incubated with α factor (0.1 µM, 
30 min.), and then induced with galactose (40 min).  Graphs (mean ± SEM, n 
= 3-4) show the signal in the upper band as a percentage of the total signal 
(% phos.). 
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treatment, and pheromone caused a further reduction.  The T306A mutant was 
ineffectual, while the S87A T306A double mutant showed a result intermediate 
between the two single mutants.  Collectively, these results suggest parallel 
effects of Far1 on substrate docking and substrate phosphorylation by Cln2-CDK.  
Chemical inhibition of CDK activity was not sufficient to reduce Cln2-Ste20 
binding, and Far1-S87A was equally disruptive with and without CDK inhibition 
(Figure 4.7B), suggesting that reduced binding causes reduced phosphorylation  
rather than vice-versa.  Notably, to our knowledge these results provide the first 
demonstration that pheromone and Far1 reduce phosphorylation of CDK 
substrates in vivo (see Discussion).  In contrast, we saw no reduction in 
phosphorylation of the Cln1/2 C-termini (Figure 4.8B) or Far1 itself (Figure 4.5B, 
top), indicating that Far1 does not inhibit all Cln-CDK phosphorylation events 
equally. 
 
Finally, we asked if the ability of Far1 to disrupt substrate phosphorylation is due 
to inhibition of Cln2-substrate docking, or Cln2-CDK kinase activity, or a 
combination of both.  To address this point, we compared CDK substrates with 
and without Cln2 docking motifs.  Using an approach elaborated in Chapter 3, we 
replaced a native docking interaction with a foreign leucine zipper (Figure 4.8Eii), 
thereby allowing phosphorylation of a single substrate to be driven by either a 
native cyclin docking site or an artificial linkage.  Then, we analyzed 
phosphorylation driven by different cyclins, and the effects of Far1.  When the 
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substrate harbored a native “LP”-type Cln2 docking site, its phosphorylation was 
inhibited strongly by Far1-S87A, but when the leucine zipper was used, the 
degree of inhibition was substantially reduced, though not eliminated (Figures 
4.7C, 4.7D).  These results imply that Far1 inhibits substrate docking strongly, 
with a residual effect on some non-docking function such as CDK kinase activity.  
This residual effect might also signify a reduction in kinase processivity mediated 
by the Cks1 subunit of the CDK complex (Koivomagi et al., 2013; McGrath et al., 
2013), though it was still evident when the role of Cks1 was presumably blocked 
(by changing threonine phosphorylation sites to serine; Figure 4.8D).  It is also 
notable that this residual effect was only seen with the G1/S cyclins Cln1 and 
Cln2 (Figure 4.7D), even though Far1-S87A could bind all cyclins (Figure 4.7E).  
Interestingly, however, when the substrate contained an “RxL” docking motif 
favored by S-phase cyclins such as Clb5 (Bhaduri and Pryciak, 2011; Loog and 
Morgan, 2005; Wilmes et al., 2004), Far1- S87A could mildly inhibit Clb5-driven 
phosphorylation (Figure 4.7D), again suggesting that docking-dependent 
phosphorylation is more susceptible to inhibition by Far1.  To help quantify the 
extent of phosphorylation, we performed related experiments using a variant 
substrate with only two electrophoretic mobility forms: unphosphorylated and 
phosphorylated (Figure 4.7F).  Here, pheromone treatment of Far1-S87A cells 
almost completely reversed phosphorylation driven by the native Cln2 docking 
site (Figure 4.7F, top), but had only a mild effect when the leucine zipper was 
used (Figure 4.7F, bottom).  Collectively, these results suggest that Far1 can 
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reduce CDK phosphorylation of substrates irrespective of docking, but substrates 
that require docking are especially sensitive to Far1.  Therefore, Far1 may 
engage cyclin-CDK complexes in a way that simultaneously disrupts both 
substrate recognition and kinase activity. 
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Figure 4.8.  Pheromone/Far1 effects on CDK phosphorylation in vivo. 
(A) Far1 and pheromone inhibit Ste20 phosphorylation by Cln2-CDK. Three 
repetitions of the experiment in Figure 4.7A are shown to demonstrate 
reproducibility of the patterns observed. 
(B) Far1 and pheromone do not affect phosphorylation of Cln1/2 tails.  Cultures 
of far1∆ or FAR1-S87A strains (PPY2327, PPY2330) harboring PGAL1-GST-
cyclin plasmids (pPP3572 or pPP3749) were induced with galactose ± α 
factor. Extracts were analyzed by anti-GST blot.  Bands indicate the extent of 
phosphorylation at CDK sites in the cyclin C-termini. 
(C) Far1 and pheromone do not inhibit leucine zipper-mediated binding.  Strains 
(as in B) expressed GST-(lz)-Cln2 or GST alone, plus a myc-tagged CDK 
substrate consisting of a Ste20Ste5PM chimera with either an LP-type docking 
site or a leucine half-zipper (panel Ev).  Plasmids: pPP2154, pPP3916; 
pPP3218, pPP3979.  Binding was assayed after induction with galactose ± α 
factor. 
(D) The ability of Far1-S87A to partially reduce phosphorylation driven by a 
leucine zipper was compared for two substrates (see panel Eiv): one with WT 
phosphorylation sites (5 SP and 3 TP) and one (“all SP”) in which the 3 TP 
sites were converted to SP, to block Cks1 from recognizing phospho-Thr as 
priming sites (Koivomagi et al., 2013; McGrath et al., 2013).  Strains: 
PPY2327, PPY2330. Plasmids: pPP2154, pPP3916; pPP3877, pPP4071. 
  
181 
(E) Substrates used in Figures 4.7 and 4.8. (i) CDK phosphorylation sites and the 
“LP”-type Cln1/2 docking site in Ste5 (Bhaduri and Pryciak, 2011), from which 
other substrates are derived.  (ii) Top, substrates used in Figures 4.7C-D.  
The native LP docking site in Ste5 is replaced with motifs shown. The 
recipient fragment, Ste5 1-260, excludes binding and phosphorylation sites 
for the MAPK Fus3 (in Ste5 267-330) (Bhattacharyya et al., 2006), preventing 
pheromone-induced phosphorylation from obscuring changes in CDK-
mediated phosphorylation.  Bottom, cartoons of cyclin docking.  (iii) 
Substrates used in Figure 4.7F.  Deleting the PM/NLS domain (Winters et al., 
2005) causes the substrate to show only two mobility forms, which simplifies 
quantification.  The top substrate has an “ND” mutation (Bhattacharyya et al., 
2006) to prevent MAPK binding.  (iv) Substrates used in Figure 4.8D.  In “all 
SP”, the 3 TP (Thr-Pro) sites in the WT Ste5 sequence are changed to SP 
(Ser-Pro).  (v) Top, Ste20, which is analyzed in Figures 4.7A and 4.8A.  
Bottom, binding partners used in Figure 4.8C. A Ste20Ste5PM chimera (Bhaduri 
and Pryciak, 2011) acted as recipient for an LP dock or a leucine zipper, to 
compare effects of Far1 on binding by each motif.  (These chimeras were 
used because the phosphorylation substrates analyzed in Figures 4.7C-D 
show variable behavior in binding assays.) 
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Discussion 
 
This study addresses long-standing uncertainties about how yeast pheromone 
signaling and the presumed CKI protein Far1 promote cell cycle arrest.  Our 
findings reveal an unsuspected mode of CDK regulation, in which an extracellular 
signal stimulates an inhibitory factor, Far1, to disrupt interactions of specific 
cyclin-CDK complexes with substrates. Far1 appears to disrupt Cln2-substrate 
docking by binding Cln2 more favorably so that it outcompetes substrates, and 
mutant analyses suggest that this effect parallels its ability to mediate G1 arrest.  
Because Cln1/2 docking enhances substrate phosphorylation (Bhaduri and 
Pryciak, 2011; Koivomagi et al., 2011b), inhibition of docking by Far1 should 
contribute to reduced substrate phosphorylation in vivo, in addition to any effects 
of Far1 on CDK activity per se.  Indeed, our findings suggest that Far1 is a multi-
mode inhibitor that separately disrupts both CDK activity and substrate docking.  
This combined effect raises the possibility that Far1 has the strongest inhibitory 
effect on substrates that are most dependent on docking, which might include 
proteins with inherently poor (e.g., non-consensus) phosphorylation sites or 
those that must be phosphorylated at multiple positions.  Similar themes could 
also apply to other kinases. 
 
 We find that the ability of Cln1/2-CDK to phosphorylate substrates in vivo 
can be inhibited by pheromone and Far1.  Remarkably, to our knowledge this is 
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the first such demonstration.  Although there are numerous prior examples in 
which CDK substrates are unphosphorylated in pheromone-arrested cells, this 
can be explained by the fact that cyclins are not expressed in G1 phase, and 
hence it does not necessarily indicate that the kinase activity of cyclin-CDK 
complexes is reduced.  Here, by expressing cyclins independent of cell cycle 
position, we could detect regulation of phosphorylation by a set amount of 
Cln1/2-CDK in vivo.  Also, by linking different cyclins to substrates using a 
common leucine zipper, we could compare their sensitivity to Far1.  Of note, 
compared to Cln1/2-CDK, Cln3-CDK seemed less susceptible to Far1 inhibition, 
which could underlie different roles for these cyclins in driving cell cycle re-entry 
after pheromone arrest (Doncic and Skotheim, 2013). 
 
 Surprisingly, Far1 could partially interfere with Cln2-substrate binding and 
phosphorylation even without pheromone treatment.  Prior findings implied that 
Far1 must be activated, because G1 arrest required pheromone-induced 
phosphorylation of Far1 at T306 (Gartner et al., 1998) and FAR1 over-expression 
was not sufficient (Chang and Herskowitz, 1992).  We suggest a new 
interpretation in which unphosphorylated Far1 is partially active but is less potent 
than when phosphorylated at T306.  This view is supported by our binding and 
phosphorylation data as well as by the partial arrest observed in FAR1-S87A 
T306A cells, which shows that T306 phosphorylation is not absolutely essential.  
It is also relevant to findings that far1∆ cells show accelerated entry into the cell 
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cycle (Alberghina et al., 2004) and that FAR1-S87A cells show a delay in Start 
(Doncic et al., 2011).  Because Far1 is expressed only during a narrow pre-Start 
window of the cell cycle (McKinney et al., 1993), the partially active state would 
normally be restricted to cells poised for G1 arrest, but detection of this state was 
enhanced when using the stabilized S87A mutant, which is expressed in a larger 
fraction of cells. This mutant also revealed that inhibitory effects of Far1 are at 
least partly independent of T306 phosphorylation. Yet, T306 phosphorylation 
makes Far1 a more potent inhibitor, likely via enhanced binding to CDK 
complexes (Gartner et al., 1998) and possibly via engaging the phospho-
threonine binding pocket in Cks1 (Koivomagi et al., 2013; McGrath et al., 2013). 
 
 The specific mechanism by which Far1 disrupts Cln2 docking is not yet 
known.  Currently, there are no structural data on the Cln2-substrate binding 
interface, but the short docking motifs (Bhaduri and Pryciak, 2011; Koivomagi et 
al., 2011b) likely bind a peptide-recognition pocket on the cyclin, as with RxL 
motif recognition by S-phase cyclins (Lowe et al., 2002).  Thus, Far1 could 
displace substrates either by having a higher affinity docking peptide or by 
interacting with a broader region of Cln2 in a way that obscures peptide 
recognition.  The latter view may be favored by the fact that two separate parts of 
Far1 are required to bind Cln2 (Peter et al., 1993). This view is also reminiscent 
of mammalian CKI proteins p21 and p27, whose RxL sequences contribute to 
cyclin binding and CDK inhibition (Adams et al., 1996; Chen et al., 1996; 
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Wohlschlegel et al., 2001), but as only a small part of a much larger binding 
interface involving both the cyclin and CDK subunits (Russo et al., 1996).  In fact, 
such multipartite interactions may have contributed to confusion about inhibitory 
mechanisms for both Far1 and p21/p27.  Namely, complexes of p21 with cyclin-
CDK sometimes retained kinase activity (Harper et al., 1995; Zhang et al., 1994), 
leading to speculation that under such conditions the CKI might contact only the 
cyclin and not the CDK (Morgan, 1996), a notion later supported by p21 mutants 
that bind only the cyclin (Chen et al., 1996).  Analogous heterogeneity of Far1-
Cln-Cdc28 complexes might explain why kinase inhibition was observed in some 
studies (Peter and Herskowitz, 1994) but not others (Gartner et al., 1998).  In 
addition, the use of generic substrates that do not require docking (e.g., histone 
H1) would have bypassed the ability of Far1 to regulate this step in either study. 
 
 We suggest that Far1 engages the cyclin-CDK complex in a way that 
disrupts multiple distinct functions, including both substrate docking and kinase 
activity but perhaps also others such as Cks1-mediated processivity (Koivomagi 
et al., 2013; McGrath et al., 2013).  Multiple concerted effects may help ensure 
maximal inhibition.  Thus, in future studies using in vitro assays, it will be 
important to compare substrates with a range of requirements, in order to dissect 
the effect of Far1 on total kinase activity, utilization of docking sites, kinase 
processivity, and multi-site phosphorylation.  Investigation of these issues will 
further illuminate how differential regulation of distinct mechanistic steps in 
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substrate phosphorylation can provide additional layers of control that fine-tune 
protein kinase networks. 
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Materials and Methods 
 
Yeast Strains and Plasmids 
Standard procedures were used for growth and genetic manipulation of yeast 
(Rothstein, 1991; Sherman, 2002).  Yeast cultures were grown at 30˚C except as 
indicated otherwise.  Strains and plasmids are listed in tables below.  A two-step 
(pop-in/pop-out) allele replacement method (Rothstein, 1991) was used to 
introduce the following mutant alleles at their native genomic loci: STE5-8A, 
FAR1-S87A, FAR1-T306A, FAR1-S87A T306A, cdc15-2, and cdc28-as2.  For 
Cdc28 inhibition we used the Cdc28-as2 [F88A] mutant (Colman-Lerner et al., 
2005) because in our strains the more severe mutant Cdc28-as1 [F88G] (Bishop 
et al., 2000) caused slow growth and cell shape defects.  PCR-mediated gene 
deletion and tagging used methods described previously (Longtine et al., 1998).  
To add epitope tags at endogenous FAR1 and CLN2 loci, a PCR-generated 
cassette containing the 3xV5 tag and an antibiotic resistance gene (kanMX6 or 
natMX6) was integrated downstream of the coding sequence.  To construct 
PGAL1-CDC20 strains, the promoter of the essential cell cycle gene CDC20 was 
replaced with a regulated promoter (PGAL1) using a PCR-generated cassette 
marked with the K. lactis URA3 gene (URA3Kl).  To promote cyclin interaction 
with substrates that lack native docking sites, we used a weak leucine zipper (Kd 
~ 800 nM) (Acharya et al., 2002; Bashor et al., 2008), wherein two hetero-
dimerizing sequences called R34 and E34(N) (Bashor et al., 2008) were fused to 
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the cyclin and substrate, respectively; further details will be described elsewhere 
(S.B. and P.M.P., in preparation). 
 
GST Co-precipitation Binding Assays 
Cultures (25 mL) were grown in synthetic media with 2% raffinose.  Expression of 
GST fusion proteins from PGAL1-GST plasmids was induced with 2% galactose, 
with or without 10 nM α factor, for 1.5 to 3 hours. For experiments using the 
cdc28-as2 allele, cultures were also treated with 15 µM 1-NM-PP1. Cells were 
harvested and stored at -80˚C, then lysed by glass bead beating using a Fast-
Prep apparatus (20 sec. at 4 m/s) and a non-ionic detergent buffer described 
previously (Lamson et al., 2002). Aliquots were removed to provide input 
controls, and then GST fusions and co-bound proteins were collected using 
glutathione-sepharose beads (GE Healthcare #17-0756-01). 
 For experiments in which we wished to examine the effects of pheromone 
signaling on Cln2 binding interactions, one complexity arises from the fact that 
the mating pathway and Cln1/2-CDK activity are mutually antagonistic.  That is, 
pheromone-arrested cells do not express the CLN1/CLN2 genes and hence lack 
Cln1/Cln2 proteins (Wittenberg et al., 1990), whereas Cln1/2-expressing cells 
inhibit pheromone signaling and degrade Far1 (Henchoz et al., 1997; McKinney 
et al., 1993; Oehlen and Cross, 1994).  Therefore, to allow us to vary 
experimental conditions without affecting protein levels and signaling responses, 
we circumvented these antagonistic effects as follows: (i) CLN2 was expressed 
  
190 
from a constitutively-active promoter (PCYC1 or PTEF1); (ii) the ability of Cln2 to 
inhibit pheromone signaling (see Figure 4.2) was prevented by using strains with 
the STE5-8A allele (Strickfaden et al., 2007), which encodes a CDK-resistant 
form of the pathway scaffold protein, Ste5; and (iii) our initial experiments used 
strains with the FAR1-S87A allele (Gartner et al., 1998), which is resistant to 
CDK-triggered degradation.  Subsequent experiments probed the role of Far1 by 
using strains with far1∆ and other FAR1 alleles. 
 
Synchronous Culture Experiments 
For experiments in PGAL1-CDC20 strains, cells were grown in liquid YPGal 
medium (containing 2% galactose) and then arrested in M phase by pelleting, 
resuspending in YPD medium (2% glucose), and incubating for 3 hr.  Cultures 
were released by two rounds of pelleting and washing in YPGal, followed by final 
resuspension in YPGal.  At 10-minute intervals, aliquots were removed to 
prepare protein samples and test cell cycle commitment.  At each time point, 2 
mL was pelleted and immediately frozen in liquid nitrogen (and whole cell 
extracts were prepared later); a separate 3 mL aliquot was treated with α factor 
(0.2 µM) and incubated at 30˚C, and then at 120 minutes after release all treated 
aliquots were fixed by adding formaldehyde to 3.7%.  Cell cycle commitment was 
scored as the percentage of cells (n = 200) that failed to arrest in G1 (i.e., as 
unbudded cells) after the pheromone treatment. 
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 For experiments in cdc15-2 strains, cultures were grown at 25°C, arrested 
at 37°C for 3 hr, then released by transfer to 25°C (using shaking water baths).  
Aliquots were taken at 10-min intervals to prepare protein samples and test cell 
cycle commitment as described above, except that 10 µM α factor was used for 
the BAR1 strains in the W303 background. 
 
Whole Cell Extracts 
Whole cell extracts were prepared by a modified version of a previous protocol 
(Lee and Dohlman, 2008). Here, 300 µL of trichloroacetic acid (TCA) buffer (10 
mM Tris-HCl, pH 8.0, 10% TCA, 25 mM ammonium acetate, 1 mM Na2EDTA) 
was added directly to frozen cell pellets (usually from 2 mL culture), and 
incubated on ice for 10 minutes. Samples were pelleted in a microcentrifuge for 
10 min at 4˚C. The pellet was resuspended in 75 µL Resuspension Buffer (0.1 M 
Tris.HCl, pH 11.0, 3% SDS), boiled for 5 min, allowed to cool at room 
temperature for 5 minutes, then re-centrifuged for 30 sec. The supernatant (60 
µL) was transferred to a new tube, 10 µL was reserved to assay protein 
concentration by a Pierce BCA Protein Assay Kit (#23225), and then 50 µL of 2x 
SDS Sample Buffer was added to the remainder.  Equivalent amounts of total 
protein (generally 20 µg) were loaded in each lane. 
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Immunoblotting 
Protein samples were analyzed by SDS-PAGE, and transferred to PVDF using a 
submerged tank device. Myc-tagged proteins were detected with rabbit anti-myc 
(1:200 Santa Cruz Biotechnologies #sc-789) and HRP-conjugated goat anti-
rabbit (1:3000, Jackson ImmunoResearch #111-035-144) antibodies.  V5-tagged, 
HA-tagged, or GST-tagged proteins were detected with mouse anti-V5 (1:5000, 
Invitrogen #46-0705), anti-HA (1:1000, Covance #MMS101R), or anti-GST 
(1:1000, Santa Cruz Biotechnologies #sc-138) antibodies, followed by HRP-
conjugated goat anti-mouse (1:3000, BioRad #170-6516) antibodies. Cdc28 was 
detected with goat anti-Cdc28 (1:200 Santa Cruz Biotechnologies #sc-6709) and 
HRP-conjugated donkey anti-goat (1:3000 Santa Cruz Biotechnologies #sc-
2020) antibodies. Enhanced chemiluminescent detection used a Pierce 
SuperSignal West Pico kit (#34080). 
 
Cyclin-CDK Phosphorylation Assays 
Following methods established in a previous study (Bhaduri and Pryciak, 2011), 
cells harboring PGAL1-GST-cyclin constructs and HA-tagged CDK substrates were 
grown in selective media with 2% raffinose and then induced with 2% galactose 
(for 40 min. to 2.5 hr) to drive cyclin expression.  Where indicated, cultures were 
pre-treated with pheromone prior to galactose addition.  Then, whole cell extracts 
were prepared, and substrate phosphorylation was assessed by SDS-PAGE and 
immunoblotting.  CDK substrates are diagrammed in Figure 4.8E.  Note that 
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most substrate fragments contain an NLS, and similar fragments localize to both 
nucleus and cytoplasm (Strickfaden et al., 2007; Winters et al., 2005), so in 
principle they should be accessible to both nuclear and cytoplasmic kinases.  
Also note that, in order to help express different cyclins at comparable levels, all 
cyclins in the PGAL1-GST-cyclin constructs were truncated to remove destabilizing 
motifs (see the Plasmids Table for precise boundaries).  These truncations 
remove NLS motifs in some cyclins such as Cln3 (Miller and Cross, 2001b) and 
Clb2 (Hahn et al., 2008; Hood et al., 2001), but the pattern of substrate specificity 
seen with these truncated cyclins is the same as that seen earlier with full-length 
cyclins (Bhaduri and Pryciak, 2011). 
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Table 4.1.   Yeast strains used in Chapter IV 
Yeast strains used in this study. 
Name Strain 
Background* 
Relevant Genotype 
PPY640 (a) MATa FUS1::FUS1-lacZ::LEU2 
PPY892 (a) MATa FUS1::FUS1-lacZ::LEU2 far1::ADE2 
PPY2075 (a) MATa FUS1::FUS1-lacZ::LEU2 STE5-8A 
PPY2076 (a) MATa FUS1::FUS1-lacZ::LEU2 STE5-8A far1::ADE2 
PPY2268 (b) MATa far1∆::kanMX6 
PPY2296 (b) MATa STE5-8A FAR1-S87A  
PPY2322 (b) MATa bar1∆::hphMX6 
PPY2326 (b) MATa bar1∆::hphMX6 far1∆::kanMX6 
PPY2327 (b) MATa bar1∆::hphMX6 STE5-8A far1∆::kanMX6 
PPY2329 (b) MATa bar1∆::hphMX6 FAR1-S87A  
PPY2330 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-S87A  
PPY2340 (b) MATa bar1∆::hphMX6 STE5-8A 
PPY2354 (b) MATa bar1∆::hphMX6 FAR1-T306A 
PPY2356 (b) MATa bar1∆::hphMX6 FAR1-S87A,T306A 
PPY2358 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-T306A   
PPY2359 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-S87A,T306A   
PPY2369 (b) MATa bar1∆::hphMX6 STE5-8A far1∆::kanMX6 cdc28-as2 
PPY2371 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-S87A cdc28-as2 
PPY2377 (b) MATa bar1∆::hphMX6 STE5-8A FAR1-3xV5::kanMX6 
PPY2380 (b) MATa bar1∆::hphMX6 STE5-8A FAR1(S87A)-3xV5::kanMX6 
PPY2384 (a) MATa ade1 CLN2-3xV5::kanR FAR1-3xV5::natMX6 cdc15-2 
PPY2391 (b) MATa bar1∆::hphMX6 CLN2-3xV5::kanMX6 FAR1-3xV5::natMX6 PGAL1-CDC20::URA3Kl 
PPY2392 (b) MATa bar1∆::hphMX6 CLN2-3xV5::kanMX6 FAR1(S87A)-3xV5::natMX6 PGAL1-
CDC20::URA3Kl 
PPY2393 (b) MATa bar1∆::hphMX6 CLN2-3xV5::kanMX6 FAR1-3xV5::natMX6 cdc15-2 
PPY2395 (b) MATa bar1∆::hphMX6 CLN2-3xV5::kanMX6 FAR1(S87A)-3xV5::natMX6 cdc15-2 
PPY2397 (a) MATa ade1 CLN2-3xV5::kanMX6 FAR1(S87A)-3xV5::natMX6 cdc15-2 
   
* Background: (a) W303 (ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1); (b) BY4741 (his3∆1 leu2∆0 ura3∆0 
met15∆0). 
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Table 4.2.   Plasmids used in Chapter IV 
Plasmids used in this study. 
Name Alias Description Source * 
pPP681 pRS316 CEN URA3 vector 1 
pPP1843 pUG-GST-GFP 2µm URA3 PGAL1-GST-GFP vector   2 
pPP2154 pHG-GST CEN HIS3 PGAL1-GST vector    3 
pPP2155 pHG-GST-GFP CEN HIS3 PGAL1-GST-GFP vector    this study 
pPP2163 pHGT-S20A CEN HIS3 PGAL1-GST-ste20(1-333)    4 
pPP2330 p306-S5-8A integrating URA3 STE5-8A 5 
pPP3025 pFA6a-KlacURA3-PGAL1 PCR template for URA3Kl-PGAL1 promoter insertion this study 
pPP3079 pADH1-CLN2-myc   CEN URA3 PADH1-CLN2-myc13  TCYC1 this study 
pPP3152 pH-TEFpr-CLN2-myc   CEN HIS3 PTEF1-CLN2-myc13  TCYC1 3 
pPP3203 pCYC1-CLN2-myc   CEN URA3 PCYC1-CLN2-myc13  TCYC1 3 
pPP3218 pM20-BXA5N-U CEN URA3 myc13-[(Ste20 80-109)-(Ste5 1-85)-(Ste20 312-939)] 3 
pPP3266 pS5kV5   CEN URA3 STE5-3xV5  TCYC1 this study 
pPP3267 pRL116V5 CEN URA3 3xV5-STE20 3 
pPP3368 pRL116V5-Ala5 CEN URA3 3xV5-STE20(mut3 = docking site mutant) 3 
pPP3369 pRL116V5-Ala13 CEN URA3 3xV5-STE20(Ala13 = CDK site mutant) 3 
pPP3508 pH5n-1-337∆NLS-ND CEN URA3 PSTE5-(Ste5 1-337[∆NLS, ND])-3xHA  TCYC1 this study 
pPP3571 pH5n-1-260-fRXL CEN URA3 PSTE5-(Ste5 1-260)-(Fin1 190-208)-3xHA  TCYC1 3 
pPP3572 pt-HGT-CLN2-F CEN HIS3 PGAL1-GST-CLN2(full length) TCYC1 3 
pPP3573 pt-HGT-CLN2-t  CEN HIS3 PGAL1-GST-CLN2(1-372) TCYC1 this study 
pPP3630 pACL437 integrating URA3 cdc28-as2 6 
pPP3640 pJS21 integrating URA3  FAR1-S87A  7 
pPP3749 pt-HGT-CLN1 CEN HIS3 PGAL1-GST-CLN1(full length) TCYC1 3 
pPP3766 pUG-GST-F20L-wt 2µm URA3 PGAL1-GST-GFP-[ste20(72-118) + ste20(120-333)] this study 
pPP3761 pS5kV5-Nhe-P4   CEN URA3 ste5(LLPP-AAAA)-3xV5  TCYC1 3 
pPP3771 pUG-GST-F20M-5CSM-wt   2µm URA3 PGAL1-GST-GFP-[ste5(263-335) + ste20(120-333)] 3 
pPP3807 pH5n-1-260-dExo84 CEN URA3 PSTE5-(Ste5 1-260)-(Exo84 281-311)-3xHA  TCYC1 3 
pPP3825 pHG-GST-S20M-5CSM-WT CEN HIS3 PGAL1-GST-[ste5(263-335) + ste20(120-333)] this study 
pPP3877 pS5kHA-1-260-E34(N) CEN URA3 PSTE5-(Ste5 1-260)-(E34[N] zipper)-3xHA  TCYC1 this study 
pPP3916 pt-HGT-CLN2-t-R34up CEN HIS3 PGAL1-GST-(R34 zipper)-CLN2(1-372) TCYC1 this study 
pPP3929 pt-HGT-CLN1-t-R34up CEN HIS3 PGAL1-GST-(R34 zipper)-CLN1(1-388) TCYC1 this study 
pPP3955 pt-HGT-Rup-CLB5-t CEN HIS3 PGAL1-GST-(R34 zipper)-CLB5(133-435) TCYC1 this study 
pPP3956 pt-HGT-Rup-CLB2-t CEN HIS3 PGAL1-GST-(R34 zipper)-CLB2(198-491) TCYC1 this study 
pPP3962 pS5kHA-1-260∆NLS-E34N CEN URA3 PSTE5-(Ste5 1-260[∆NLS])-(E34[N] zipper)-3xHA  TCYC1 this study 
pPP3964 pt-HGT-CLN3-t-R34up CEN HIS3 PGAL1-GST-(R34 zipper)-CLN3(1-395) TCYC1 this study 
pPP3979 pM20-BXA5N-E34N CEN URA3 myc13-[(E34[N] zipper)-(Ste5 1-85)-(Ste20 312-939)] this study 
pPP4032 pIU-FAR1-T306A integrating URA3  FAR1-T306A this study 
pPP4033 pIU-FAR1-S87A,T306A integrating URA3  FAR1-S87A,T306A this study 
pPP3265 pFA6a-3xV5-kanMX6 3xV5::kanMX6 C-terminal tagging cassette 8 
pPP4011 p2275 integrating URA3 cdc15-2 (= G206D) 9 
pPP4034 pFA6a-3xV5-natMX6 3xV5::natMX6 C-terminal tagging cassette this study 
pPP4071 pS5kHA-1-260-E34N-3sp pPP3877 w/ Ste5 T4S,T29S,T102S this study 
pPP4146 pHGT-SIC1-1-214 CEN HIS3 PGAL1-GST-Sic1 (1-214) this study 
pPP4147 pHGT-WHI5-FL CEN HIS3 PGAL1-GST-Whi5 (full length) this study 
pPP4150 pHGT-WHI5 1-125 CEN HIS3 PGAL1-GST-Whi5 (1-125) this study 
pPP4151 pHGT-WHI5 1-150 CEN HIS3 PGAL1-GST-Whi5 (1-150) this study 
pPP4152 pHGT-WHI5 1-172 CEN HIS3 PGAL1-GST-Whi5 (1-172) this study 
    
* Source: (1) (S korski and Hieter, 1989); (2) (Winters et al., 2005); (3) (Bhaduri and Pryciak, 2011); (4) (Takahashi and 
Pryciak, 2007); (5) (Strickfaden et al., 2007); (6) (Colman-Lerner et al., 2005); (7) (Doncic et al., 2011); (8) (Lu et al., 2012); 
(9) Alejandro Colman-Lerner lab. 
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CHAPTER V 
Conservation of LP recognition in fungal G1 cyclins  
and unusual hyper-potency in some cyclins 
 
 
 
The study has been devised and results have been interpreted by myself and Dr. 
Pryciak. All experiments have been performed by myself.  
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Introduction: 
 
In Chapters 2 and 3 of this dissertation, we investigated the molecular 
mechanisms behind the highly specific interactions between yeast G1/S cyclins 
and their substrates. We found that small hydrophobic motifs in substrates can 
interact with a distinct region on S. cerevisiae Cln2 and some G1 cyclins from 
other yeasts.  Many fungi that separated from S. cerevisiae before the Whole-
Genome-Duplication (WGD) have only one G1/S cyclin often known as Cln12 
and one G1 cyclin, Cln3. In many fungi the distinction between G1 and G1/S 
cyclins are not very clear and they are referred to as G1 cyclins in general. Some 
yeasts like Candida albicans carry additional G1 cyclins (Figure 5.1 A). Many of 
these fungal G1 cyclins are important for polarized morphogenesis, which, in 
some pathogenic species, is linked to virulence. In Ashbya gossypii, deletion of 
G1 cyclin Cln12 leads to severe morphological defects (Hungerbuehler et al., 
2007) with swollen hyphae displaying aberrant branching patterns. The AgCln12 
localizes to the hyphal tips (Gladfelter et al., 2006), which is consistent with their 
potential role in polarity control. In contrast, deletion of AgCln3 does not cause 
any morphological defect. In the pathogenic yeast Candida albicans, not one but 
three G1 cyclins have been shown to be important for filamentous hyphal growth, 
which contribute to its virulence. Apart from the usual G1 cyclin CaCln3 there are 
two other G1 cyclins, namely Hgc1, which is homologous to S. cerevisiae Cln1 
and Cln2, and another cyclin named Ccn1. Deletion of all of these has been 
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associated with defective hyphal morphogenesis and reduced virulence (Bishop 
et al., 2010; Chapa y Lazo et al., 2005; Loeb et al., 1999; Zheng and Wang, 
2004; Zheng et al., 2007).  
 
Further separated from budding yeast, the fission yeasts Schizosaccharomyces 
pombe and Schizosaccharomyces japonicus each have one G1 cyclin known as 
Puc1 which is a close relative of budding yeast Clns. Deletion of S. pombe Puc1 
increases the length of G1 and causes cells to undergo S phase at greater cell 
size than wt cells (quite akin to how cln2-m4 pushes cells to larger cell size at the 
time of Start). This delay is completely abolished, however, when the Sic1 
equivalent CKI in fission yeast, Rum1, is deleted (Martin-Castellanos et al., 
2000). Filamentous growth is also common in bread molds like Neurospora 
crassa although very little is known about the involvement of its only G1 cyclin 
NcCln1 in its polarized hyphal morphogenesis.  
 
All of these above fungi belong to the phylum of Ascomycota (Figure 5.2 A), 
which forms the largest phylum of fungi with over 64000 species. The fungal 
phyla Basidiomycota, which had separated from the Ascomycota about 400 
million years ago, contains sexually and asexually reproducing filamentous fungi 
including mushrooms like Coprinopsis cinerea, economically important smut 
Ustilago maydis (pathogenic to maize) and pathogenic yeasts like Cryptococcus 
neoformans. Several of these organisms simply contain one G1 cyclin. In U. 
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maydis, the sole G1 cyclin UmCln1 has been shown to play an important role in 
hyphal morphogenesis and mating, which is important for the shift from asexual 
to sexual reproduction under nutritional stress (the first step in infection) (Castillo-
Lluva and Perez-Martin, 2005). In the pathogenic fungus Cryptococcus 
neoformans, which reproduces asexually by budding, deletion of the only G1 
cyclin CnCln1 results in significant increase in cell size at the time of the initiation 
of DNA replication and budding (quite similar to cln2-m4 case in Chapter 3), thus 
suggesting a key role of G1 cyclins in the cell cycle of this organism (Virtudazo et 
al., 2010).  
 
Based on all of the above observations, it is clear that in many different fungi 
separated over large evolutionary distances, G1 cyclin-CDK complexes generally 
play similar roles of controlling polarized morphogenesis of buds or filaments and 
commitment to cell cycle entry. Our results in the budding yeast model system 
suggest a role of LP-type docking motifs in Cln2-CDK’s ability to drive polarized 
growth during budding (Chapter 3). This prompted us to investigate whether the 
G1 cyclins from different close and distant relatives of S. cerevisiae use similar 
molecular mechanisms to identify their substrates. More specifically, we were 
interested in knowing whether G1 cyclins from various fungi can use the “LP” 
type of substrate docking motifs we earlier characterized in Chapter 2. Our initial 
observations (Chapter 3) indicated that indeed a number of these G1 cyclins 
from a variety of yeasts are able to use the LP docking motif for substrate 
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phosphorylation and in fact “m4”-like mutations in those cyclins abrogated this 
recognition ability but not cyclin function.  In this Chapter, we present evidence 
that not only different ascomycetes yeast, but also different basidiomycetes fungi 
have G1 cyclins that recognize the LP docking motif. However, there may be 
additional sequence features necessary for some other G1 cyclins. One 
remarkable observation that emerged out of these experiments was the hyper-
potency of some cyclins belonging to different organisms. They may provide 
clues to the mechanisms of atypical cell cycle regulation in some yeast like the 
fission yeast S. pombe (Fisher and Nurse, 1996). 
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Results and Discussions 
 
Conservation of “LP” recognition in foreign G1 cyclins: 
 
In order to investigate whether “LP” recognition is conserved in G1 cyclins across 
fungal evolution, we expressed several foreign cyclins from yeasts belonging to 
the Saccharomyces clade and the Candida clade in budding yeast as leucine-
zipper fusion proteins (Chapter 3) and tested their ability to phosphorylate 
substrates containing either “LP” type or leucine-zipper docking sites. Apart from 
having Cln1/2- and Cln3- like G1 cyclins, some of these yeasts like Candida 
albicans have other G1 specific cyclins known as Ccn1 and Hgc1 (Figure 5.1 A). 
We tested Ccn1 cyclins from three different yeasts along with one Hgc1 
candidate. All of these cyclins were expressed without the region that controls 
their stability so as to minimize differences arising from differential control by the 
proteasomal machinery. The boundaries were decided based on fungal 
alignments, which showed variable regions rich in CDK phosphorylation sites (for 
an example of the strategy, see Figure 3.2C). These cyclins were tested for their 
ability to phosphorylate substrates containing either a native “LP” docking site 
from Ste5 and Ste20 or a leucine-zipper docking site, which provided for an in 
vivo control of the activity of these foreign cyclins when expressed in the budding 
yeast host (Figure 5.1 B). Almost all of these cyclins, with the exception of 
CaHgc1, were expressed comparably to budding yeast G1 cyclins and they were 
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Figure 5.1.  G1 cyclins from related yeasts have similar docking 
preferences  
 
(A) Homology tree of fungal (Sachharomycetales) G1 and B-type cyclins. Some 
species have additional G1 cyclins called Ccn1. The Ccn1 group is related but 
distinct from Cln3 and Cln1/2 groups. Adapted from Figure 1 of (Ofir and 
Kornitzer, 2010) 
(B) G1 cyclins from a variety of yeasts were expressed as GST-(lz) fusions to 
test in vivo phosphorylation of substrates with either a defective docking site or 
two LP docking sites (from Ste5 or Ste20) or the leucine zipper. All cyclins were 
truncated to remove their C-terminal tails, which control their stability. 
Abbreviations: Sc = Saccharomyces cerevisiae; Sk  = Saccharomyces kluyveri; 
Kw = Kluyveromyces  waltii; Ag = Ashbya gossypii; Ca = Candida albicans. 
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functionally active as displayed by the phosphorylation of the zippered substrate. 
In general most cyclins were not able to phosphorylate the substrate when there 
was no functional docking site present. All Cln1/2 and Ccn1 cyclins were able to 
use both the Ste5 and the Ste20 docking sites to phosphorylate the CDK sites 
derived from Ste5 native sequence. It is important to note here that the docking 
site from Ste5 (LLPP) is slightly different in composition from the Ste20 docking 
site (SLDDPIQF) but in each case, hydrophobic residues like L and F seemed to 
be key. However, the two Cln3 cyclins tested here were not able to 
phosphorylate these substrates in spite of being very potent on the zipper-
docking substrate. CaHgc1 was consistently expressed very weakly as 
compared to the other substrates. As a result, it is not clear whether its inability to 
phosphorylate native-dock substrates stems from its low expression or true lack 
of “LP” recognition, although it was able to phosphorylate the zipper-dock 
substrate somewhat efficiently. One very interesting thing that emerged from this 
experiment is the hyperpotency of S. kluyveri Ccn1 cyclin. Although all others 
were unable to phosphorylate a substrate lacking a functional dock, SkCcn1 was 
able to robustly phosphorylate it and continued to display stronger and more 
complete phosphorylation on substrates containing both native and zipper-docks, 
in spite of being expressed at the same levels as other cyclins. This surprising 
observation suggested that SkCcn1 might have the ability to activate budding 
yeast CDK1 so strongly that it can phosphorylate minimal consensus CDK sites 
without the help of any docking motif. This hyperpotency phenotype will be 
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further explored later in this Chapter. Overall, these observations clearly showed 
that LP recognition property is well conserved in a wide variety of G1 cyclins 
which suggests conservation of function in related yeasts 
  
We wanted to further explore the conservation of “LP” recognition in G1 cyclins of 
more distantly related fungi. Both fission yeasts and molds are a considerable 
evolutionary distance away from budding yeasts and their immediate relatives, 
which are known as Hemiascomycetes (Figure 5.2 A) but still within the larger 
phylum of Ascomycetes (note, G1 cyclins from different members of 
Hemiascomycetes were tested in Figure 5.1 B). Outside of this phylum, there is 
another phylum named Basidiomycetes (Figure 5.2 A), which separated from 
Ascomycetes about 400 million years ago when plants invaded the earth. 
Members of Basiodiomycetes include mushrooms, rusts, smuts and additional 
pathogenic budding yeasts. In an experiment very similar to the one described in 
Figure 5.1 B, we tested several different G1 cyclins belonging to various groups: 
Puc1s from fission yeasts Schizosaccharomyces pombe and 
Schizosaccharomyces japonicus; Cln1s from molds Neurospora crassa and 
Blastomyces dermatitidis; Cln1s from several Basidiomycetes species (smut: 
Ustilago maydis, mushroom: Coprinopsis cinerea, budding yeast like: 
Cryptococcus neoformans) (Figure 5.2 A). Each cyclin was expressed as a 
leucine-zipper fusion protein and tested against substrates containing wt or  
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Figure 5.2.  G1 cyclins from distant fungi recognize LP-type docking motifs 
 
(A) Expected Phylogenetic tree of fungi, showing two major phyla Ascomycetes 
and Basidiomycetes and sub-classes within Ascomycetes. (Adapted from Figure 
2 of Hellborg et al., 2008) 
(B) G1 cyclins from a variety of distant fungi were expressed as GST-(lz) fusions 
along with S. cerevisiae Cln2 and Cln3 to compare in vivo phosphorylation of 
substrates with either a defective docking site or an LP docking site from Ste5 or 
the leucine zipper. All cyclins were truncated to remove their C or N-terminal 
regions that control their stability. 
Abbreviations: Sc = Saccharomyces cerevisiae; Sp  = Schizosaccharomyces 
pombe; Sj = Schizosaccharomyces japonicus; Um = Ustilago maydis;  
Cc = Coprinopsis cinerea; Cn = Cryptococcus neoformans ; Nc = Neurospora 
crassa; Bd = Blastomyces dermatitidis. 
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mutant native docks from Ste5 or a zipper-dock. Apart from S. pombe Puc1, 
which was consistently poorly expressed, most cyclins were fully functional in 
vivo and remarkably were able to phosphorylate a native Ste5 substrate in a 
docking dependent manner (Figure 5.2 B) whereas ScCLN3 and SjPuc1 were 
not. This clearly showed that “LP” recognition is highly conserved across large 
evolutionary distance amongst fungi, raising the possibility that a functional role 
for this type of docking has also been conserved across fungal evolution. It might 
be interesting to explore whether this recognition has an in vivo role in these 
fungi. Since all of these cyclins are involved in polarized morphogenesis in these 
fungi, “LP” recognition could play a role in the phosphorylation of polarity related 
proteins by G1 cyclins. A similar role of “LP” recognition was uncovered in 
budding yeast (Chapter 3). However, none of these new cyclins displayed 
hyperpotency in substrate phosphorylation. Our results demonstrated that G1 
cyclins from fungi which are separated by large evolutionary distance form S. 
cerevisiae still maintained LP recognition. This argues strongly for the 
conservation of a functional role of LP recognition in these fungi.  
 
Differences in sequence requirements between Cln1/2s and Ccn1s 
 
While we were comparing different classes of G1 cyclins for their ability to use 
“LP” type docking motifs, we noticed that Ccn1s needed additional sequence 
features apart from the core “LP” motif which possibly let to somewhat different  
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Figure 5.3.  Clns and Ccn1s have subtly different sequence requirements 
for docking 
 
Representative cyclins from the Cln1/2 group and the Ccn1 group from different 
yeasts were expressed as GST-(lz) fusions and compared for their ability to 
phosphorylate in vivo substrates with either two docking sites from Ste5, different 
in length or docking sites from Exo84 or Sic1. 
Abbreviations: Sc = Saccharomyces cerevisiae; Kw = Kluyveromyces  waltii;  
Ca = Candida albicans. 
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Figure 5.3.  Clns and Ccn1s have subtly different sequence requirements 
for docking 
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binding preferences as well (Figure 3.5). We tested “LP” type motifs from three 
different substrates previously used in Chapter 2, namely from Ste5, Exo84 and 
Sic1. One of the Ste5 substrates, the Ste5-1-283 contains an intact LLPP motif 
followed by only two native residues. When we compared two Cln1/2s from 
twodifferent yeasts with two Ccn1s from two different yeasts, we found that while 
Cln1/2s recognized all the different docks, Ccn1s only recognized the Ste5 dock 
but not the docks from Exo84 or Sic1 (Figure 5.3). Ccn1s were able to recognize 
the truncated Ste5 (1-283) protein, thus suggesting that whatever additional 
sequence features are required lies within this 1-283 region of Ste5. It cannot be, 
however, that Ccn1s are using an entirely different sequence for phosphorylating 
Ste5, because Ccn1s can use a “LP” type docking motif from Ste20 (Figure 
5.1B). This brings out subtle differences in substrate recognition between the two 
classes of G1 cyclins and suggests that in spite of some overlap, these two 
distinct classes of cyclins probably are able to target different substrates in vivo.  
This difference further suggests that the Cln1/2 group may have somewhat 
different functions from the Ccn1 group during cell cycle, with one more suited for 
a certain role than the other and vice-versa.  
 
Hyperpotency of some cyclin-CDK complexes in vivo 
 
Our simple in vivo shift-based phosphorylation assay using a standard substrate 
-/+ a docking site helped us compare the relative strengths of different cyclin-  
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Figure 5.4.  Hyper-potent cyclins – S. pombe Cdc13 & S. kluyveri Ccn1  
 
 
(A) S. cerevisiae G1 or B-type cyclins were expressed as GST-(lz) fusions and 
compared for their ability to phosphorylate in vivo, substrates with either an LP 
docking site from Ste5 or the leucine zipper. All cyclins were truncated to remove 
their C or N-terminal regions that control their stability. 
(B) Full length S. cerevisiae G1 cyclin Cln2 and S. pombe mitotic cyclin Cdc13 
were expressed as GST- fusions and compared for their ability to phosphorylate 
in vivo, substrates with either a wild-type or a mutant LP docking site from Ste5.  
(C) S. cerevisiae Cln2 and Cln3, S. Kluyveri Ccn1 and S. pombe Cdc13 were 
expressed as GST- fusions and compared for their ability to phosphorylate in 
vivo, substrates with either no docking site or an LP docking site from Ste5 or 
Ste20. Apart from S. pombe Cdc13, all other cyclins were truncated to remove 
their C-terminal regions that control their stability.  
Abbreviations: Sk  = Saccharomyces kluyveri; Sp  = Schizosaccharomyces 
pombe. 
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Figure 5.4.  Hyper-potent cyclins – S. pombe Cdc13 & S. kluyveri Ccn1 
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CDK1 complexes. Most CDK complexes were not able to phosphorylate a 
substrate without the help of a docking site. However, two complexes were able 
to, thus exhibiting exceptional potency. In general, although the budding yeast 
mitotic cyclin Clb2-CDK1 complex showed higher potency than other budding 
yeast cyclin-CDK complexes on a zipper-dock substrate (evidenced by more 
complete conversion to the fully phosphorylated form), it was still unable to 
phosphorylate the substrate in the absence of a functional docking motif (Figure 
5.4 A). In contrast, the S. pombe mitotic cyclin, Cdc13, in complex with the 
budding yeast CDK1, was able to phosphorylate the same substrate even in the 
absence of a functional docking site (Figure 5.4 B). This hyperpotent behavior 
was also seen in the case of S. kluyveri G1 cyclin Ccn1, in complex with the 
budding yeast CDK1 in an earlier experiment (Figure 5.1 B). One question that 
arises is whether these hyperpotent cyclins still use the native docking motif in 
spite of being able to phosphorylate without it. So we compared the SkCcn1 and 
SpCdc13 side by side with ScCln2 and ScCln3 against substrates containing 
either no functional docking site or docking sites from Ste5 or Ste20 (Figure 5.4 
C). Both SkCcn1 and SpCdc13 were able to phosphorylate the substrate that 
lacked docking, whereas ScCln2 and ScCln3 were not. However, although 
SpCdc13 was not able to phosphorylate the two +dock substrates any better than 
ScCln2, SkCcn1 was able to phosphorylate both these substrates more 
completely with the help of docking sites. This demonstrated that SkCcn1 was 
still using the “LP” type docking motifs in spite of probably activating the CDK to a 
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greater extent than other cyclins. However, SpCdc13 did not seem to recognize 
these LP-type docking motifs. As expected, ScCln3 was unable to use any of 
these three substrates. Overall, these results clearly point to the fact that different 
cyclins have the ability to activate the CDK to different extents, which might have 
interesting consequences for the cell cycle. 
 
The hyperpotency of SpCdc13 is especially interesting because early cell cycle 
work in S. pombe showed that Cdc13-CDK1 complex was enough to take the cell 
through all stages of cell cycle (Start-DNA replication-mitosis) (Fisher and Nurse, 
1996) in the absence of G1 and S phase cyclins. This helped fuel the idea of the 
quantitative model for the cell cycle where substrate specificity stemmed from 
different levels of activity of the CDK complex at the early part versus the later 
part of the cell cycle and robust oscillations of activity of a single cyclin-CDK 
module was deemed enough to generate these temporally separated periods of 
low and high CDK activity. On the contrary, in other eukaryotes including budding 
yeast, the cell cycle could not be entirely driven by any one type of cyclin-CDK 
complexes (Table 5.1). To our knowledge, a minimum cyclin-CDK module has 
not been identified for budding yeast but based on evidences it seems likely that 
a budding yeast cell cycle can be driven by a combination of one of the three G1 
cyclins and an ectopically expressed mitotic cyclin (Clb1 or Clb2)  
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Table 5.1: Cyclin gene deletion and their phenotypes 
 
 
genotype phenotype rescue references 
budding yeast 
 cln1 cln2 cln3Δ unviable, arrest in G1 
sic1Δ, 
ectopicCLB5 
(Epstein and Cross, 
1992; Richardson et 
al., 1989; Schwob 
and Nasmyth, 1993; 
Tyers, 1996) 
 clb5 clb6Δ viable, delayed S phase 
CLB5promoter-
CLB2and swe1Δ 
(Hu and Aparicio, 
2005; Schwob and 
Nasmyth, 1993) 
 clb3 clb4 clb1 clb2Δ unviable 
 
(Fitch et al., 1992) 
 clb5 clb6 clb3 clb4 
clb1Δ clb2tsGAL-CLB5 unviable, arrest in G2 
 
(Schwob et al., 
1994) 
 clb5 clb6 clb3 clb4 
clb1 clb2ΔGAL-CLB1 viable 
 
(Haase and Reed, 
1999) 
fission yeast 
 puc1 cig1 cig2Δ viable, delay in G1 rum1Δ 
(Martin-Castellanos 
et al., 2000) 
 cdc13Δ unviable 
 
(Hagan et al., 1988) 
mouse 
 
cycD1−/−D2−/− D3−/− 
embryos grow but die at 
mid/late gestation with 
haematopoietic defects, MEFs 
are viable 
 
(Kozar et al., 2004) 
 cycE1−/−E2−/− 
death in late embryogenesis, 
failure of trophoblast giant cell 
endoreplication, MEFs are 
viable 
wt placenta 
rescues 
embryonic 
development (Geng et al., 2003) 
 cycA1−/− viable, male infertile 
 
(Liu et al., 1998) 
 cycA2−/− 
death after day 5.5 
p.c.,cycA1−/− A2−/− MEFs are 
viable 
 
(Kalaszczynska et 
al., 2009; Murphy et 
al., 1997) 
 cycB1−/− death in early embryogenesis 
 
(Brandeis et al., 
1998) 
 cycB2−/− viable and fertile 
 
(Brandeis et al., 
1998) 
 
Reproduced from (Uhlmann et al., 2011)  
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(Epstein and Cross, 1992; Fitch et al., 1992; Haase and Reed, 1999; Hu and 
Aparicio, 2005; Richardson et al., 1989; Schwob et al., 1994; Schwob and 
Nasmyth, 1993; Tyers, 1996). Although the requirement for G1 cyclins can be 
bypassed by certain genetic manipulations, these modified cells often lack the 
fitness of wild type cells (Schwob and Nasmyth, 1993; Skotheim et al., 2008; 
Tyers, 1996).  
 
The current model for cell cycle regulation says that early events in the cell cycle, 
like Start and DNA replication, are fueled by a less active but highly specific form 
of the CDK whereas later events like mitosis are fueled by a highly active form of 
the CDK which does not have high substrate specificity (Koivomagi et al., 
2011b). Our in vivo results with SpCdc13 hints at the possibility that its 
hyperpotency makes it suitable to drive the cell cycle in a different way than most 
other cyclin-CDK modules found in other organisms.  
 
In budding yeast, S phase (DNA replication) is normally driven by Clb5/6-CDK1 
complexes whereas Mitosis requires mainly Clb1/2-CDK1. Although all of these 
are B-type cyclins and at least in some cases they can substitute for each other, 
several differences exist between these two groups such that not all roles of 
Clb5/6 in the cell cycle are redundant with Clb1/2 and vice versa (reviewed in 
Chapter 1).  
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Mechanistically, there are two main differences between these two groups of 
cyclins. Recent studies have demonstrated the Clb2-CDK1 is a more potent 
enzyme than Clb5-CDK1, which allows it to have a wider range of substrates 
(Koivomagi et al., 2011b; Loog and Morgan, 2005). However, some substrates 
are still more sensitive towards Clb5 because Clb5 can target those substrates 
through its hydrophobic patch (hp) region whereas Clb2 is not as efficient in this 
hp-mediated targeting of those substrates (Bhaduri and Pryciak, 2011; Loog and 
Morgan, 2005). An alignment of different B-type cyclins from a variety of yeasts 
pointed out that the hp region in the Clb1/2 group from the Saccharomyces clade 
has evolved quite differently from the classical MRAIL like hp of the Clb5/6s, 
which target RxL type docking sites in substrates(Archambault et al., 2005). It 
raises the possibility that the hp region in Clb1/2 has evolved to have different 
functions – it could bind to a different kind of sequence, it could affect the 
localization of the cyclin or both. Indeed, there is evidence for both roles of the 
atypical hp region in Clb2 (Bailly et al., 2003; Hu et al., 2008).  
 
One interesting question here is whether a functionally different hydrophobic 
patch is a specialty of the mitotic cyclins from the Saccharomyces  clade or all 
mitotic B-type cyclins in fungi have an altered role for their hp region. Organisms 
further away from this clade, those belonging to the Basidiomycetes phylum, 
have only one mitotic cyclin. Future work will aim to investigate whether B-type 
cyclins from these simpler systems can recognize RxL motifs in substrates. 
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Another interesting thing that would be looked at in future studies is if other 
cyclins display hyperpotent behavior. A likely candidate that will be tested along 
with others is the Cdc13 cyclin from another fission yeast, S. japonicas. Also it 
will be important to test whether this hyperpotent phenotype applies to other CDK 
phosphorylation sites, for examples, the ones present in Ste20 or Whi5. Currently 
our observations only pertain to CDK sites in Ste5.  
 
Finally, based on above results, it is clear that “LP” recognition is a highly favored 
method of substrate selection by fungal G1 cyclins. It will be interesting to know 
whether this method has an in vivo role in these organisms. In C. albicans, The 
Ccn1 cyclin has been shown to be involved in polarized morphogenesis, which is 
important for its pathogenicity. Future work would aim to address if “LP” 
recognition is necessary for this role of CaCcn1. Our preliminary results showed 
that mutating the substrate-binding groove in CaCcn1 significantly reduced its 
ability to promote hyperpolarized growth when overexpressed in S. cerevisiae.  
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Materials and Methods 
 
Yeast Strains and Plasmids 
Standard procedures were used for growth and genetic manipulation of yeast 
(Rothstein, 1991; Sherman, 2002). Cells were grown at 30°C in synthetic (SC) 
medium with 2% glucose and/or raffinose. Strains and plasmids are listed in 
tables below. 
 
In vivo CDK Phosphorylation Assays 
As described previously (Bhaduri and Pryciak, 2011; Pope et al., 2014), cells 
harboring PGAL1-GST-cyclin constructs and HA-tagged CDK substrates were 
grown in synthetic raffinose media, and then induced with 2% galactose (for 2.5 
hr) to drive cyclin expression; substrates were based on the Ste5 N-terminus, 
with or without docking sites as indicated. Whole cell extracts were prepared, and 
substrate phosphorylation was assessed by SDS-PAGE and immunoblotting. 
 
Whole Cell Extracts 
Whole cell extracts (5ml cultures, Od660=0.6) were prepared by a modified 
version of a previous protocol (Lee and Dohlman, 2008). Here, 300 µL of 
trichloroacetic acid (TCA) buffer (10 mM Tris-HCl, pH 8.0, 10% TCA, 25 mM 
ammonium acetate, 1 mM Na2EDTA) was added directly to frozen cell pellets 
(usually from 2 mL culture), and incubated on ice for 10 minutes. Samples were 
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pelleted in a microcentrifuge for 10 min at 4˚C. The pellet was resuspended in 
150 µL Resuspension Buffer (0.1 M Tris.HCl, pH 11.0, 3% SDS), boiled for 5 
min, allowed to cool at room temperature for 5 minutes, then re-centrifuged for 30 
sec. The supernatant (120 µL) was transferred to a new tube, 20 µL was 
reserved to assay protein concentration by a Pierce BCA Protein Assay Kit 
(#23225), and then 100 µL of 2x SDS Sample Buffer was added to the 
remainder.  Equivalent amounts of total protein (generally 20 µg) were loaded in 
each lane. 
 
Immunoblotting 
Protein samples were analyzed by SDS-PAGE and transferred to PVDF using a 
submerged tank device. HA-tagged or GST-tagged proteins were detected with 
mouse anti-HA (1:1000, Covance #MMS101R) or anti-GST (1:1000, Santa Cruz 
Biotechnologies #sc-138) antibodies, followed by HRP-conjugated goat anti-
mouse (1:3000, BioRad #170-6516) antibodies. Enhanced chemiluminescent 
detection used a Biorad Clarity kit (#170-5060). 
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Table 5.2 : Yeast strains used in Chapter V 
Name Background* Relevant Genotype Source† 
    
BY4741 (S288c) MATa his3∆1 leu2∆0 ura3∆0 met15∆0 Bachman/Boeke 
    
 
Table 5.3 : Plasmids used in Chapter V 
Name Alias Description Source 
 
pPP2154 
 
pHG-GST 
 
CEN HIS3 PGAL1-GST vector  
 
(1) 
pPP3501 pS5kHA-1-283 CEN URA3 ste5 1-283- 3xHA TCYC1 this study 
pPP3509 pH5n-1-337-wt CEN URA3 ste5 1-337-(wt)- 3xHA   TCYC1 (1) 
pPP3547 pH5n-1-260-S20CSM CEN URA3 ste5 1-260-(Ste20 80-115wt)- 3xHA   TCYC1 (1) 
pPP3572 pt-HGT-CLN2-F CEN HIS3 GAL-GST-CLN2 full length TCYC1 (1) 
pPP3714 pH5n-1-337-P4 CEN URA3 ste5 1-337-(LLPP-AAAA)- 3xHA   TCYC1 (1) 
pPP3737 pt-HGT-Cdc13 CEN HIS3 GAL-GST-S. pombe Cyclin Cdc13 full length  TCYC1 this study 
pPP3802 pH5n-1-260-dSic1 CEN URA3 ste5 1-260-(Sic1 121-150)- 3xHA TCYC1 (1) 
pPP3807 pH5n-1-260-dExo84 CEN URA3 ste5 1-260-(Exo84 281-311)- 3xHA   TCYC1 (1) 
pPP3877 pS5kHA-1-260-E34(N)  CEN URA3 ste5(1-260)-[E34(N) zipper]-  3xHA    TCYC1 (2) 
pPP3916 pt-HGT-CLN2-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN2(1-372)   TCYC1 (2) 
pPP3919 pt-HGT-Rup-Sklu-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Sklu CLN1/2(1-364)  TCYC1 this study 
pPP3920 pt-HGT-Rup-Kwal-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CLN1/2(1-363)  TCYC1 this study 
pPP3921 pt-HGT-Rup-Agos-CLN1/2 CEN HIS3 PGAL1-GST-[R34 zipper]-Agos CLN1/2(1-364)  TCYC1 this study 
pPP3929 pt-HGT-CLN1-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN1(1-388)  TCYC1 (2) 
pPP3955 pt-HGT-Rup-CLB5-t CEN HIS3 GAL1pr-GST-[R34 zipper]-CLB5(133-435)  TCYC1 this study 
pPP3956 pt-HGT-Rup-CLB2-t CEN HIS3 GAL1pr-GST-[R34 zipper]-CLB2(198-491)  TCYC1 this study 
pPP3957 pt-HGT-Rup-Kwal-CCN1 CEN HIS3 PGAL1-GST-[R34 zipper]-Kwal CCN1(1-379)  TCYC1 this study 
pPP3958 pt-HGT-Rup-Sklu-CCN1  CEN HIS3 GAL1pr-GST-[R34 zipper]-SkluCCN1(1-405)  TCYC1 this study 
pPP3959 pt-HGT-Rup-Calb-CCN1-a CEN HIS3 PGAL1-GST-[R34 zipper]-Calb CCN1(1-469)  TCYC1  this study 
pPP3961 pt-HGT-Rup-Calb-HGC1 CEN HIS3 GAL1pr-GST-[R34 zipper]-CalbHGC1(1-406)  TCYC1 this study 
pPP3963 pt-HGT-Rup-Agos-CLN3 CEN HIS3 PGAL1-GST-[R34 zipper]-Agos CLN3(1-324)  TCYC1 this study 
pPP3964 pt-HGT-CLN3-t-R34up CEN HIS3 PGAL1-GST-[R34 zipper]-CLN3(1-395)  TCYC1 (2) 
pPP4128 pt-HGT-Rup-Sj-Puc1 CEN HIS3 GAL1pr-GST-[R34 zipper]-SjapPUC1(FL)  TCYC1 this study 
pPP4130 pt-HGT-Rup-Cc-CLN-t CEN HIS3 GAL1pr-GST-[R34 zipper]-CcinCLN(1-359 w/ exon fusion)  TCYC1 this study 
pPP4131 pt-HGT-Rup-Nc-CLN-t CEN HIS3 GAL1pr-GST-[R34 zipper]-NcraCLN(1-309 w/ exon fusion)  TCYC1 this study 
pPP4132 pt-HGT-Rup-Bd-CLN-t CEN HIS3 GAL1pr-GST-[R34 zipper]-BderCLN(1-313 w/ exon fusion)  TCYC1 this study 
pPP4137 pt-HGT-Rup-Sp-Puc1 CEN HIS3 GAL1pr-GST-[R34 zipper]-SpomPUC1(FL)  TCYC1 this study 
pPP4144 pt-HGT-Rup-UmCLN102-374 CEN HIS3 GAL1pr-GST-[R34 zipper]-UmayCLN(102-374)  TCYC1 this study 
pPP4145 pt-HGT-Rup-CneoCLN-t CEN HIS3 GAL1pr-GST-[R34 zipper]-CneoCLN(1-332 w/ exon fusion)  TCYC1 this study 
* Source:  (1) (Bhaduri and Pryciak, 2011); (2) (Pope et al., 2014) 
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CHAPTER VI 
 
Concluding remarks 
 
 
 
 
Purpose and main outcomes:  
Several cell cycle events require specific forms of the cyclin-CDK complexes. It 
has been known for some time that cyclins not only contribute to cell cycle 
progression by activating the CDK but also by choosing substrates and/or 
specifying the location of the CDK holoenzyme. There are several examples of 
B-type cyclins identifying certain peptide motifs in their specific substrates 
through a conserved region in their structure. However, such interactions were 
not known for the G1 class of cyclins, which are instrumental in helping the cell 
decide whether or not to commit to a new cell cycle, a function that is non-
redundant with B-type cylins in budding yeast (reviewed extensively in Chapter 
1). In Chapter 2 of this dissertation we have presented evidences that some G1 
cyclins in budding yeast, Cln1 and Cln2, identify specific substrates by interacting 
with a particular type of substrate patch. This interaction is mediated by a 
conserved region of the cyclins’ structure, and both this region and the substrate 
patch differ from those used by B-type cyclins. In Chapter 3, we have further 
shown that the substrate-binding region in Cln1/2 is highly conserved amongst a 
variety of fungal G1, thus suggesting a conserved function. We discovered that 
the main effect of disrupting this interaction is to delay cell cycle entry in budding 
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yeast, possibly resulting from incomplete multi-site phosphorylation of substrates. 
Also, interestingly, in Chapter 4, we found that a CDK inhibitor can regulate the 
cyclin-CDK complex by inhibiting cyclin-substrate interaction. In Chapter 5, apart 
from finding that G1 cyclins from many distant fungi, such as molds and 
mushrooms, have maintained this substrate interaction function, we discovered 
that some cyclins have the ability to make the CDK hyperpotent in activity, thus 
suggesting additional roles for such complexes.  
 
Salient features of the study and future directions: 
In Chapter 2, we identified short hydrophobic (Leucine and Proline rich) docking 
sites in several CDK substrates, which specifically bind to budding yeast G1/S 
cyclins Cln1/2 and enhance phosphorylation of CDK substrates in a cyclin-
specific manner in vivo. These docking sites are modular in that they can 
promote phosphorylation from a variety of distances and positions relative to the 
CDK sites.  Furthermore, cyclin specificity of the same phosphorylation sites can 
be switched simply by exchanging docking sites among different substrates. It 
was surprising how easily we identified similar “LP” type docking motifs from 
several CDK substrates suggesting that this type of interaction may be very 
commonly used by the G1/S cyclin-CDKs in yeast to target their substrates. 
Subsequent studies from Mart Loog and colleagues have also shown the use of 
these docking motifs in phosphorylation of CDK substrates by G1/S cyclin-CDKs. 
Collectively, these findings suggest that docking interactions play a prevalent but 
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previously unappreciated role in driving phosphorylation of G1/S CDK substrates. 
Docking motifs, in principle, are capable of affecting substrate phosphorylation in 
a number of ways: determining cyclin specificity without any contribution from the 
CDK sites themselves; promoting phosphorylation of suboptimal CDK sites, 
which are poorly phosphorylated by most forms of the CDK but form an 
overwhelming majority of all phosphorylated CDK sites in yeast (Holt et al., 
2009); promoting multi-site phosphorylation of substrates in a processive manner 
(Koivomagi et al., 2013); and introducing additional regulation by interacting with 
regulators like phosphatases (Malleshaiah et al., 2010). 
 
One key question that arose was how important are these substrate specific 
docking interactions with G1/S cyclin-CDK for the progression of the cell cycle. 
The best way to ask this question was to mutate the substrate-binding region in 
Cln2 and look for cell cycle phenotypes. However, unlike in the substrates where 
the docking motif occurred in largely unstructured areas, the binding site in the 
cyclin was envisioned to be a part of highly structured cyclin box folds. Any 
tampering in this region had the potential to interfere with the function of the 
cyclin. In the absence of an actual structure of Cln2 with a docking peptide, it was 
very difficult to predict where in Cln2 one can find the docking region and some 
initial attempts using targeted or unbiased large-scale mutational approaches 
failed. So in Chapter 3, we employed a strategy to not only identify different 
regions to mutate but also to control for any loss of activity upon mutation in vivo 
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(detailed in Chapter 3). Through these efforts, we were able to find a Cln2 mutant 
(m4) that was specifically defective in phosphorylating docking-dependent (“LP” 
type) substrates but otherwise fully functional. The residues making up this 
substrate-binding region describe a mild depression near the hp cleft in models 
of Cln2.  A comparison with a bona-fide structure of a B-type cyclin revealed that 
the m4 region was close to but separate from the well-characterized hp region on 
B-type cyclins. This m4 mutation caused Cln2 to lose its in vivo interactions with 
several substrates and also rendered it incapable of promoting multi-site 
phosphorylation in vitro.  
 
Although the m4 mutations caused disruption of docking dependent binding and 
phosphorylation, it cannot be ruled out that m4 mutations might not disrupt the 
actual binding interface in Cln2, instead it might cause a conformation change in 
Cln2 which masks the actual binding interface. Such possibilities can only be 
distinguished by solving the crystal structure of Cln2 with a LP peptide.  
 
In vivo, this mutant Cln2 was defective in fully phosphorylating Whi5 after release 
from pheromone arrest in G1 and also failed to promote robust transcription of 
several genes. These mechanistic insights were translated into a cell cycle 
phenotype when we observed that if cells had to rely on this mutant Cln2, they 
could not start a new cell cycle (budding and DNA replication) until they were 
substantially bigger in size. One of the roles that Cln2 has always been 
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associated with is bud morphogenesis (Cvrckova and Nasmyth, 1993). After 
release from a pheromone arrest in G1, mutant Cln2 was delayed in budding. 
Also, while overexpressed wild type Cln2 promoted hyperpolarized bud growth, 
m4 failed to do that as robustly.  Interestingly, we mutated the same region in a 
few other G1 cyclins from neighboring yeasts and in each case the mutant cyclin 
showed a reduced ability to promote polarized bud morphogenesis. Overall, it 
appears that docking ability of Cln2 is especially important for the robust 
execution of several molecular events leading to the commitment point at Start. 
In this short interval, docking helps promote sharp and full phosphorylation of the 
early substrates of the CDK, several of which require phosphorylation at multiple 
CDK sites for their regulation. Therefore our results say that substrate docking of 
Cln2 is very important for a rapid and decisive commitment to cell cycle entry.  
 
Some phenotypes of m4 were not very pronounced, especially when cells were 
released from a prolonged pheromone arrest, which helps cells overcome the 
cell size threshold at cell cycle entry. We hypothesize that inhibitors and negative 
regulators, which probably make use of the m4 region, cannot inhibit the cln2-m4 
allele as strongly they can inhibit the wt allele of Cln2. This difference may lead to 
attenuation of some of m4 phenotypes. Our hypothesis is based on observations 
such as the aggravation of m4 phenotypes in the absence of CKI Far1 and the 
doubling of cln2-m4 half-life when compared to Cln2-wt. The latter observation 
may indicate that the proteasomal machinery also uses the docking interaction to 
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identify Cln2 but alternatively the m4 mutations can render Cln2 more stable by 
some other means, for example, by creaking a more stable folding which is 
harder to degrade (Nick Pace et al., 2014). 
 
The docking site in Cln2 could also be multipurpose just like the docking sites in 
its substrates (see above), such that it may also bind not only substrates but also 
regulators like CDK inhibitors and members of the proteolytic machinery. Indeed 
two observations indirectly suggest this possibility – one being the increased half-
life of cln2-m4 and the other being the mitigation of some m4 phenotypes (like 
overall increase in cell size) in the absence of the CDK inhibitor Far1. In fact, 
Far1 does inhibit substrate binding by Cln2, as shown in Chapter 4. Once 
stimulated by pheromone, Far1 is able to specifically inhibit Cln2-CDK’s 
interaction with its substrates as well as its ability to phosphorylate docking 
dependent substrates in vivo. Far1 can competitively inhibit this substrate 
interaction because it can bind Cln2 more strongly than substrates. A mutant 
Far1, which fails to inhibit Cln2’s substrate binding, also fails to promote 
pheromone arrest. Interestingly, Far1 also separately inhibits another function of 
the Cln2-CDK complex, most likely CDK activity. Based on our observations, it 
seems likely that Far1 mediated inhibition is most effective on substrates that will 
critically depend on docking. Such substrates could contain inherently poor or 
suboptimal phosphorylation sites and/or might need to be phosphorylated at 
multiple positions. Another interesting thing that emerged is the specificity of Far1 
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mediated inhibition of CDK activity – only Cln1/2-CDK complexes were inhibited 
while Cln3, Clb5 and Clb2-CDK complexes were not affected even though Far1 
could bind all cyclins equally well. Currently it is not known whether Far1 has a 
LP docking motif but two independent regions in Far1 have been shown to bind 
Cln2 (Peter et al., 1993) thus suggesting that Far1 may employ a larger interface 
to interact with Cln2. 
 
Finally, in Chapter 5, we have shown that this substrate binding function is 
conserved in G1 cyclins of both yeasts and non-yeast fungi like mushrooms and 
molds which shared the last common ancestor with yeasts about 400 million 
years ago. This strongly suggests that there is a functional relevance for this 
specific docking interaction in these fungi. Quite like budding yeast, in several of 
these fungi, G1 cyclins are entrusted with the job of promoting polarized hyphal 
morphogenesis, which is a critical requirement for virulence in some of the 
pathogenic fungi. It’s likely that similar to budding yeast, this same type of 
docking interaction is involved in promoting polarized growth in these other fungi.  
 
Some of these exogenous cyclins demonstrated hyperpotency in activity. Such 
hyperpotency likely results from the ability of these cyclins to activate the CDK to 
a higher degree, although alternate explanations cannot be ruled out. For 
example, these cyclins may change the conformation of the CDK in such a way 
that it can bind Cks1 (phosphor-adapter subunit of cyclin-CDK complexes) better 
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and thus promote more efficient use of phosphorylation sites. Or even, these 
cyclins could make the cyclin-CDK complex resistant to the CKI Far1.  
 
This hyperpotent behavior also has important implications for cyclin evolution. 
These hyperpotent cyclins may represent an ancestral form of cyclins, which may 
have been designed to drive a basic eukaryotic cell cycle completely on their 
own. But subsequent increase in complications in that basic cell cycle might have 
fueled the need to generate more specialized cyclin-CDK modules in order to 
temporally and spatially separate distinct events during the cell cycle. So the 
modern low-activity but high-specificity cyclins may have evolved from these 
apparently hyperpotent ancestral cyclins.  
 
Collectively, we have uncovered a novel type of substrate interaction between 
budding yeast G1/S cyclins and several early substrates of the CDK. This 
interaction is specific to this type of cyclin and involves a conserved interface on 
the cyclin, which binds to short leucine-proline rich patches on the substrates. 
These docking sequences also allow for other regulatory inputs by interacting 
with inhibitors and regulators, both at the level of the cyclin and the substrates. 
Our observations lead to several possibilities that warrant future studies. For 
example, future studies may address how these two different classes of docking 
interactions evolved, for instance, whether they were both present in some 
ancient cyclin and diverged into two specific groups at a later time. Also, another 
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obvious question that arises is whether the Cln3 group has yet another type of 
docking interaction. Another interesting question is to investigate the role of “LP” 
docking in polarized growth and virulence in a pathogenic fungus like Candida 
albicans, where the G1 cyclin Ccn1 has been shown to be involved in hyphal 
growth critical for virulence. Our results in Chapter 3 show that an m4 like 
mutation in CaCcn1 reduces its ability to promote hyperpolarized bud growth in 
budding yeast.  
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CHAPTER VII 
 
Appendix 
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Figure A1. Phosphorylation of Ste5 N-terminal by Cln2 is reversed by 
phosphatase treatment 
 
 
A HA-tagged Ste5 N-terminal fragment, which lacks the NLS domain, resolves 
into two bands (faster: unphosphorylated; slower: terminally phosphorylated. The 
HA-tagged Ste5 1-315∆NLS fragment expressed from its native promoter, was 
monitored in time course after galactose-induced expression of GST-tagged 
Cln2.  Reduced electrophoretic mobility signifies phosphorylation. The maximally 
phosphorylated 180m sample was treated with either Calf-intestine Alkaline 
phosphatase (CIP: NEB # M0290S) (180+CIP) or water (180+mock) for 1 hr. 
Phosphorylation of the 180m sample is fully reversed by treatment with CIP. 
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Figure A1. Phosphorylation of Ste5 N-terminal by Cln2 is reversed by 
phosphatase treatment 
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Figure A2. Cyclin specific phosphorylation of Ste20 regulatory domains in 
the absence of B-type cyclin-CDK inhibitor Sic1 
 
In a strain lacking B-type cyclin-CDK inhibitor Sic1, a V5-tagged Ste20 fragment, 
expressed from its native promoter, was monitored after galactose-induced 
expression of GST-tagged cyclins. Reduced electrophoretic mobility signifies 
phosphorylation. A variant of Cln3 lacking ten CDK sites (Cln310A) was used to 
increase its stability.  Absence of Sic1 did not alter cyclin specificity of the Ste20 
fragment. Results from two independent experiments are shown. 
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Figure A3. The Cln2 docking site in Ste20 enhances phosphorylation of a 
Ste20 80-333 N-terminal fragment 
 
PGAL1-Cln2-induced phosphorylation was assayed for a V5-tagged form of Ste20 
N-terminal fragment (80-333), with or without mutations in the docking site (mut3) 
or the 13 confirmed CDK sites (CDK*). Results from two independent 
experiments are shown. 
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